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Isolation and Functional Characterization of a Dioxin-Inducible CYP1A Regulatory 
Region From Zebrafish (Danio rerio) 
Gary T. ZeRuth 
ABSTRACT 
 
 
Cytochrome P4501A1 (CYP1A1) is a phase I bio-transformation enzyme 
involved in the metabolism of xenobiotics via the oxygenation of polycyclic aromatic 
hydrocarbons (PAHs) including the carcinogen, benzo(a)pyrene.  Induction of the 
CYP1A1 gene is regulated at the transcriptional level and is ligand dependent with the 
prototypical 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD) being the most potent known 
inducer of CYP1A1 transcription.  This process is mediated by the AHR/ARNT signaling 
pathway whereby ligand binds AHR in the cytoplasm allowing its translocation to the 
nucleus where it binds with its hertrodimerization partner, ARNT and subsequently binds 
DNA at cognate binding sites termed xenobiotic responsive elements (XREs) located in 
the 5’ flanking region of the CYP1A1 and other genes.  
The zebrafish (Danio rerio) has recently become an important model system for 
the study of TCDD-mediated developmental toxicity due to their relative ease of 
maintaining and breeding, external fertilization, abundant transparent embryos, and 
sensitivity to TCDD similar to mammalian models.  It is therefore essential to 
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characterize the molecular mechanisms of AHR mediated gene regulation in this 
organism. 
The upstream flanking region of a putative CYP1A gene from zebrafish was 
identified by the screening of a PAC genomic library.  Sequencing revealed a region 
which contains 8 putative core xenobiotic response elements (XREs) organized in two 
distinct clusters.  The region between –580 to –187 contains XRE 1-3 while the region 
between –2608 to –2100 contains XRE 4-8.  Only XRE 1, 3, 4, 7, and 8 exhibited TCDD-
dependant association of AHR/ARNT complexes when evaluated by gel shift assays.  
The use of in vitro mutagenesis and Luciferase reporter assays further showed that only 
XRE’s 4, 7, and 8 were capable of conveying TCDD-mediated gene induction.  The role 
of nucleotides flanking the core XRE was investigated through the use of EMSA and 
reporter assays.  Similar methods were employed on additional transcription factor 
binding sites identified by in silico analyses revealing two sites conforming to an HNF-
3α and CREB motif, respectively, which demonstrate importance to regulation of the 
gene. 
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Chapter One 
 
Introduction 
 
Isolation of AHR and ARNT 
The aryl hydrocarbon hydroxylase, (AHH), was identified as being greatly varied 
in inducibility amongst different strains of mice in response to polycyclic aromatic 
hydrocarbons, (PAHs), and halogenated aromatic hydrocarbons, (HAHs) (Nebert and 
Gelboin, 1969; Poland et al., 1974). Through the use of classical murine genetics, it was 
further ascertained that these variations were controlled by a single gene locus termed Ah 
(Green, 1973; Schmidt and Bradfield, 1996; Thomas and Hutton, 1973). The Ah locus 
was later found to code for a receptor, the aryl hydrocarbon receptor (AHR), which is 
capable of binding ligand with high affinity leading to the subsequent induction of AHH 
(Poland et al., 1976).  Polymorphisms in the Ahr were found to be the cause of the 
variable  inducibility of AHH between mouse strains and[125I]-photoaffinity labeling led 
to the discovery of three alleles encoding for high affinity receptors designated Ahrb-1, 
Ahrb-2, and Ahrb-3 and a single allele encoding the low affinity Ahrd allele.(Poland and 
Glover, 1990; Poland et al., 1987) Purification of the AHR and the development of 
antibodies specific to the receptor revealed that differences existed not only amongst 
mouse strains, but the molecular weight varied remarkably between species as well 
(Hahn et al., 1994; Poland and Glover, 1987; Poland et al., 1991).  These innovations 
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additionally led to the generation of the first AHR cDNA and the revelation that the 
receptor was the second member of the basic-helix-loop-helix Per-ARNT-Sim (bHLH-
PAS) family of proteins identified (Burbach et al., 1992; Ema et al., 1992).  
Interestingly, the first member of the bHLH-PAS family isolated was the 
heterodimerization partner of the AHR, the aryl hydrocarbon nuclear translocator protein, 
ARNT, cloned approximately one year earlier (Hoffman et al., 1991).  ARNT was 
isolated in an attempt to identify constituents of AHR signaling absent in an induction 
defective mouse hepatoma cell line containing normal concentrations of AHR capable of 
binding ligand but which failed to subsequently localize to the nucleus. (Hoffman et al., 
1991; Legraverend et al., 1982) Due to the ability of ARNT to restore function to the 
loss-of-function mutants, the name aryl hydrocarbon nuclear translocator protein was 
actually a misnomer as it was later found that ARNT is not required for the nuclearization 
of liganded AHR but instead acts as a dimerization partner required for the binding of 
DNA.(Dolwick et al., 1993b; Elferink et al., 1990; Reyes et al., 1992) Indeed, studies by 
Pollenz et al. (1994) showed that AHR was capable of translocating to the nucleus 
following TCDD treatment in ARNT deficient cells and that ARNT was confined to the 
nucleus both prior to and following ligand exposure while unliganded AHR was 
primarily cytosolic.(Pollenz et al., 1994) The unveiling of the scheme of 
heterodimerization between AHR and ARNT laid the foundation for the identification 
and characterization of novel members of the emerging super-family of bHLH-PAS 
proteins. 
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bHLH-PAS Proteins 
 While other proteins had been previously identified which contain bHLH 
domains, including the well characterized MyoD, AHR and ARNT possess a domain 
adjacent to the bHLH which shows homology to the Drosophila Period (Per) and Single 
minded (Sim) genes and is termed Per-ARNT-Sim (PAS) after the identifying members 
(Burbach et al., 1992; Ema et al., 1992; Hoffman et al., 1991; Huang et al., 1993). The 
PAS region is typically composed of approximately 300 amino acids and is divided into 
PAS A and PAS B subdomains each consisting of 50 amino acid degenerate repeats 
(Burbach et al., 1992; Gu et al., 2000; Nambu et al., 1991).  Having a role in 
dimerization, the PAS domain has been implicated in heterodimerization between Per and 
Sim and homodimerization of Per (Huang et al., 1993).  In the case of AHR, the PAS 
domains serve as a binding site for chaperone proteins (Whitelaw et al., 1993) and ligand 
(Burbach et al., 1992; Dolwick et al., 1993a; Schmidt and Bradfield, 1996; Whitelaw et 
al., 1993) as well as assisting in DNA binding (Dolwick et al., 1993a) while AHR/ARNT 
dimerization occurs concertedly within the HLH and PAS domains (Reisz-Porszasz et al., 
1994; Schmidt and Bradfield, 1996).  In addition to the basic, DNA binding domain, the 
HLH, and the PAS domains, the majority of bHLH-PAS proteins contain a C-terminal 
transcriptional activation domain (TAD).  Unlike the previous domains, however, which 
share sequence homology, the TADs lack conservation amongst members of the super-
family (Gu et al., 2000).  A graphical depiction of the domain organization within 
selected bHLH-PAS proteins is shown in Figure 1.1.  
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 The existence of transcriptional activation domains supports the fact that most 
bHLH-PAS proteins serve as transcriptional regulators which act upon target genes in 
order to elicit an adaptive response to environmental stimuli. (Furness et al., 2007; 
Kewley et al., 2004; Massari and Murre, 2000) In order to form active transcription 
factors, bHLH-PAS proteins are required to dimerize and are thus divided into two 
distinct classes.  Class I proteins are capable of detecting environmental stimuli but must 
dimerize with a Class II protein in order to adopt an active, DNA binding form.  While 
Class I proteins are incapable of homodimerization or dimerization with another Class I 
member, Class II bHLH-PAS proteins are far more promiscuous and confined to the 
nuclear compartment where they serve as master regulators capable of homo or 
heterodimerization.  Some examples of Class I proteins include HIF1 and HIF2α 
(hypoxia inducible factors); regulators of the cellular response to hypoxia, (Tian et al., 
1997; Wang et al., 1995; Wang and Semenza, 1995) SIM 1 and 2 (single minded 
proteins); involved in neurogenesis and mid-line development, (Ema et al., 1996; Probst 
et al., 1997) the circadian rhythm protein, Clock, (Gekakis et al., 1998; King et al., 1997) 
and the AHR (aryl hydrocarbon receptor); involved in xenobiotic metabolism.  Class II 
receptors include ARNT and ARNT2 (aryl hydrocarbon receptor translocator proteins), 
BMAL1 and 2 (brain and muscle ARNT-like proteins), and Per.  Figure 1.1 shows the 
domain structures of representative bHLH-PAS proteins. Of all the bHLH-PAS proteins, 
AHR and ARNT remain the best characterized members. 
 Unlike the Class I AHR which only binds ARNT, ARNT exhibits promiscuity by 
dimerizing with AHR, hypoxia inducible factors HIF1α and HIF2α, and Single mined 
5 
 
proteins Sim1 and Sim2 (Furness et al., 2007; Kewley et al., 2004).  ARNT -/- mice die 
in utero at gestational day (GD) 10.5 due to a failure of the placenta to vascularize.  Other 
defects observed include forebrain hypoplasia, placental hemorrhaging, visceral arch and 
neural tube abnormalities, and delayed rotation of the embryo (Kozak et al., 1997).  
Phenotypically similar to HIF1α knockout mice, (Ke and Costa, 2006) these findings 
implicate ARNT as a compulsory, HIF associated, developmental transcription factor.  
 ARNT2 is a close structural homolog of ARNT, bearing 57% sequence similarity 
in the mouse with divergence primarily within the COOH-terminus (Hirose et al., 1996). 
Furthermore, unlike the ubiquitously expressed ARNT, ARNT2 is expressed primarily in 
the CNS and kidneys in mice (Jain et al., 1998).  ARNT2 -/- mice perish perinatally 
bearing a phenotypic resemblance to SIM-1 knock-out mice suggesting that ARNT2 may 
be the heterodimerization partner of SIM-1 required for neurogenesis.  Data also supports 
the hypothesis that ARNT or ARNT2 may have overlapping function prior to embryonic 
day (ED) 8.5.  While ARNT2 can form dimers with AHR and HIF1α, its primary 
function appears to be as a pairing partner for SIM  (Jain et al., 1998).  
AHR Ligands 
 Unlike the Class II ARNTs which primarily serve as dimerization partners for the 
Class I bHLH-PAS proteins, the AHR serves as a “sensor” of environmental cues; 
therefore ligand activation must ensue to initiate the pathway.  Ligand binds the AHR in 
the form of a structurally diverse array of chemicals both natural and synthetic in nature 
which are capable of activating the receptor subsequently leading to the regulation of a 
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Figure 1.1.  Comparison of bHLH-PAS Protein Structures 
 
AHR
ARNT
ARNT2
HIF1α
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BMAL1
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Fig. 1.1.  Comparison of bHLH-PAS Protein Structures.  Schematic overview of the 
domain structure of representative bHLH-PAS proteins.  The domains are indicated. b: 
Basic region, HLH: Helix-loop helix domain, PAS A and PAS B: Per-ARNT-Sim motifs, 
TAD: Transactivation domain.  The scale at the bottom represents number of amino acids.   
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battery of genes.  Representative AHR ligands are shown in Figure 1.2.  The most well 
characterized AHR ligands are the polycyclic aromatic hydrocarbons (PAHs) such as 
benzo[a]pyrene and 3-methylcholanthrene and the halogenated aromatic hydrocarbons 
(HAHs) represented by dibenzo-p-dioxins, biphenyls, and dibenzofurans. Environmental 
pollutants, exposure to these chemicals contributes to a broad spectrum of toxic and 
biological effects.   
 PAHs typically exist as the product of combustion and can lead to cancers due to 
the generation of ROS (reactive oxygen species) resulting from the metabolism of the 
insulting compound and consequent DNA and protein adduct formation and cellular 
damage (Gelboin, 1980).  While HAHs also lead to toxicological responses in mice 
which include wasting syndrome, thymic involution, tumor promotion, teratogenicity, 
immunosuppression, reduced fertility, epidermal hyper and metaplasia, and death, 
(Poland and Knutson, 1982; Safe, 1990) unlike PAHs, the molecular mechanism behind 
these effects are not understood but most, if not all, of these responses rely on the AHR.  
The most potent known agonist of AHR is 2,3,7,8-tetrachlorodibenzo-p-dioxin, (dioxin, 
TCDD), which has an affinity for the receptor in the pM range versus PAHs which 
exhibit binding affinities in the nM to μM range.  The toxic effects of TCDD are thought 
to stem from the regulation of genes targeted by the activated AHR as opposed to direct 
genotoxicity of the compound or its metabolic by-products. Interestingly, the severity of 
the response to TCDD depends on multiple factors including the type of cell, sex, age, 
and species exposed supporting a gene regulatory mechanism of toxicity over that of 
direct cellular damage.   
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 To date, no endogenous AHR ligand has been identified however a number of 
naturally occurring, non-anthropogenic chemicals have been shown to bind the AHR and 
induce target genes, albeit much more weakly than TCDD.  A variety of dietary plant 
derivatives consisting largely of flavonoids have been identified as weak AHR 
agonists/antagonists and may explain an evolutionary purpose for the AHR as an 
activator of xenobiotic metabolism enzymes (Denison and Nagy, 2003).  The activation 
of AHR in the absence of exogenous ligand as well as numerous developmental defects 
in AHR null mice suggest that an endogenous, unidentified AHR ligand likely exists and 
may possibly be in the form of an indole, tetrapyrole, or an amino acid metabolite 
(Denison and Nagy, 2003).  While natural or endogenous AHR ligands have yet to be 
confirmed, in regard to the elucidation of the molecular mechanisms behind AHR 
signaling and the impact on human health, activation by the classical PAHs and HAHs 
are relevant.  The precise risk to human health is still unknown but TCDD was upgraded 
to a Group 1 “human carcinogen” in 1997 by the International Agency for Research on 
Cancer and remains the prototypical AHR ligand. 
AHR-mediated Signaling 
 Ligand binding to the AHR is thought to be supported by the fact that the latent 
AHR exists as a complex with several other proteins consisting of the 90kD heat shock 
protein, Hsp90, the 23kD p23, and the Hepatitis B virus X-associated protein 2, XAP2 
(Carver et al., 1998; Denis et al., 1988; Kazlauskas et al., 1999; Ma and Whitlock, 1997; 
Meyer et al., 1998; Perdew, 1988).  Immunoprecipitation experiments from two 
independent laboratories first identified interactions between AHR and a dimer of the  
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FIGURE 1.2.  Common AHR Ligands 
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Fig. 1.2.  Common AHR ligands.  Chemical structures of representative AHR 
ligands and inducers.  Classical halogenated aromatic hydrocarbons are shown at the 
top.  Classical polycyclic aromatic hydrocarbons are shown in the middle.  Naturally 
occurring dietary AHR ligands are shown at the bottom. 
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molecular chaperone, Hsp90  (Denis, 1988; Perdew, 1988).  The role of Hsp90 is thought 
to be one in which it stabilizes the AHR in a conformation susceptible to ligand binding  
to the PAS domain of AHR (Antonsson et al., 1995; Carver et al., 1994; Coumailleau et 
al., 1995; Denis, 1988; Perdew, 1988; Pongratz et al., 1992) and to repress dimerization 
with ARNT and DNA binding in the absence of ligand and an additional unidentified 
event (Heid et al., 2000; McGuire et al., 1994; Pongratz et al., 1992).  Indeed, it has been 
established that liganded AHR enters the nucleus along with Hsp90 but dimerization with 
ARNT and DNA binding require dissociation from the heat shock protein (Heid et al., 
2000). 
 In addition to Hsp90, the latent AHR is also complexed with a molecule of the 
FKBP52 immunophilin-like, Hepatitis B virus X-associated protein (XAP2, Ara9, AIP1) 
(Carver and Bradfield, 1997; Ma and Whitlock, 1997).  Originally it was ascertained that 
XAP2 maintained the cytoplasmic localization of AHR,  thus enhancing its ability to be 
activated by ligand (Bell and Poland, 2000; Berg and Pongratz, 2002; Carver et al., 1998; 
Kazlauskas et al., 2000; LaPres et al., 2000; Ma and Whitlock, 1997; Meyer and Perdew, 
1999; Meyer et al., 2000; Petrulis et al., 2003) however, recent studies have shown that 
these observations may be specific to the Ahb-1 allele and that other species do not exhibit 
association with XAP2 to the level observed with the b-1 receptor nor does XAP2 
maintain a cytoplasmic localization, but instead merely inhibits nucleocytoplasmic 
shuttling by interfering with the association of nuclear import receptors (Pollenz and 
Dougherty, 2005; Pollenz et al., 2006).  The lack of necessity for XAP2 in AHR 
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signaling is supported by the fact that AHR exhibits normal functioning in 
Saccharomyces cerevisiae which does not possess a homolog of XAP2 (Gu et al., 2000). 
 The third protein known to exist in the heterotetrameric latent AHR complex is 
p23 which is known to interact with Hsp90 in other systems (Chadli et al., 2000; Grenert 
et al., 1997; Sullivan et al., 1997).  Studies involving the yeast homologs of Hsp90 and 
p23, Hsp82 and Sba1 respectively, suggest that p23 blocks the ATPase activity of Hsp90, 
stabilizing the Hsp90-AHR interaction (Cox and Miller, 2004).  Earlier studies confirmed 
this role for p23 when loss the protein from the AHR-Hsp90 complex resulted in ligand-
independent interaction between AHR and ARNT.  The addition of molybdate, a 
chemical known to stabilize p23-Hsp90 interactions, restored normal function suggesting 
that a role of p23 is to stabilize the Hsp90-AHR latent complex (Kazlauskas et al., 1999). 
The association of p23 with Hsp90 along with the observation that the AHR may 
associate with p60 and Hip indicates that the latent AHR complex may be similar to that 
seen in other steroid hormones (Nair et al., 1996). 
 The proposed model for AHR signaling then follows that a small, hydrophobic 
ligand, typified by TCDD, passes through the plasma membrane where it binds to the 
latent AHR complex within the PAS domain of AHR between amino acids 232-334 
(Burbach et al., 1992).  The binding of ligand is supported by the folding of the AHR 
PAS domain into a favorable lignd binding conformation due to its association with 
Hsp90 (Gu et al., 2000).  Binding of ligand presumably causes a conformational change 
both displacing p23 and allowing for the nuclear translocation of the complex.  Within 
the nucleus, it is suspected that AHR, due in part to the displacement of p23 by ligand, 
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can form a dimer with ARNT, possibly after phosphorylation of ARNT (Chen and 
Tukey, 1996; Long et al., 1998).  AHR-ARNT dimerization leads to the dissociation of 
the molecular chaperone proteins and the formation of an active, DNA binding complex.  
The activated AHR-ARNT recognizes cognate enhancer sequences termed xenobiotic 
response elements (XREs) located within the regulatory region of target genes.  The XRE 
core consensus sequence is defined as: 5’-(T/G)NGCGTG-3’ whereby the basic region of 
ARNT binds to 5’-GTG and the AHR basic region binds the remaining nucleotides 
(Bacsi et al., 1995; Denison et al., 1988; Fisher et al., 1990; Hapgood et al., 1989; Lusska 
et al., 1993; Swanson et al., 1995) and the specificity of binding may be controlled, in 
part, by the PAS domain of AHR (Dolwick et al., 1993b).  Binding of AHR-ARNT to the 
XREs of target genes results in gene regulatory events which are largely dependent on the 
COOH-terminal TAD domains of AHR and ARNT (Jain et al., 1994; Whitelaw et al., 
1994). 
 The endpoint of ligand-mediated AHR signaling is the degradation of the AHR.  
Indeed, studies have shown that AHR is rapidly depleted in both cell culture and animals 
following TCDD exposure, (Giannone et al., 1995; Ma et al., 2000; Pollenz, 1996; 
Pollenz, 2002; Pollenz et al., 1998; Roman et al., 1998) the degradation event is 
connected to the nuclear localization of the AHR, (Song and Pollenz, 2002) and likely 
occurs via the 26S proteosome (Davarinos and Pollenz, 1999; Ma and Baldwin, 2000; 
Wentworth et al., 2004).  The mechanism by which the AHR is degraded is yet unknown 
but it is suspected that ubiqitination is involved considering most proteins targeted to the 
proteosome are ubiquitinated.  To date, no evidence of ubiquitination has been identified.   
13 
 
CYP1A1 Regulation 
A member of the P450 family of cytochromes, the aryl hydrocarbon hydroxylase or 
Cytochrome P1-450 1A1 (CYP1A1) is the most well characterized target of ligand- 
activated AHR and has become the prototype for the study of AHR-mediated signaling.  
The product of the inducible CYP1A1 locus is a heme-thiolate monooxygenase 
responsible for the metabolism of lipophilic aromatic hydrocarbons. These xenobiotic 
metabolizing enzymes receive electrons from NADPH-P450 reductase which activates an 
oxygen capable of being inserted into a specific substrate or group of substrates.  In the 
case of CYP1A1, these substrates are planar aromatic hydrocarbons and the 
monooxygenation event of CYP1A1 opens the benzene rings of the PAH allowing for its 
subsequent metabolism.  Ligands of the AHR, PAHs then induce their own metabolism.  
Due to the toxic 2,3,7,8-chlorination of TCDD and similar HAHs, these persistent 
chemicals are poorly metabolized by xenobiotic metabolism enzymes yet induce 
transcription of XMEs via the activation of AHR nonetheless. 
 Early experiments revealed that TCDD-mediated CYP1A1 induction did not 
occur in AHR or ARNT deficient cells (Jones et al., 1986) and was a primary response 
which occurs in the absence of protein synthesis (Whitlock, 1999).  Further investigation 
demonstrated that TCDD-mediated induction of the gene was controlled by cis-regulatory 
elements contained within ~500bp of the 5’ upstream region of the gene in mice (Jones et 
al., 1985) which functioned as an enhancer up or downstream of an MMTV promoter 
regardless of orientation (Jones et al., 1986).  Several features of the enhancer were  
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subsequently characterized.  Using various truncations of the rat CYP1A1 enhancer 
region upstream of a CAT reporter gene driven by an SV-40 promoter and gel retardation 
assays, two regions composed of 15 nucleotides which were required for gene induction 
following treatment with 3-MC were isolated.  Comparisons of the two regions revealed a 
5 bp sequence, GCGTG, common between the two required regions which were 
designated “xenobiotic responsive elements” or “XREs” (Fujisawa-Sehara et al., 1987).  
Experiments with the murine CYP1A1 enhancer region expanded the protein-DNA 
interaction to a core sequence, 5’-T(A/T)GCGTG-3’.  This sequence was specifically 
recognized by AHR/ARNT heteromers but showed that binding of the 7bp core sequence 
alone by the liganded receptor was not sufficient to drive activation of the downstream 
gene; indicating that the sequence flanking the XRE core is essential for transactivation 
(Denison et al., 1988; Hapgood et al., 1989).  Subsequent studies attempting to 
characterize the role flanking nucleotides play in binding AHR/ARNT in vitro and in 
transactivating a downstream reporter produced a modified consensus: 5’-
(T/G)1YG2C3G4T5G6(A/C)7(C/G)8(A/T)9 -3’ (Lusska et al., 1993; Shen and Whitlock, 
1992; Swanson et al., 1995).  Indeed, Shen and Whitlock showed that either a C at 
position 1, G at position 7, A at position 8, or G at position 9 abolished XRE function in 
CAT reporters (Shen and Whitlock, 1992).  These observations are in agreement with 
studies done by Swanson et al (Swanson et al., 1995).  Significantly, experiments which 
placed tandem repeats of an XRE upstream of an SV-40 controlled CAT gene showed a 
4-fold increase in both induced and constitutive CAT activity in constructs containing 
two XREs versus a single XRE (Fujisawa-Sehara et al., 1987).  It is also of importance 
that either linker scanning mutants, whereby the core XRE was replaced with unrelated 
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DNA of the same length, or truncations of the enhancer revealed that the elimination of 
any one of four mouse XREs resulted in a 25% decrease in TCDD induced activity.  
Removal of all four XREs eliminated responsiveness to TCDD (Fisher et al., 1990). 
Additionally, another important component of the CYP1A1 enhancer, a GC-box was 
identified between -952 and -943 upstream of the mouse CYP1A1 transcriptional start 
site which was capable of being bound in vitro by Sp1 (or a related factor) and when 
removed, produced a 5-fold decrease in reporter activity. Interestingly, this site is 
incapable of function in the absence of bound XREs (Fisher et al., 1990). 
 The enhancer region defined above is non-functional unless linked to a functional 
transcriptional promoter (Jones et al., 1986; Neuhold et al., 1989).  Likewise, the murine 
CYP1A1 promoter contains several regulatory elements which fail to function in the 
absence of the enhancer.  A TATAAA box is located at position -30 upstream of the 
transcriptional start site, a proximal and a distal CTF/NF1 site are located at positions -59 
and -136 respectively, and a G-box is located at position -130 (Jones and Whitlock, 
1990). The TATAAA box is an essential component of the CYP1A1 promoter as 
mutation of this sequence reduces gene activation by >80%. The distal CTF/NF1 site and 
the G-box appear to bind a functionally equivalent protein as elimination of either one 
has no effect on gene activity; however, when both are eliminated a 50% reduction in 
inducible activity is observed.  Furthermore, footprinting experiments reveal that 
mutation of the G-box shifts protection at that site toward the distal CTF/NF1 site (Jones 
and Whitlock, 1990).  The proximal CTF/NF1 site (identified by others as a BTE site in 
the rat CYP1A1 promoter) also contributes significantly to promoter function (Jones and 
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Whitlock, 1990; Yanagida et al., 1990).  A number of proteins have been shown capable 
of binding this sequence including Sp1, Gut-enriched Kruppel-like factor (GKLF), and 
BTEB1, 3, and 4 (Imataka et al. 1992, Sogawa et al. 1993, Zhang et al. 1998, Shields et 
al. 1998, Kaczynski et al. 2001, Kaczynski et al. 2002).  While Sp1 binding leads to 
enhanced activation of the gene, (Yanagida et al. 1990, Kobayashi et al. 1996) GKLF and 
BTEB1, 3, and 4 binding leads to transcriptional repression of CYP1A1 (Imataka et al., 
1992; Kaczynski et al., 2002; Sogawa et al., 1993; Zhang et al., 1998b).  Kaczynski et al. 
have proposed a model whereby the constitutively expressed BTEB proteins repress 
CYP1A1 activity by competing with Sp1 at the BTE site but this model has yet to be 
confirmed. 
 In the absence of ligand, the CYP1A1 enhancer/promoter is inactive and assumes 
a nucleosomal configuration (Wu and Whitlock, 1992; Wu and Whitlock, 1993).  Studies 
using DNaseI protection and LMPCR have revealed that binding of AHR/ARNT 
heteromers at the XREs within the CYP1A1 enhancer results in a disruption of chromatin 
structure localized to approximately 180bp surrounding the XRE, followed by the loss of 
the nucleosome at the promoter.  The relaxation of the nucleosomal promoter allows the 
binding of TBP, NF1, and general transcription factors initiating transcription (Ko et al., 
1997; Morgan and Whitlock, 1992; Okino and Whitlock, 1995).  As hundreds of base 
pairs remain in a nucleosomal configuration between the XRE containing enhancer and 
the promoter, the possibility of direct communication between the two regions is 
unlikely.   Additional studies determined that the loss of the nucleosome at the promoter 
was the result of communication via the TAD of AHR bound at the enhancer (Ko et al., 
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1996; Ko et al., 1997).  Interestingly, the TAD containing C-terminus of AHR appears to 
have no effect on the nucleosomal re-arrangement of the enhancer implying that its effect 
on the promoter involves the recruitment or binding to other factors involved in 
stabilizing the promoter chromatin (Ko et al., 1996).  A likely model is one in which 
AHR/ARNT binds at the enhancer and associates with a complex of other proteins 
involved in both chromatin remodeling and stabilization of the general transcription 
factors at the promoter. 
 A number of other proteins have been implicated in the regulation of CYP1A1 
which may act to either remodel chromatin or stabilize the transcriptional machinery at 
the promoter.  It has previously been established that Sp1 interacts in vivo with the HLH-
PAS domain of AHR/ARNT via its zinc finger domain (Kobayashi et al., 1996). 
Interaction between these two proteins lends to a potential model in which a DNA loop is 
formed by binding of Sp1 at the promoter to AHR/ARNT heteromer at the enhancer.  
Furthermore, AHR or ARNT have been shown to interact in vitro with the general 
transcription factors TFIIB, IIF, and TBP (Rowlands et al., 1996; Swanson and Yang, 
1998) supporting the role of AHR/ARNT in stabilizing the general transcription complex. 
 Other observed interactions include the HAT co-activator, CBP, interacting at the 
transactivation domain of ARNT (Kobayashi et al., 1997) and RIP-140, retinoblastoma 
protein (Rb), Nedd8, and promyelocytic leukemia nuclear bodies (PML) interacting with 
AHR (Fujii-Kuriyama and Mimura, 2005; Hankinson, 2005), all of which have been 
shown to enhance reporter gene expression.  Recent studies have also demonstrated the 
involvement of the p-160 HAT coactivators, SRC-1 (NCoA-1), NCoA-2 (GRIP-1, TIF-
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2), and p/CIP (AIB, ACTR) in mediating TCDD-dependent CYP1A1 expression.  ChIP 
assays and real time PCR reveal that all three proteins associate with the CYP1A1 
enhancer region in vivo within 15 minutes of TCDD treatment, while antibodies specific 
to each reduce XRE-driven expression of reporter genes (Beischlag et al., 2002; Fujii-
Kuriyama and Mimura, 2005; Hankinson, 2005; Hestermann and Brown, 2003; Kumar 
and Perdew, 1999).  Overexpression of the coactivators enhances reporter gene activity 
and shows that all three are capable of interacting with AHR while SRC-1 and NCoA-2 
interact with ARNT (Beischlag et al., 2002).  Further studies need to be performed to 
elucidate the precise roles the p-160 family of receptors play in AHR-dependent 
signaling. 
 Brahma/SW12-related Gene 1 Protein (Brg-1) is the ATPase subunit of certain 
ATP-dependent chromatin remodeling complexes and has been shown to associate with 
the TAD of AHR (Wang and Hankinson, 2002).  Overexpression of exogenous Brg-1 
enhanced expression of XRE–driven reporters in Hepa-1 cells and restored endogenous 
CYP1A1 activity in Brg-1 deficient cells when co-expressed with SRC-1 while an ATP-
ase deficient Brg-1 mutant failed to do so.  Finally, ChIP analysis demonstrated that Brg-
1 associates with the mouse CYP1A1 enhancer region in a TCDD and ARNT dependent 
manner implicating its role in AHR-mediated induction of the gene (Fujii-Kuriyama and 
Mimura, 2005; Hankinson, 2005; Wang and Hankinson, 2002). 
 The TRAP/DRIP/ARC mediator complex has also been shown to be involved in 
AHR-mediated regulation of CYP1A1.  ChIP analyses show that two sub-units of the 
mediator complex, Med220 and CDK8 associate with the murine CYP1A1 enhancer 
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shortly after binding of AHR/ARNT and p/CIP (10-30 min).  RNAi experiments revealed 
that depletion of endogenous Med220 resulted in inhibition of endogenous CYP1A1 
induction following treatment with TCDD (Wang et al., 2004).  While Med220 and 
CDK8 have been shown to associate with the CYP1A1 enhancer in vivo, other subunits 
of the mediator complex have previously been shown to bind to the general 
transcriptional complex suggesting a role for mediator to bridge the enhancer and 
promoter regions of CYP1A1 (Malik and Roeder, 2000). 
 A hypothetical model for CYP1A1 regulation based on the current literature is 
shown in Figure 1.4.  Additional interactions are currently being evaluated.  Indeed, the 
estrogen receptor alpha (ERα) has recently been in the spotlight for its possible role as 
yet another cofactor. While an overwhelming battery of coactivators have been 
implicated in AHR-mediated signaling, it is important to consider that many have 
suggested roles based on over-expression of proteins to levels far exceeding what a cell 
would experience in a normal, physiological setting or in vitro interactions of artificially 
expressed proteins.  Furthermore, even as new resources such as ChIP analyses and 
quantitative real-time PCR arise as valuable tools in assessing the proteins involved 
within this pathway, these procedures are not flawless and could possibly lead to the false 
implication of elements which, in reality, are not involved.  Care must be taken in the 
analysis of future studies to avoid this.  Even as a large number of factors are currently 
suggested to regulate TCDD-mediated gene induction, it is probable that more will arise. 
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Figure 1. 4.  Model of CYP1A1 Regulation by AHR 
 
 
 
 
 
 
 
 
 
Fig. 1.4.  Model of CYP1A1 Regulation by AHR.  Hypothetical schematic overview of 
AHR-mediated transcriptional regulation of CYP1A1.  Numbers indicate proposed events 
chronologically.  Transcription factors and co-activators are shown bound to DNA and 
proteins respectively.  See text and references for additional details. 
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AHR Regulated Genes 
 In addition to CYP1A1, ligand activated AHR leads to the induction of a battery 
of other genes such as Glutathione S-transferase Ya (Gst-Ya), Uridine Diphoshate-
Glucuronosyl transferase (UGT1A1), Aldehyde dehydrogenase (ALDH), Quinone  
oxidoreductase (NQO1), and additional members of the P450 family of cytochrome 
monooxygenases.  CYP1A2 and CYP1B1 are both phase I biotransformation enzymes 
known to be regulated by AHR.  CYP1B1 is expressed constitutively in extrahepatic  
tissues such as the mammary, ovary, and prostate (Shimada et al., 1996; Sutter et al., 
1994) and has been implicated in the bioactivation of benzo[a]pyrene and other 
procarcinogens.  Importantly, CYP1B1 has been shown to be regulated by the AHR and 
contains three XREs within a 190bp span of its promoter region (Tang et al., 1996).  
Apart from AHR-mediated inducibility and a role in PAH metabolism, CYP1B1exhibits 
more differences than similarities to CYP1A1.  CYP1B1 is largely expressed in tissues 
originating from the mesenchyme while CYP1A1 is expressed ubiquitously.  CYP1B1 is 
constitutively expressed while CYP1A1 generally shows little to no basal activity in the 
absence of liganded AHR.  Differences also exist structurally in that CYP1A1 consists of 
seven exons, like most other P450s, while CYP1B1 consists of only three exons. While 
the regulation of CYP1B1 is poorly understood, it is known that the mouse and human 
CYP1B1 promoters lack a TATA box, CTF/NF1 sites, or BTE sites as are found in the 
CYP1A1 regulatory region.  Instead, the gene is under the control of a TATA-like 
sequence located at position -27 relative to the transcriptional start site and a series of 
Sp1 sites located within the proximal promoter (Wo et al., 1997).  Intriguingly, 
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AHR/ARNT has been shown to bind at only one of the three CYP1B1 XREs while the 
other two are bound by a complex of proteins termed anomalous complex or anC (Eltom 
et al., 1999; Zhang et al., 1998a). The anC, which binds specifically due to two 
nucleotides flanking the consensus XRE sequence, likely functions to inhibit maximal 
CYP1B1 induction in the presence of high levels of activated AHR/ARNT by competing 
for binding with AHR/ARNT at the 5’ XRE.  On the contrary, anC is also likely 
responsible for the constitutive activity of Cyp1b1 by synergistically activating the XRE 
bound to AHR/ARNT in the presence of very low levels of activated AHR (Zhang et al., 
2003).  The specific proteins which make up the anomalous complex or the exact 
molecular mechanisms behind the regulation of CYP1B1 are currently unclear.  
 CYP1A2 is involved in aromatic amine metabolism and the metabolism of a 
number of drugs including caffeine and theophylline.  CYP1A2 is inducible by PAHs but 
unlike CYP1A1, is expressed constitutively and predominately in the liver.  The CYP1A2 
gene, in mammals, is on the same chromosome and orientated in a head-to-head fashion 
with CYP1A1, separated by approximately 23kb.  Two regions were identified within the 
~2.5kb upstream region of the CYP1A2 gene which are essential for 3-MC-mediated 
transcriptional activation (Quattrochi et al., 1994).  One of the identified regions, termed 
X1, contains an XRE-like sequence which weakly associates with AHR in the presence 
of 3-MC.  Elimination of this region resulted in an approximately 50% reduction in 
activity.  The second identified region, termed X2, did not associate with AHR in vitro 
but may play a role in 3-MC-mediated induction due to a putative AP1 site (Quattrochi et 
al., 1994).  Recent studies using a dual reporter vector under control of the 23kb region 
between human CYP1A1 and CYP1A2 shows that an XRE cluster near the CYP1A1 
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transcriptional start site may work bi-directionally to regulate CYP1A2 (Ueda et al., 
2006).  Further studies need to be performed to elucidate the mechanisms behind 
CYP1A2 regulation. 
 CYP2S1 was identified in 2001 as the only member of the novel, 2S, family of 
cytochrome P450s (Rivera et al., 2002; Rylander et al., 2001).  CYP2S is a member of 
the CYP2 family which like Cyp2a5 and CYP2A6, from mouse and human respectively, 
is inducible by dioxin (Gokhale et al., 1997; Rivera et al., 2002).  Expression of CYP2S 
is similar to that observed for CYP1B1, being prominent in epithelial tissues including 
skin, trachea, lung, and intestine (Rylander et al., 2001; Saarikoski et al., 2005).  CYP2S1 
also resembles CYP1B1 in that it lacks a TATA box within the promoter (Rivera et al., 
2007).  Several XREs were identified within the 5.2kb region upstream of the 
translational start codon of the mouse Cyp2s1 gene; however studies using reporter 
vectors containing combinations of mutated XREs show that TCDD-mediated induction 
is attributed only to a region containing three overlapping XREs between -393 and -408 
(Rivera et al., 2007).  AHR/ARNT was capable of binding all three of the overlapping 
XREs in a ligand dependant manner as shown by EMSA.  Each of the three XREs was 
also able to induce a reporter gene in cell culture; however simultaneous mutation of any 
two of the three trimeric XREs severely reduced TCDD responsiveness to near control 
levels as did mutation of all three (Rivera et al., 2007).  A regulatory region containing a 
series of overlapping XREs such as exhibited in CYP2S1 has not been previously 
identified.  Interestingly, the mouse region which contains the trimeric XREs also was 
found to contain three overlapping HREs of which at least one binds HIF1α/ARNT and 
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is responsive to hypoxia. (Rivera et al., 2007) The human Cyp2s1 promoter was also 
found to contain two overlapping XREs and two overlapping HREs and is responsive to 
both dioxin and hypoxia (Rivera et al., 2002).  Elucidation of the molecular mechanisms 
of CYP2S1 regulation is not only important because CYP2S1 may be partially important 
for the toxic effects of PAHs and dioxin, but additionally may help gain a better 
understanding of AHR-mediated signaling.  
 While AHR additionally regulates a number of phase II xenobiotic metabolizing 
enzymes which contain XREs within their regulatory regions, these genes also typically 
contain antioxidant response elements (ARE) which are bound by nuclear factor 
erythroid 2 p45-related factor (Nrf2), the product of another target gene of AHR (Kohle 
and Bock, 2007; Miao et al., 2005).  In addition to activation by AHR, Nrf2 can be 
activated by reactive oxygen species resulting from phase I XME metabolism of PAHs 
(Kohle and Bock, 2007; Marchand et al., 2004).  Although functional AREs and XREs 
have not been identified in the regulatory regions of all phase II genes known to be 
regulated by AHR, analysis of NQO1 in AHR (-/-) and Nrf2 (-/-) null mice showed that 
TCDD-inducible expression required both AHR and Nrf2 (Kohle and Bock, 2007; Ma et 
al., 2004).  These findings led to a model whereby phase II XMEs may be regulated 
directly by AHR binding to XREs, by coordinate binding of AHR and Nrf2, or by AREs 
being bound by Nrf2 which is itself regulated by AHR and ROS.  These mechanisms of 
cross-talk have yet to be confirmed but may be important in gaining a better 
understanding of the complexities of AHR-mediated signaling. 
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 Cyp1a1 I (-/-) and cyp1a2 (-/-) null mice have shown relatively little protection 
against the toxic effects of TCDD when compared to the extensive protection exhibited 
by Ahr (-/-) null mice (Bunger et al., 2003; Gonzalez and Fernandez-Salguero, 1998; 
Smith et al., 2001; Uno et al., 2004) suggesting that induction of these genes may play 
little role in mediating TCDD toxicity.  Microarray studies have identified numerous 
genes which are putatively regulated by AHR and have shown that the scope of genes 
may be far outside that of xenobiotic metabolizing enzymes including genes involved in 
reproduction, growth and development, cell cycle control, and differentiation (Tijet et al., 
2006; Yoon et al., 2006).  Recent advances in technology such as microarray analyses 
may help identify the genes responsible for the toxic response to dioxin, yet it is 
imperative that an understanding of the molecular mechanisms of AHR gene regulation 
be gained through the characterization of well-defined AHR targets. 
TCDD-mediated Developmental Toxicity in Zebrafish 
 In zebrafish, embryonic dioxin exposure leads to a series of fairly well 
characterized developmental defects which include disruption of erythropoiesis, altered 
regional blood flow, craniofacial malformation, impaired lower jaw development, 
apoptosis and local circulation failure in the dorsal midbrain, edema, retarded 
development, and death (Antkiewicz et al., 2005; Belair et al., 2001; Dong et al., 2002; 
Henry et al., 1997; Hill et al., 2003; Teraoka et al., 2002).  The defects associated with 
TCDD toxicity are exhibited between 48-120 hours postfertilization (hpf) with a 
reduction in the number of myocytes, reduced blood flow, and a change in the 
morphology of pronephric glomerulus being the earliest observed defects (Carney et al., 
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2006).  The reduced peripheral blood flow and reduction in the number of myocytes 
which occur at 48 hpf as well as a change in the morphology of the heart are the earliest 
onset of cardiovascular dysfunction which ensues throughout the first 120 hpf 
(Antkiewicz et al., 2005; Carney et al., 2006; Henry et al., 1997; Teraoka et al., 2002).  
The morphological changes in the zebrafish heart following TCDD exposure are 
primarily due to the blockage of the common cardinal vein from migrating dorsally 
toward the heart between 72 and 96 hpf (Antkiewicz et al., 2005; Bello et al., 2004; 
Carney et al., 2006).  Heart morphology is further affected by an aberration of the normal 
looping of the heart which occurs concurrently to defective remodeling of the common 
cardinal vein (Antkiewicz et al., 2005; Carney et al., 2006; Chen et al., 1997).  These 
events lead to a heart which is mis-positioned and has an elongated atrium and a compact 
ventricle,  although it is unclear whether these are direct effects of AHR regulation or 
secondary to a decrease in cardiac output (Antkiewicz et al., 2005; Carney et al., 2006). 
 Osmoregulatory defects are also observed in zebrafish embryos exposed to 
dioxin.  Edema is observed in the pericardium and yolk sac at 72 and 96 hpf respectively 
(Belair et al., 2001; Dong et al., 2002; Henry et al., 1997).  Given that the gills do not 
play a role in osmoregulation until after 96 hpf (Rombough, 2002) and studies have 
shown that the pronephric kidney is not affected by TCDD prior to the onset of edema, 
(Hill et al., 2004) the likely cause of edema is linked to skin permeability and/or the 
circulatory defects defined above. 
 Additional adverse effects of TCDD on zebrafish development include inhibited 
growth of the cartilage which forms the lower jaw, increased apoptosis in the dorsal 
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midbrain, a reduced brain volume, and a reduction of definitive erythrocytes (Belair et 
al., 2001; Henry et al., 1997; Teraoka et al., 2002).  The molecular mechanisms behind 
these defects are largely unknown but it is not likely that cranio-facial malformations or a 
failure of primitive erythrocytes to switch to definitive erythrocytes is secondary to 
cardiac dysfunction.  The role AHR plays in mediating these effects will be a significant 
focus for studies in years to come. 
AHR and ARNT in Fishes 
 Although polymorphisms are apparent in fish as they are in mammals, most fish 
exhibit multiple AHR genes whereas only a single gene is present in mammals.  These 
multiple products are most likely the result of gene duplication events which occurred 
throughout the course of evolutionary history (Hahn, 2002).  In zebrafish (Danio rerio) 
two known Ah receptors were isolated and designated zfAHR1 and zfAHR2 (Andreasen 
et al., 2002; Tanguay et al., 1999).  Interestingly, while the zfAHR1 is the ortholog of the 
mammalian receptors, it is the zfAHR2 which is responsible for the TCDD-mediated 
AHR activity in this species (Andreasen et al., 2002; Prasch et al., 2003).  Studies by 
Andreason et al. show that zfAHR2 is expressed relatively ubiquitously while zfAHR1 is 
limited to expression primarily in the liver (Andreasen et al., 2002).  The functional 
differences between the two receptors likely lies in the ligand binding domains and 
transactivation domains of the proteins as shown by experiments using zfAHR1/zfAHR2 
chimeras (Andreasen et al., 2002).  Like other piscine AHRs, zfAHR2 exhibits great 
similarity to mammalian AHR in the b-HLH-PAS domains but lacks the Q-rich region in 
the C-terminus essential for mammalian transactivation (Hahn, 2002; Tanguay et al., 
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1999).  Studies by Kumar et al. however, suggest that the requirement of this Glutamine 
rich region, in humans at least, may be limited to a single hydrophobic residue (Leu-678) 
indicating that abundant glutamines may not be required per se for transactivation and 
fish AHRs may possess the necessary hydrophobic residue (Kumar and Perdew, 1999).  
Furthermore, while the Q-rich domain was deemed necessary for hAHR transactivation, 
in mice the Q-rich region of the AHR enhanced the transactivation ability but was not 
required (Jain et al., 1994; Sogawa et al., 1995). 
 Only a single ARNT has been identified in most teleost fishes.  Two splice 
variants of an ARNT1 homolog have been isolated in rainbow trout (Onchorhynchus 
mykiss) and designated rtARNTa and rtARNTb (Pollenz et al., 1996).  These proteins are 
identical over the first 533 amino acids which include the b-HLH and PAS domains but 
diverge in the carboxyl end due to an additional 373 bp sequence in rtARNTb which 
causes a frame shift in the product.  While both rtARNTa and rtARNTb are capable of 
binding AHR in vitro, only rtARNTb appears able to facilitate transactivation of 
CYP1A1, likely due to the inefficiency of rtARNTa to bind DNA.  Pollenz et al. also 
showed that rtARNTa is capable of behaving as a dominant negative inhibitor of 
rtARNTb mediated gene induction; however, while rtARNTb is expressed ubiquitously, 
rtARNTa is expressed at much lower levels and restricted in its distribution (Pollenz et 
al., 1996).  Interestingly, a single ARNT was isolated from the Atlantic killifish 
(Fundulus heteroclitus) as well; however, phylogenetic analyses revealed that, unlike 
rtARNT, the protein was a homolog of mammalian ARNT2 (Powell et al., 1999).  In 
zebrafish, the three alternatively spliced ARNTs originally identified by Tanguay et al. 
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were also homologous to mammalian ARNT2 and were designated zfARNT2a, b, and c 
(Tanguay et al., 2000).  zfARNT2b was shown to bind zfAHR2 in vitro and could 
moderately induce XRE-driven reporters in COS-7 cells, yet zfARNT2 morphants and 
zfARNT2 -/- embryos still exhibited the same endpoints of TCDD toxicity observed in 
wild type fish (Prasch et al., 2004) suggesting that zfARNT2 is not the ARNT involved in 
mediating TCDD toxicity.  Three additional alternatively spliced ARNTs were 
subsequently isolated from the zebrafish and found to be homologous to the rtARNTb 
and mammalian ARNT1.  Designated zfARNT1a, b, and c, these three proteins were 
found to be expressed continuously throughout the timecourse critical for TCDD-
mediated developmental toxicity, albeit at considerably lower levels than zfARNT2.  
Furthermore, zfARNT1b and c were capable of forming dimers with zfAHR2, capable of 
binding DNA in vitro, and inducing XRE-driven reporter constructs.  Most importantly, 
zfARNT1 morphants showed protection against three of the endpoints of TCDD toxicity: 
pericardial edema, reduced blood flow, and reduced lower jaw growth (Prasch et al., 
2006).  It is important to note that there may be a species specific difference in XRE 
recognition sequences by AHR and ARNT.  Tanguay et al. reported that 
zfAHR2/rtARNTb dimers failed to bind the murine XRE containing the core sequence 5’ 
–TTGCGTG- 3’ but actively bound the rainbow trout XRE containing the sequence 5’ –
TAGCGTG- 3’ (Tanguay et al., 1999).  Upon isolation of zfARNT1, Prasch et al. showed 
binding of zfAHR2/zfARNT2b and c dimers to the same murine XRE indicated above 
(Prasch et al., 2006).  Surprisingly, mouse AHR/rtARNTb dimers bound both murine and 
rainbow trout XRE containing oligonucleotides (Tanguay et al., 1999).  Further research 
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will have to be done to elucidate the potential differences in DNA recognition between 
species. 
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Chapter Two 
 
 
Isolation of the zfCYP1A upstream region 
 
 To obtain the sequence of the zfCYP1A1 promoter/enhancer, zfCYP1A1 cDNA 
sequence was used to query the Sanger zebrafish genome database.  No sequence could 
be recovered that contained significant identity to zfCYP1A1 so a zebrafish genomic 
PAC library (Amemiya and Zon, 1999) was screened using primers specific to the 5’-
untranslated region (5’-UTR) and most 5’-region of the open reading frame (ORF) of the 
zfCYP1A1 cDNA.  Two PACs, designated #133 and #150, containing putative 
zfCYP1A1 genes were identified. Restriction enzyme digestion and Southern analysis of 
the two PACs identified identical bands that hybridized to the zfCYP1A1 cDNA probe.  
A 0.5 kb and 2.5kb HindIII fragment as well as a 12 kb SpeI fragment were subcloned 
from PAC #150 and sequenced. The 2.5 kb HindIII fragment contained the putative ATG 
start codon and the first 134 bp of coding sequence that showed 100% identity to the 
zfCYP1A1 cDNA in Genbank (accession #BC094977). The fragment also contained 14 
bp of the 5’UTR with 100% identity to the zf-CYP1A1 cDNA.  After nucleotide 14, the 
sequence showed minimal identity to zfCYP1A1 cDNA but contained a putative splice 
acceptor site at the region when identity was lost. The remaining sequence within the 2.5 
kb HindIII fragment showed no identity to the CYP1A1 cDNA and contained substantial 
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regions of repetitive DNA that were 80%–90% AT-rich. These results indicate that the 
zfCYP1A1 gene contains an intron within the 5’UTR sequence.  This is consistent with 
the structure of other CYP1A1 genes (Carvan et al., 1999; Kubota et al., 1991; Powell et 
al., 2004; Sogawa et al., 1986).  The size of the intron is estimated to be >2500 bp, but 
the entire sequence could not be obtained due to the high levels of AT-rich regions, 
numerous regions of repetitive DNA, and a lack of unique restriction sites to allow 
subcloning of smaller fragments.  Thus, to obtain the remaining 5’UTR and its 5’-
flanking region, the SpeI fragment was sequenced with an oligonucleotide 
complementary to the missing portion of the 5’UTR. This approach identified the 
remaining 74 bp of the 5’UTR and putative CAAT and TATA boxes. Subsequent 
sequence analysis identified the splice donor site for intron 1 and a putative 
promoter/enhancer that spanned a region 2629 bp upstream from the transcription start 
site.  Several elements were identified within the isolated region which are characteristic 
of previously characterized CYP1A regulatory regions.  A putative TATA box is located 
at position -31 relative to the transcriptional start site which has been designated +1.  
Additionally, two CTF/NF1 sites were identified at positions -53 and -438 and an Sp1 
site at -2474.  These sites have all been implicated in the regulation of CYP1A1 in other 
organisms (Fisher et al., 1990; Jones and Whitlock, 1990; Yanagida et al., 1990). 
Importantly, eight putative XREs were identified which conform to the consensus 
sequence: T/GNGCGTG.  These XREs were designated 1-8 with XRE1 being nearest the 
TATA box.  Thus, the results indicate that zfCYP1A promoter/enhancer  
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Figure 2.1.  Comparison of CYP1A Regulatory Regions from Different Species 
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Figure 2.1.  Comparison of CYP1A regulatory regions from different species.  
The location of XREs, indicated by rectangles, are shown in relation to the putative 
transcriptional start site.  Functional XREs are shaded.  The TATA box is represented 
by a shaded circle.  CTF/NF1 or BTE sites are indicated by triangles.  Shaded 
triangles have been previously functionally characterized.  Small shaded squares 
indicate putative HNF-3 sites.  Zf = zebrafish; rt = rainbow trout; fh = Fundulus 
heteroclitus; r = rat; m = mouse; h = human. 
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contains numerous XREs and other consensus regulatory sequences and bears an overall 
structure that is similar to the mouse, rat, and trout.  A comparison of the zebrafish region 
to other characterized CYP1A regulatory regions is shown in Figure 2.1. 
Induction of the zfCYP1A gene by TCDD 
 Since zebrafish have undergone a gene duplication event, they can contain 
multiple copies of genes as well as pseudogenes that are nonfunctional (Postlethwait et 
al., 1998; Woods et al., 2000).  Therefore it was pertinent to verify that the isolated 
zfCYP1A gene could support gene regulation and was inducible by TCDD. To address 
this question, total RNA was isolated from ZFL cells that were treated with vehicle or 
TCDD for 6 h. RT-PCR was carried out to amplify CYP1A and actin mRNA.  To confirm 
that expression was from the identified zfCYP1A promoter, the CYP1A primers were 
complementary to the 5’UTR and ORF and designed to be on either side of the first 
intron.  Thus, the expected band from the amplification of CYP1A mRNA was 217 bp 
whereas a band that was generated by amplifying genomic DNA would be >3 kb.  The 
results show that a band of 217 bp was weakly visible in the untreated ZFL but was 
dramatically elevated in the presence of TCDD. (Fig. 2.2)  Amplification of actin shows 
that the changes in the level of CYP1A are not related to differences in the level of RNA 
used in the assay. Thus, the data are consistent with previous studies that have identified 
TCDD-inducible CYP1A in zebrafish (Henry et al., 2001; Miranda et al., 1993) and 
support the hypothesis that the identified zfCYP1A gene is indeed inducible by TCDD. 
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Figure 2.2.  Induction of the zfCYP1A gene by TCDD 
 
 
 
 
 
 
 
Figure 2.2.  Induction of the zfCYP1A gene by TCDD.  A.  The location of 
the forward and reverse primers used for reverse transcriptase PCR are 
indicated with arrows and shown in relation to the zfCYP1A gene.  B.  
Triplicate samples of were exposed to 2nM TCDD (TC-6) or 0.05% DMSO 
(0) for 6 hours and total RNA was prepared.  mRNA was amplified following 
reverse transcription with PCR primers specific to β-Actin (357 bp) or 
CYP1A (217 bp).  PCR products were visualized in a 2% agarose gel 
containing ethidium bromide and exposed to UV light.  Specific markers of 
357,  323, and 200 bp are indicated.   
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While the previous experiments suggest that the identified zfCYP1A gene was 
inducible by TCDD, it was still important to show that the 5’flanking region contained 
specific regions that conferred TCDD-responsiveness. Unfortunately, due to the extreme 
AT-rich content and high level of repetitive DNA that is present between -600 and -2000, 
it was not possible to generate a construct containing the full 2600 bp of the 
promoter/enhancer. Thus, PCR was utilized to amplify the region between -580 and -187 
(containing XREs 1-3) and the region between -2608 and -2100 (containing XREs 4-8). 
These fragments were ligated in the forward and reverse orientations both upstream and 
downstream of the SV-40 promoter in the pGL3promoter vector.  TCDD mediated 
induction of luciferase activity was then evaluated in the mouse Hepa-1 cell line.  The use 
of the mouse Hepa-1 line and not the zebrafish ZFL line for these studies was based on 
the ability to grow large numbers of cells and the ability to obtain high levels of 
transfection efficiency that facilitated the analysis of the luciferase and β-galactosidase 
activities.  The results shown in Figure 2.3 reveal that the -2608 to -2100 fragment 
confers TCDD responsiveness to the SV40 promoter regardless of its location or 
orientation. However, the maximal induction (approximately 40-fold) was observed in 
the -2608/-2100Rup construct in which the 506bp zfCYP1A fragment was placed in a 
reverse orientation upstream of the SV40 promoter. In this context, the magnitude of the 
response and the overall level of induction were approximately five-fold higher than 
when the fragment was inserted in the forward orientation (-2608/-2100Fup). 
Interestingly, when the -2608 to -2100 fragment was placed downstream of the SV40 
promoter in either the forward or reverse orientation (-2608/-2100Fdown and -2608/-
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2100Rdown), it was also capable of inducing significant levels of luciferase activity in a 
TCDD-dependent manner. However, in this context, the orientation of the zfCYP1A 
fragment made no difference in the overall level of the response although the magnitude 
of the response was 5-fold less than that observed for the -2608/-2100Rup. 
In contrast to the results with the -2608 to-2100 fragment, the constructs 
containing the proximal region between -580 to -187 (-580/-187Fup and -580/-
187Fdown) did not exhibit elevations in luciferase activity in the presence of TCDD. 
Even when placed in the reverse orientation, the proximal fragment failed to confer 
TCDD-responsiveness to the reporter gene construct (Fig. 2.3).  This finding is intriguing 
since the region between -580 to -187 contains three putative XREs.  It was important 
then to assess the function of XREs 1-3 in the context of their native promoter.  PCR was 
used to amplify the region between -580 and +71 and the resulting fragment was ligated 
into pGL3Basic to generate the -580/+71Basic construct.  This construct was transfected 
into Hepa-1 cells and treated with TCDD.  The results in Figure 2.4A show that -580/+71 
exhibits high levels of constitutive activity which is approximately 35-fold higher than 
naked vector however failed to convey TCDD-mediated induction.  These results confirm 
the observations made on the -580/+71Fup and -580/+71Fdown constructs and 
additionally validates the function of this region as a functional promoter.  As a positive 
control, Hepa-1 cells were transfected with p-1897Om1A3luc that contains the full length 
trout CYP1A3 promoter/enhancer. This construct was induced approximately threefold in 
the Hepa-1 line. To determine whether the lack of TCDD-responsiveness by the -
580/+71Basic construct was related to the analysis in a murine background, the construct  
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Figure 2.3.  Analysis of the Effect of Orientation and Position on TCDD-induced 
Luciferase Activity 
 
 
 
 
 
 
 
Figure 2.3.  Analysis of the effect of orientation and position on TCDD-induced 
Luciferase activity.  The indicated reporter constructs as well as pSV-β-galactosidase 
were transfected into  Hepa-1 cells and treated with either 2nM TCDD or 0.05% 
DMSO for seven hours.  Luciferase activity was measured with a Turner Instruments 
luminometer.  β-Galactosidase levels were measured by spectrophotometry (OD420).   
Normalization was carried out by dividing the relative luciferase levels for each 
sample by the corresponding level of β-galactosidase .  White bars represent DMSO 
treated cells while black bars indicate cells treated with TCDD.  Bars represent the 
mean ± SE of three independent samples.  * indicates statistically significant from 
vehicle treated controls.  P<0.001 
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was transfected into the zebrafish liver cell line, ZFL. This line contains zfAHR2 and is 
responsive to AHR ligands (Miranda et al., 1993; Woods et al., 2000).  The results show 
that that -1897Om1A3luc is responsive to TCDD in the ZFL cells and was induced 
approximately threefold (Fig. 2.4B) as was observed in Hepa-1 cells, (Fig. 2.4A) whereas 
-580/+71Basic exhibits elevated activity well above the parental vector, but is still not 
responsive to TCDD. Thus, these studies show that the region of the zfCYP1A gene 
containing defined TATA and CAAT boxes (-580 to +71) can function to promote gene 
expression in both mouse and zebrafish backgrounds.  The region which confers TCDD 
responsiveness, however, appears to be located between -2100 and -2608. 
 In order to determine whether or not the zebrafish CYP1A enhancer region was 
able to convey a similar TCDD-responsiveness to the endogenous zfCYP1A promoter as 
was observed with the SV-40 promoter of the pGL3promoter vector, the -2100/-2608 
region was ligated in either the forward or reverse orientation upstream of the -580/+71 
region and transfected into Hepa-1 cells.  These constructs were designated p-2608/-
2100Uf or p-2608/-2100Ur, respectively.  Interestingly, the results show that while the 
region driving the SV-40 promoter exhibited an approximately threefold greater 
induction in the reverse versus the forward orientation, (Fig. 2.3) in the context of the 
native promoter the difference was markedly less yielding approximately 18-fold 
induction in the forward orientation and 22-fold induction in the reverse orientation. (Fig. 
2.5)  Despite this difference, the results show that the -2100/-2608 portion of the 
zfCYP1A regulatory region is capable of conveying TCDD-mediated induction to its 
endogenous promoter.  As positive controls, the mouse CYP1A1 regulatory region  
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Figure 2.4.  Luciferase Reporter Analysis of the Ability of the region between -580 
and +71 to Function as a Promoter 
 
 
 
 
 
 
Figure 2.4.  Luciferase reporter analysis of the ability of the region between -580 
and +71 to function as a promoter.  The indicated reporter constructs as well as 
pSV-β-galactosidase were transfected into Hepa-1 cells (A) or ZFL cells (B) and 
treated with 2nM TCDD or 0.05% DMSO for 7 hours.  Luciferase activity was 
measured with a Turner Instruments luminometer.  β-Galactosidase levels were 
measured by spectrophotometry (OD420).   Normalization was carried out by 
dividing the relative luciferase levels for each sample by the corresponding level of β-
galactosidase .  White bars represent DMSO treated cells while black bars indicate 
cells treated with TCDD.  Bars represent the mean ± SE of three independent 
samples.  * indicates statistically significant from vehicle treated controls.  P<0.001 
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between -1315 and -819 and the rainbow trout CYP1A3 regulatory region between -1897 
and -1392 which have been previously shown to exhibit TCDD-responsiveness, 
(Carvan et al., 1999; Jones et al., 1986) were ligated upstream of the zf-580/+71 region 
and transfected into Hepa-1 cells.  While these constructs respectively yielded 
approximately ten and threefold levels of induction, the magnitude of the response by the 
zf-2100/-2608 region was far greater indicating that zfCYP1A is highly responsive to 
TCDD in Hepa-1 cells.     
In vitro analyses of AHR/ARNT association with zfXREs 
Since the fragments containing XREs 1-3 did not confer TCDD-responsiveness, it was of 
interest to determine whether they represented bona-fide regions that actually bound to 
AHR/ARNT complexes. To carry out these studies it was first important to establish the 
conditions for the detection of zfAHR2/ARNT complexes in vitro. Previous studies 
carried out in COS-1 cells have shown that the zfAHR2 can drive reporter gene 
expression in the presence of zfARNT2b. (Abnet et al., 1999; Tanguay et al., 2000) 
However, recent studies have challenged these findings by showing that zfARNT2b does 
not support TCDD-mediated responses in vivo (Prasch et al., 2004; Prasch et al., 2003). 
Thus, studies were carried out using rtARNTb and zfARNT2b since rtARNTb has been 
shown to form a functional dimer with mAHR in vitro (Necela and Pollenz, 1999; Necela 
and Pollenz, 2001; Pollenz et al., 1996).  For these studies, zfAHR2, zfARNT2b, and 
rtARNTb were synthesized in reticulocyte lysates, incubated with TCDD, and analyzed 
by electrophoretic mobility shift assays (EMSA). The results shown in Figure 2.6 reveal 
that complexes containing zfAHR2 and rtARNT2b produce a specific shift that is 
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Figure 2.5.  Analysis of TCDD-mediated Induction from Reporter Constructs 
Containing the zfCYP1A Promoter Region Between -580 and +71 and CYP1A 
Enhancer Regions from Different Species 
 
Fig. 2.5.  Analysis of TCDD-
mediated Induction from 
Reporter Constructs 
Containing the zfCYP1A 
Promoter Region Between -
580 and +71 and CYP1A 
Enhancer Regions from 
Different Species.  A.  The 
indicated reporter constructs as 
well as pSV-β-galactosidase 
were transfected into Hepa-1 
cells and treated with 2nM 
TCDD or 0.05% DMSO for 7 
hours.  Luciferase activity was 
measured with a Turner 
Instruments luminometer.  β-
Galactosidase levels were 
measured by 
spectrophotometry (OD420).   
Normalization was carried out 
by dividing the relative 
luciferase levels for each 
sample by the corresponding 
level of β-galactosidase .  
White bars represent DMSO 
treated cells while black bars 
indicate cells treated with 
TCDD.  B. Fold induction was 
determined by dividing nRLU 
of vehicle treated cells by 
dioxin treated cells.  Bars 
represent the mean ± SE of 
three independent samples. 
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TCDD dependent and can be competed with antibodies specific to the zfAHR2 protein. 
In contrast, no shift was detected in the samples activated with zfAHR2 and zfARNT2b. 
These results are consistent with the hypothesis that TCDD-mediated signaling does not 
utilize ARNT2 proteins, but occurs through dimers with AHR and ARNT1 proteins 
(Prasch et al., 2004; Prasch et al., 2003).  
 To assess the functionality of the XREs present in the zfCYP1A promoter, duplex 
oligonucleotides were prepared that contained the core XRE as well as 6–7 nucleotides of 
flanking sequence. Each XRE was then evaluated for binding to zfAHR2/rtARNTb 
complexes by EMSA (Fig. 2.7).  The results show that only five of the eight XREs 
associate with zfAHR2/rtARNTb dimers in a TCDD-dependent manner. XRE3, XRE7, 
and XRE8 showed the most intense shifts, while XRE1 and XRE 4 associated with 
AHR/ARNT dimers in a TCDD-dependent manner, but showed slightly less intensity. 
Since all XREs were labeled to the same specific activity, the reduced intensity of the 
shifted bands likely represents a reduced level of affinity between the AHR/ARNT dimer 
and the XRE.  XRE2 and XRE6 showed no detectable shifts, while XRE5 showed a very 
weak shift after prolonged exposure of the film (data not shown). Identical results were 
obtained when the zfXREs were evaluated in the presence of mouse AHR/ARNT 
complexes. To verify that the lack of binding by XRE2, XRE5, and XRE6 was not due to 
the use of zfAHR2 and rtARNTb, studies were repeated using zfAHR2 and zfARNT2b. 
However, the use of zfAHR2/zfARNT2b heterodimers also failed to produce a detectable 
shift (data not shown). Thus, these results show that only a subset of the XREs are  
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Figure 2.6.  In vitro Analysis of the Association of zfAHR2 with XREs 
 
 
 
 
 
 
Fig. 2.6.  In vitro analysis of the association of zfAHR2 with XREs.  A.  The indicated 
proteins were expressed in vitro, resolved by SDS-PAGE, and blotted to nitrocellulose.  
Blots were stained with zf-4 IgG (1.0 μg/mL), rt-84 IgG (1.0 μg/mL), or anti-ARNT2 
antibodies (1:250) followed by GAR-HRP or RAG-HRP IgG (1:10,000).  Reactivity was 
visualized by ECL.  B. Equal amounts of zfAHR2 were mixed with equal amounts of 
either zfARNT2b or rtARNTb and incubated with TCDD (16 nM) or DMSO (1.0%) for 2 
h at 30°C. Samples were mixed with [32]P-labeled mXRE in the presence or absence of the 
indicated antibodies and resolved on 5% acrylamide/0.5% TBE gels, dried, and exposed 
to film. 
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Figure 2.7.  Association of zfAHR2 and rtARNTb with zfXREs 
       
   
 
                                                                                                                                                        
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7.  Association of zfAHR2 and rtARNTb with zfXRES.  Equal amounts of 
zfAHR2 were mixed with equal amounts of rtARNTb and incubated with TCDD (16 
nM) or DMSO (1.0%) for 2 h at 30°C. Samples were mixed with the indicated [32]P-
labeled zfXREs and resolved on 5% acrylamide/0.5% TBE gels, dried, and exposed 
to film. 
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functional in binding to AHR/ARNT in vitro and that there are slight differences in their 
affinities for AHR/ARNT dimers. In addition, the results suggest that the inability for the 
-580 to -187 fragment to respond to TCDD in the reporter gene studies is not due to the 
inability of the XREs to associate with AHR/ARNT complexes. 
Functional characterization of individual XREs within the zfCYP1A regulatory 
region 
 Due to the 1.7kb AT-rich region which separates the proximal (-580 to +71) and 
distal (-2100 to -2608) cluster of XREs in the zfCYP1A regulatory region, PCR and 
PCR-dependant site directed mutagenesis could not be performed to amplify the 
complete 2.7kb fragment.  Thus, the previous characterization of the zfCYP1A regulatory 
region utilized constructs containing only the regions between -2100 to -2608 and -580 to 
+71.  Before site directed mutagenesis could be employed on the p-2608/-2100Ur 
construct in order to determine the functionality of individual XREs, it was imperative to 
determine whether its ability to drive a luciferase reporter was representative of the full 
length promoter/enhancer.  Thus, a full-length construct was generated by cutting the 
zfCYP1A promoter/enhancer region from the original PAC clone and ligating it into 
pGL3.  The full-length p-2699/+71 and p-2608/−2100Ur constructs were then transfected 
into Hepa-1 cells and the level of TCDD-induced luciferase activity quantified. It can be 
observed in Figure 2.8 that the full-length p-2699/+71 was highly inducible by TCDD 
and averaged approximately 20-fold induction over control treated cells. This is 
consistent with the p-2608/−2100r construct that averaged approximately 32-fold 
induction.  The p-2699/+71 construct did exhibit reduced levels of total RLU in both 
48 
 
control and TCDD exposed cells by comparison to the p-2608/−2100Ur construct, but the 
difference between the two constructs may have been due in part to a significantly higher 
level of transfection efficiency for p-2608/−2100Ur than the larger, AT-rich p-2699/+71. 
Therefore, these studies indicate that both the p-2608/−2100Ur and the p-2699/+71 
construct are highly responsive to TCDD exposure and validate the use of p-
2608/−2100Ur for the analysis of the regulation of the zfCYP1A gene.                                                   
Previous experiments have shown that the region between -580 and +71 which 
contains XREs 1-3 is incapable of conveying TCDD-mediated gene induction (Fig. 2.4) 
even though XRE1 and XRE3 are able to bind AHR/ARNT in vitro in a TCDD-
dependant manner (Fig. 2.7).  To determine whether XRE1 and XRE3 contribute to 
maximal induction by acting in concert with XREs in the distal cluster, in vitro 
mutagenesis was employed on p-2608/-2100Ur in order to render XREs 1 and 3 non-
functional, alone or in combination.  The mutants, designated p-2608/-2100Ur(-1), p-
2608/-2100Ur(-3), or p-2608/-2100Ur(-1-3), or the non-mutated control were transfected 
into Hepa-1 cells and assayed for luciferase activity.  The results seen in Figure 2.9 
indicate that the loss of XRE1 or XRE3 does not significantly affect the overall levels of 
maximum gene induction by TCDD.  Considering the fact that these XREs are capable of 
binding AHR/ARNT in vitro, it is intriguing that XRE1 and 3 do not play an apparent 
role in the regulation of the downstream gene.  It should be noted that the distance of the 
elements from the transcriptional start site is likely not the reason behind the functionality 
of these XREs, as they failed to drive an SV-40 promoter when placed within the same 
position as the functional, distal region of XREs.  While it is possible that activated  
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Figure 2.8.  Comparison of TCDD-induced Luciferase Activity Between the             
p-2699/+71 and p-2608/-2100Ur Constructs 
  
 
     
 
 
 
 
Figure 2.8.  Comparison of TCDD-induced Luciferase activity between the 
p-2699/+71 and p-2608Ur constructs.  Hepa-1 cells were transfected with 
either p-2699/+71 or p-2608/−2100Ur and treated with TCDD (2 nM) or 
DMSO (0.05%) for 15 h. Luciferase activity was measured using a Turner 
Instruments luminometer and β-galactosidase activity was determined by 
spectrophotometry (OD 420). (A) The normalized relative luciferase units are 
shown for the indicated plasmids. Open bars represent control treated cells 
while black bars indicate TCDD treated cells.  Each bar = mean ± S.E. from 
four independent experiments. (B) The fold induction is shown for the 
indicated plasmids. Fold induction was determined by dividing the normalized 
RLU of samples treated with TCDD by the normalized RLU of control treated 
samples presented in (A). 
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AHR/ARNT is capable of binding these elements in vitro but not in vivo, the reason for 
this would likely be due to chromatin condensation within the region containing XREs 
1 and 3 or the inaccessibility of the elements due to interference by other proteins binding 
nearby as.opposed to differences in intracellular binding affinities versus those observed 
by EMSA.  Further experimentation will be required to elucidate the reasons for the lack 
of function of these XREs 
 Contrary to what was observed for the XREs within the proximal region, the 
distal region between -2100 and -2608 containing XREs 4 through 8, is capable of 
conveying TCDD-mediated gene induction (Figs. 2.3 and 2.5).  Additionally, EMSA has 
shown that XREs 4, 7, and 8 are capable of being bound by AHR/ARNT in a TCDD 
dependant fashion (Fig. 2.7).  Therefore, in vitro mutagenesis was also performed on 
these three XREs in order to determine their individual contributions to maximal gene 
induction.  Transfection into Hepa-1 cells and subsequent luciferase analysis shows that 
individual mutation of XRE4, XRE7, or XRE8 resulted in significant reductions in both 
raw levels of luciferase activity as well as fold-change of induction (Fig. 2.10).  While the 
transcriptional activity of each XRE does not appear to be equivalent by assessing the 
degree of reduction observed by individual XRE mutations, this inequality is more 
apparent when more than one XRE is mutated.  Indeed, while elimination of any one of 
the active XREs (4, 7, or 8), resulted in a 30–50% decrease in TCDD-mediated luciferase 
activity, XRE4 or XRE7 alone supported approximately 25% of the maximal luciferase 
induction in the absence of additional functional XREs while XRE8 alone showed 
minimal activity above p-2608/−2100Ur(−478) or the p-580/+71Basic control. Therefore,  
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Figure 2.9.  Functional Analysis of zfXREs 1 and 3 
 
                  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 2.9.  Functional analysis of zfXREs 1 and 3.  Hepa-1 cells were 
transfected with the indicated plasmids and treated with TCDD (2 nM) 
or DMSO (0.05%) for 15 h. Luciferase activity was measured using a 
Turner Instruments luminometer and β-galactosidase activity was 
determined by spectrophotometry (OD 420). (A) The normalized 
relative luciferase units are shown for the indicated plasmids. Open bars 
represent control treated cells while black bars indicate TCDD treated 
cells.  Each bar = mean ± S.E. from three independent experiments. (B) 
The fold induction is shown for the indicated plasmids. Fold induction 
was determined by dividing the normalized RLU of samples treated with TCDD 
by the normalized RLU of control treated samples presented in (A). 
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these results suggest that in this model system, each of the regulatory sequences does not 
provide the same level of regulation to the CYP1A gene as suggested by Fisher et al. 
(Fisher et al., 1990).  To verify that the previous results were not due to the analysis of 
the zfCYP1A promoter in a mouse cell line, studies were repeated using the zebrafish ZFL 
liver cell line. This line contains zfAHR2 as well as zfARNT1 and zfARNT2 and is 
capable of supporting TCDD-mediated gene regulation (Carvan et al., 2000; Miranda et 
al., 1993; Pollenz and Dougherty, 2005; Wentworth et al., 2004; ZeRuth and Pollenz, 
2005).  In comparison to the mammalian cell lines, transfection of the ZFL cells was 
much less efficient and the cells exhibited a higher level of basal activity that resulted in 
lower levels of fold induction in several constructs. Nevertheless, the results in the ZFL 
line (Fig. 2.11A) showed several similarities to the results in the Hepa-1 line (Fig. 2.10). 
First, single mutations of XRE4 or XRE7 resulted in a significant reduction in TCDD-
inducible luciferase activity. Second, mutation of XRE8 did not affect the luciferase 
induction as significantly as loss of XRE4 or XRE7. Thus, as in the Hepa-1 cells, the 
contribution of each XRE4 and XRE7 to the induction of the luciferase reporter was 
much more prominent than XRE8. To compare the trend of the results across the 
different cell lines used in the studies, the results were scaled with the overall fold 
induction of wild type p-2608/−2100Ur construct set at 100%. The fold induction yielded 
by constructs harboring XRE mutations was plotted as a percentage of the maximal 
induction (Fig. 2.11B).  The results show that there is a similar trend of the various 
constructs when analyzed in Hepa-1 or zebrafish cells with mutation of XRE4 or XRE7 
having a more dramatic impact than mutation of XRE8. The graph also contains results 
from studies completed in the HepG2 line that is of human origin. In this cell line, the  
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Figure 2.10.  Functional Analysis of zfXREs 
 
 
 
 
  
 
Fig. 2.10.  Functional analysis of zfXREs.  The indicated plasmids were transfected into 
Hepa-1 cells as described for Fig. 2.9. (A) The normalized relative luciferase units are 
shown for the indicated plasmids. Open bars represent control treated cells while black 
bars indicate TCDD treated cells. Each bar = mean±S.E. from five independent 
experiments. Schematics of the constructs are shown to the left of their respective bars. 
Open rectangles indicate XREs. Shaded rectangles indicate mutated XREs. The TATAA 
box and luciferase cassette are shown. (B) The fold induction is shown for the results 
presented in (A) and was determined by dividing the normalized RLU of samples 
treated with TCDD by the normalized RLU of control treated samples. a. Statistically 
different from p-2608/−2100Ur (p < .001). b. Statistically different from p-
2608/−2100Ur(−7) (p < .01). c. Statistically different from all constructs except p-
2608/−2100Ur(−478) and p-580/+71Basic (p < .001). d. Statistically different from p-
2608/−2100Ur(−8) (p < .001). e. Statistically different from all constructs except p-
2608/−2100Ur(−4−7) and p-580/+71Basic (p < .001). f. Statistically different from all 
constructs except p-2608/−2100Ur(−4−7) and p-2608/−2100Ur(−478) (p < .001).
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basal level of luciferase activity in controls was low for all the constructs and this 
resulted in very high levels of fold-change in the presence of TCDD. It can be observed 
that the overall trend obtained with the  various constructs in the HepG2 line follows that 
observed in the Hepa-1 and ZFL cells despite the fact that that overall fold induction 
varies dramatically between the cell lines. 
In order to determine whether the inability of XRE8 to function alone was due to 
the truncation of the fragment immediately upstream of the core sequence, a new 
construct was made extending the 5’ end of the insert up to -2727 and designated p-
2727/-2100Ur.  XREs 4, 7, and 8 were mutated individually or in combination as done 
previously with p-2608/-2100Ur and evaluated for luciferase activity in the Hepa-1 cell 
line.  The results in Figure 2.12 show that p-2727/-2100Ur exhibited approximately 60% 
higher levels of basal and induced luciferase activity over p-2608/-2100Ur while the 
overall fold-induction increased by approximately 17% between the constructs.  
Considering the differences in the level of activity and fold-induction is consistent 
between p-2608/-2100Ur and p-2727/-2100Ur equivalent mutants, it can be inferred that 
the region between -2727 and -2608 contributes to the overall transcriptional activity of 
the construct however does not change the functionality of XRE8 or its ability to regulate 
the gene in the absence of additional functional XREs.  The molecular mechanism that 
underlies the inability of XRE8 to function alone is not presently clear but it is possible 
that XRE8 is inaccessible prior to AHR/ARNT binding at XRE 4 and 7 or that 
AHR/ARNT binding to XRE8 cannot effectively recruit transcriptional coactivators.  
Indeed, chromatin relaxation and/or DNA bending has been shown to occur following  
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Figure 2.11.  Functional Analysis of zfXREs in Different Cell Lines 
 
 
 
 
 
 
Fig. 2.11.  Functional analysis of zfXREs in different cell lines.  (A) The 
indicated plasmids were transfected into ZFL cells and treated with TCDD (2 
nM) or DMSO (0.05%) for 15 h.  Luciferase activity was measured using a 
Turner Instruments luminometer and β-galactosidase activity was determined by 
spectrophotometry (OD 420).  The normalized relative luciferase units are shown 
for the indicated plasmids. Open bars represent control treated cells while black 
bars indicate TCDD treated cells. Schematics of the constructs are shown to the 
left of their respective bars as described for Fig. 2.10A. Each bar = mean±S.E. 
from three independent experiments. The number in parentheses indicates the 
fold-change for TCDD samples compared to DMSO treated controls. a. 
Statistically different from p-2608/−2100Ur (p < .001). b. Statistically different 
from paired control. c. Statistically different from p-2608/−2100Ur(−4) and p-
2608/−2100Ur(−7) (p < .005). (B) Scaled line graph showing the TCDD-induced 
luciferase activity as a percentage of the wild type p-2608/−2100Ur construct. 
Data were derived from Hepa-1 cells (circles), ZFL cells (triangles), or HepG2 
cells (squares). 
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AHR/ARNT binding at an XRE (Elferink and Whitlock, 1990; Okino and Whitlock, 
1995) and this may impact protein–protein interactions or may prevent access to XRE8 
prior to AHR/ARNT binding at XREs 4 or 7. In addition, a putative XF-1 site overlaps 
XRE8 and this could also contribute to its lack of function in the absence of binding at 
XRE4 and XRE7 as XF-1 binding has been previously been observed in the mouse 
CYP1A1 enhancer (Saatcioglu et al., 1990). Since ChIP assays cannot distinguish 
binding to enhancer regions that are on the same fragment of amplified DNA, and the 
sequential association of AHR/ARNT with XREs in any gene has not been resolve. The 
importance of these findings will require additional analysis. 
  The pattern of expression controlled by the zfCYP1A and mCYP1A1 regulatory 
region varies in different cell lines 
 During the course of the studies in this report, it was noted that the overall level of 
gene induction of different reporter constructs varied dramatically when tested in 
different cell lines. To formally investigate this observation, four different reporter 
constructs containing regions from the zebrafish of mouse CYP1A1 promoter/enhancer 
were evaluated in seven different cell lines. The two constructs derived from zebrafish 
were the full-length p-2699/+71 construct (ZFL) and p-2727/−2100Ur (ZFA).  The 
mouse constructs included one containing the region from −1674/+47 from the mouse 
CYP1A1 promoter/enhancer (MFL), or the region spanning −1316/−819 ligated upstream 
of the zebrafish CYP1A promoter region, −580/+71 (MMA). The cell lines utilized for 
these studies and their tissue of origin are detailed in Fig. 2.13A. Interestingly, two 
distinct patterns of induction were observed.  The results show that the constructs  
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Figure 2.12.  Comparison of XRE8 Function Between the p-2608/-2100Ur and p-
2727/-2100Ur Constructs 
 
 
 
 
Fig. 2.12.  Comparison of XRE8 function between the p-2608/-2100Ur and p-
2727/-2100Ur constructs.    The indicated plasmids were transfected into Hepa-1 
cells and treated with TCDD (2 nM) or DMSO (0.05%) for 15 h.  Luciferase activity 
was measured using a Turner Instruments luminometer and β-galactosidase activity 
was determined by spectrophotometry (OD 420).  The normalized relative luciferase 
units are shown for the indicated plasmids. Open bars represent control treated cells 
while black bars indicate TCDD treated cells.  Each bar = mean±S.E. from three 
independent experiments. The number in parentheses indicates the fold-change for 
TCDD samples compared to DMSO treated controls.  * indicates percent of -2608/-
2100Ur fold induction.  # indicates percent of -2727/-2100Ur fold induction. 
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Figure 2.13.  Characterization of Mouse and Zebrafish CYP1A Promoter and 
Enhancer Regions in Various Cell Lines 
 
 
 
 
Fig. 2.13.  Characterization of mouse and zebrafish CYP1A promoter and 
enhancer regions in various cell lines.  (A) Species and tissue of origin, AHR 
allele, and presence or absence of ARNT2 for each of the cell lines. (B and C) 
Fold induction of luciferase when the designated constructs were transfected into 
the indicated cell lines and treated with TCDD (2nM). Each data point is the 
mean of at least three different samples. ZFL = p-2699/+71, ZFA= p-
2608/−2100Ur, MFL= mouse-1647/+57, MMA= Mm-1315/−819Uf. 
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containing the zebrafish CYP1A promoter/enhancer (ZFL and ZFA), were more 
responsive in the Hepa-1, B19, and A498 cell lines than the constructs containing the 
mouse CYP1A1 regions (Fig. 2.13 B and C).  In contrast, the hRPE, TCM, C2C12, and 
HepG2 cell lines significantly favor the full-length mouse promoter/enhancer over the 
constructs containing the zebrafish regions.  The data presented in Figure 2.13B also 
supports previously detailed results which show that the zebrafish region -2100 to -2608 
conveys an approximately 2-fold higher level of induction than does the mouse CYP1A1 
region between -819 and -1316.  It was previously detailed in this report that p-2608/-
2100Ur construct exhibited increased levels of luciferase activity and fold-induction over 
the full-length p-2699/+71 construct. The data presented in Figure 2.13 supports these 
findings although it is interesting to note that the increase is significantly more dramatic 
in the cell lines which favor the zebrafish constructs (Fig 2.13B) versus those which favor 
the full-length mouse construct (Fig 2.13C).  Intriguingly, the contrary is observed in Fig. 
2.13C wherein the full-length mouse construct, MFL, produced considerably greater 
levels of induction than both p-2727/-2100Ur and p-2699/+71.  It is also important to 
recognize that the mouse enhancer region between -819 and -1316 yielded significantly 
less activity when driving the zebrafish CYP1A promoter (MMA) than the full-length 
MFL in these four cell lines.  The molecular basis for the differences in response of the 
various reporters in the different cell lines is currently unclear. However, there does not 
appear to be a correlation to the level or species of AHR protein, the tissue type, or level 
of expression of ARNT2.  The findings presented above suggest that the differences 
observed between the transcriptional activities in various cell lines may be due, in part, to 
interactions between the enhancer and promoter regions.  It is possible that differences in 
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the expression, binding affinities, or transactivation domains of cell specific factors may 
contribute to the observed results. 
 
Analysis of the zebrafish CYP1A Proximal Promoter 
 Since the different levels of response exhibited between the mouse and zebrafish 
regulatory regions may be due, in part, to their respective proximal promoters, it was of 
interest to characterize the zebrafish CYP1A promoter region.  To do this, successive 
truncations of the zebrafish CYP1A promoter region were cloned upstream of pGL3 
Basic, transfected into Hepa-1 cells treated with either DMSO or TCDD, and assayed for 
luciferase activity.  The results shown in Figure 2.14 indicate that up to three regions are 
required for maximal promoter function while one region may have an inhibitory effect 
on transcription.  The loss of the region between -580 and -490 resulted in a 40% 
decrease in activity while further truncation down to -439 results in an additional 10% 
loss. Transcription Element Search Software (TESS) identified two Sp1 binding sites and 
a CTF/NF1 binding site within these regions which may be responsible for the decrease 
in activity.  Interestingly, loss of the region between -439 and -398 caused an increase in 
activity back to the levels yielded by p-580/+71 Basic suggesting that an inhibitory 
element may reside within this region.  In silico analysis identified an Sp1 site 
overlapping a USF1 site within these 40 bases which are possibly involved in the 
observed inhibition.  Further truncation down to -206 resulted in another 50% decrease in 
activity which may be due to the loss of putative ERα and HNF-3γ sites located within 
the lost region.  CTF/NF1 sites and G-boxes have both been implicated in the control of  
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Figure 2.14.  Analysis of the Zebrafish CYP1A Proximal Promoter 
 
 
 
 
 
 
 
 
 
 
Fig. 2.14.  Analysis of the zebrafish CYP1A proximal promoter.  The indicated 
plasmids were transfected into Hepa-1 cells and treated with TCDD (2 nM) or 
DMSO (0.05%) for 15 h.  Luciferase activity was measured using a Turner 
Instruments luminometer and β-galactosidase activity was determined by 
spectrophotometry (OD 420).  The normalized relative luciferase units are shown 
for the indicated plasmids. Open bars represent control treated cells while black 
bars indicate TCDD treated cells.  Each bar = mean±S.E. from three independent 
experiments.  The schematics to the left represent the portions of the promoter 
contained within the respective construct.  Shaded circles = TATA box; 
Rectangles = CTF/NF1 sites; Triangles = ERα sites; Diamonds = Sp1 sites. 
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the mouse CYP1A1 promoter as well as the existence of a possible inhibitory region. 
(Jones and Whitlock, 1990) Further studies will have to be performed to characterize the 
importance of these elements in the zebrafish CYP1A promoter.   
Functional analysis of XRE flanking sequence 
 Previous results suggest that just the presence of a core 5’-GCGTG XRE 
sequence is not sufficient to ascribe function to a putative XRE in vivo (Denison et al., 
1988). For example, zfXRE5 has the same orientation and core sequence as zfXRE4, but 
does not associate with AHR/ARNT dimers in vitro and does not appear to participate in 
AHR-mediated regulation of zfCYP1A in cell culture.  Thus, it was of interest to 
determine whether nucleotides flanking XRE5 contribute to the lack of function of this 
sequence in cell culture and in vitro.  To gain some insight into this question, the 
sequences of all eight zfXREs as well as the six XREs present in the mouse CYP1A1 
were aligned and compared (Fig. 2.14).  As previously detailed by Swanson et al. 
(Swanson et al., 1995) and others, it can be observed that all XREs contain the 5’GCGTG 
core at positions −2 through +3, however, those XREs with defined activity in vivo also 
show consensus residues at positions 4, 5, 6 and 8. In contrast, XRE1, XRE2, XRE3, 
XRE5 and XRE6 as well as mouse XRE C that lack function in vivo, do not fit the 
consensus at residues 6 and 8. Thus, in vitro mutagenesis was used to change T >A at 
position 6 and T >G at position 8 in XRE5 so that it more resembled XRE4 (termed 
XRE5 > 4). In addition, the converse changes were made in XRE4 to convert it to XRE5 
(termed XRE4 > 5).  To assess whether the changes affected the ability of AHR/ARNT 
dimers to associate with the sequences in vitro, EMSA was utilized. The results in Figure  
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Figure 2.15.  Comparison of Mouse and Zebrafish XRE Flanking Regions 
 
 
 
 
 
Fig. 2.15.  Comparison of mouse and zebrafish XRE flanking regions.  
Core XREs and flanking sequences from zebrafish CYP1A (XREs: 1–8) and 
mouse CYP1A1 (XREs: A–F) were aligned. Shaded region indicates 
conserved nucleotides. Nucleotide positions are numbered below and ability of 
the XRE to bind in vitro or function in cell culture is indicated to the right, Y: 
yes, N: no. Nucleotides in non-functional XREs which diverge from conserved 
bases are circled. 
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2.15A confirm that XRE5 does not associate with AHR/ARNT dimers with the same 
efficiency as zfXRE4 and the XRE4 > 5 mutations at positions 6 and 8 do not appear to 
affect binding in vitro. In contrast, when the binding of XRE5 > 4 is compared to that of 
XRE5, there is an approximate 50% increase in association with AHR/ARNT.  It was 
next pertinent to determine whether the various nucleotide changes results in increased or 
decreased ability to drive luciferase expression in cell culture. Thus, the various 
constructs were introduced into Hepa-1 cells and the overall level of TCDD-induced 
luciferase activity compared. Interestingly, mutation of XRE4 > 5 slightly reduced the 
level of luciferase induction in comparison to p-2608/−2100Ur(−78), but the level of 
change was not significant over several experiments. (Fig. 2.15B) Likewise, mutation of 
XRE5 > 4, resulted in a slight elevation of the luciferase activity and overall level of fold 
induction, but the elevation was never significant. Thus, the XRE5 > 4 mutation 
functions like the XRE8, in that it can associate with AHR·ARNT dimers in vitro, but 
does not appear to support higher levels of TCDD-mediated induction of luciferase in the 
absence of other XREs.  Collectively these results suggest that nucleotides within the 3’-
flanking sequence of the core XRE can influence association of AHR·ARNT in vitro, but 
changes in culture may be too subtle to detect.   
 The role of nucleotides flanking the core XRE motif in binding of AHR/ARNT 
dimers has been evaluated by a number of labs (Shen and Whitlock, 1992; Swanson et 
al., 1995). For example, Swanson et al. (Swanson et al., 1995) have shown that binding in 
vitro does not occur when a G is located at position 4. In addition, Shen and Whitlock 
(Shen and Whitlock, 1992) have shown that an A or C must be present at position 4 and a  
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Figure 2.16.  Effect of Mutating Nucleotides Flanking XREs on AHR/ARNT 
Binding In Vitro 
 
 
 
 
 
 
 
 
Fig. 2.16.  Effect of mutating nucleotides flanking XREs on 
AHR/ARNT binding in vitro.  (A) EMSA autoradiograph shows the 
ability of in vitro translated zebrafish AHR2 and rainbow trout ARNTb 
to bind synthetic double-stranded oligonucleotides containing zebrafish 
XRE4 (4), zebrafish XRE5 (5), XRE4 with mutations at positions 6 and 
8 (4 > 5), or XRE5 with mutations at positions 6 and 8 (5 > 4). Arrow 
indicates the AHR·ARNT·DNA complex. (B) The indicated plasmids 
were transfected into Hepa-1 cells and treated with TCDD (2 nM) or 
DMSO (0.05%) for 15 h.  Luciferase activity was measured using a 
Turner Instruments luminometer and β-galactosidase activity was 
determined by spectrophotometry (OD 420). The normalized relative 
luciferase units are shown for the indicated plasmids. Open bars 
represent control treated cells while black bars indicate TCDD treated 
cells. Each bar = mean±S.E. from three independent samples. The 
number in parentheses indicates the fold-change for TCDD samples 
compared to DMSO treated controls. a. Statistically different from p-
2608/−2100Ur (p < .001). 
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G or C must be present at position 5 for function in cell culture. These investigators also 
suggested that a G abolishes function at position 6 (Shen and Whitlock, 1992). These 
rules partially explain why a number of the putative zfXREs are non-functional, as 
zfXREs 1,2, 3, and 6, have T or G at position 4, and all have a T at position 6 (as does the 
non-functional mouse XRE C).  However, XRE5 is also non-functional yet matches the 
consensus at positions 4 and 5. Importantly, when the residues at positions 6 and 8 were 
changed to those found in the functional XRE4, there was a significant increase in the 
binding to AHR/ARNT dimers in vitro, although the binding did not reach the level 
associated with wild type XRE4. (Fig 2.15A) However, when these same mutations were 
made at XRE5 in the p-2608/−2100Ur reporter construct, there was a slight, but not 
significant elevation in TCDD-mediated induction of luciferase activity compared to 
controls. (Fig. 2.15B) Thus, it appears that bases at positions 6 and 8 may play a role in 
DNA binding in vitro, but the changes do not support function in the model system used 
to assess activity. This hypothesis is supported by the correlate studies that changed the 
bases at positions 6 and 8 in the functional XRE4 so they mimicked those of XRE5. In 
this case, the changes did not affect either the in vitro binding or activation in cells. 
Indeed, others have suggested that function is abolished when an A is located at position 
5 (Shen and Whitlock, 1992), however, zebrafish XRE4 binds AHR/ARNT and is 
functional yet has an A at position 5. Thus, to truly assess the function of individual 
XREs, it will be necessary to determine binding to specific sites at the endogenous gene. 
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Identification of additional cis-regulatory regions which impact the induction of 
zfCYP1A 
 Since not all of the putative XREs in the zfCYP1A regulatory region were 
functional and since the pattern of expression varied in different cell lines, it was of 
interest to determine whether additional cis-regulatory regions were involved in the 
TCDD-mediated induction of the CYP1A gene. Analysis of the zfCYP1A enhancer by 
Transcription Element Search Software (TESS) revealed an extensive list of putative 
binding sites within the distal 500 bp enhancer region which contains XREs 4-8. To pare 
down the number of sites to a more manageable list, TESS was used to evaluate the 
mouse CYP1A1 enhancer and identify common sites that shared similar relative positions 
within the enhancers of both genes.  A summary of sites identified is shown in Figure 
2.16.   To begin to assess the function of the various sites, in vitro mutagenesis was used 
to modify an Sp1 site located at −2474, HNF-3 sites located next to XRE7 and XRE5, an 
AP2 site, and a CREB site. Each site was mutated within the wild type p-2608/−2100Ur 
construct and evaluated for TCDD-inducible activity in the Hepa-1 cell line.  
Interestingly, mutation of the AP2, Sp1 and proximal HNF3 sites did not cause a change 
in either the magnitude or level of induction (Fig. 2.17).  In contrast, mutation of the 
putative CREB binding site caused a modest reduction in the both the basal and TCDD-
induced luciferase activity. Similarly, mutation of the HNF-3 binding site located at 
position −2547 caused an even more dramatic reduction in both the basal and TCDD-
induced luciferase activity that was reduced 10-fold below the level of the p-580/+71 
construct. This finding is intriguing as it suggests that the removal of the site acts to  
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Figure 2.17.  Putative Transcription Factor Binding Sites Within the zfCYP1A 
Regulatory Region That Are Common to Both Mouse and Zebrafish 
 
 
 
 
 
 
 
Fig. 2.17.  Putative transcription factor binding sites within the zfCYP1A 
regulatory region that are common to both mouse and zebrafish.  Putative 
transcription factor binding sites identified by TESS within the zfCYP1A 
enhancer that are common to both mouse and zebrafish. Specific binding regions 
are boxed and labeled. Binding sites that were targeted for mutagenesis studies 
are double boxed. 
69 
 
Figure 2.18.  Analysis of cis-regulatory Elements Within the zfCYP1A Enhancer 
 
 
 
 
 
 
 
 
 
Fig. 2.18.  Analysis of cis-regulatory elements within the zfCYP1A enhancer.  
The indicated plasmids were transfected into Hepa-1 cells and treated with TCDD (2 
nM) or DMSO (0.05%) for 15 h.  Luciferase activity was measured using a Turner 
Instruments luminometer and β-galactosidase activity was determined by 
spectrophotometry (OD 420). Open bars represent control treated cells while black 
bars indicate TCDD treated cells. *Bar is statistically different from p-
2608/−2100Ur. The transcription factor denoted in the construct name indicates that 
the specific transcription factor binding site has been mutated in that construct. –
HNF-3(5) and –HNF-3(7) indicates HNF-3 binding sites flanking XRE 5 and XRE 
7, respectively. The fold induction is shown in the graph on the right and was 
determined by dividing the normalized RLU of samples treated with TCDD by the 
normalized RLU of control treated samples. *Statistically different from p-
2608/−2100Ur (p < .001). 
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repress the overall activity of the construct. Indeed, HNF-3 has been implicated in 
chromatin remodeling functions (Roux et al., 1995), nucleosome positioning (Shim et al., 
1998), and has a supportive role in xenobiotic-mediated transcriptional regulation 
(Bombail et al., 2004; Rodriguez-Antona et al., 2003).  It is quite possible that in the 
absence of protein binding to this site, the nucleosome is shifted toward the promoter 
and thereby blocks access of the transcriptional machinery from assembling. Another 
possibility is that mutation of this site causes a bending of the DNA such that the 
enhancer itself contacts the promoter blocking both assembly of transcriptional 
machinery as well as AHR/ARNT from accessing the XREs.  Furthermore, HNF-3 has 
been shown to work cooperatively with C/EBP (Christoffels et al., 1998) and NF1/CTF 
(Jackson et al., 1993) in regulating the carbamolyphosphate synthetase I (CPS) and serum 
albumin genes, respectively. Since both C/EBP and NF1/CTF binding sites can be found 
in the zfCYP1A promoter/enhancer as determined by in silico analysis, it is interesting to 
speculate that such cooperative interactions with HNF-3 occur in this system as well. 
 To determine what effect the HNF-3 mutation had on a construct containing the 
full-length zfCYP1A regulatory region, the p-2608/+71(-HNF-3(7)) construct in which 
the PCR amplified region between -2100 and -2608 from p-2608/-2100Ur(-HNF-3(7)) 
was used to replace the same region of the p-2699/+71 construct was transfected into 
Hepa-1 cells and evaluated for luciferase activity.  The results in Figure 2.18 indicate that 
contrary to the mutation in the p-2608/-2100Ur construct which resulted in ablation of 
both basal and inducible activity, the mutation in the p-2608/+71 construct resulted in a 6 
and 8-fold increase in basal and inducible activity, respectively.  The overall fold-
induction between p-2608/+71 and p-2608/+71(-HNF-3(7)), however was consistent.   
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Figure 2.19.  Effect of HNF-3 Mutation on the Full-length p-2699/+71 Construct 
 
 
 
 
 
Fig.  2.19. Efect of HNF-3 mutation on the full-length p-2699/+71 construct.  
The indicated plasmids were transfected into Hepa-1 cells and treated with TCDD 
(2 nM) or DMSO (0.05%) for 15 h.  Luciferase activity was measured using a 
Turner Instruments luminometer and β-galactosidase activity was determined by 
spectrophotometry (OD 420). Open bars represent control treated cells while 
black bars indicate TCDD treated cells.  Each bar = mean±S.E. from three 
independent samples.  The fold induction was determined by dividing the 
normalized RLU of samples treated with TCDD by the normalized RLU of 
control treated samples. 
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This data supports a role for HNF-3 in maintaining the position of the nucleosome as, if 
the loss of the site in the context of p-2608/-2100Ur results in a shifting of the 
nucleosome 3’-ward such that it blocks assembly at the promoter then the loss of the site 
in the full-length construct may shift the nucleosome into the 1.7kb AT-rich region which 
lacks any transcription factor binding sites. Positioning of the nucleosome within this 
region may open up the upstream enhancer region leading to the enhanced activity 
observed.  While the mechanisms behind the observations  at this site are unclear, the 
results clearly suggest that binding of AHR/ARNT alone is likely not sufficient to obtain 
a full transcriptional response and other binding proteins are required. This may explain 
the large differences in overall level of luciferase induction of the various reporters in the 
different cell lines and the need to assess gene regulation in the proper cellular context.  
Future studies should be designed to assess the binding of additional factors to the 
CYP1A enhancer in genomic DNA. The large distance between the enhancer and 
promoter regions of the zebrafish CYP1A gene make this ideal for procedures such as in 
vivo footprinting and ChIP analyses as binding at the two regions should be easily 
differentiated.  It is anticipated that the future analysis of the zfCYP1A gene will provide 
significant informa tion on how the AHR mediates gene regulation in both aquatic and 
mammalian organisms. 
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Chapter 3 
Discussion of Impact, Relevance, and Future Direction 
 
 The data presented herein confirms the isolation of the upstream regulatory region 
for a dioxin-inducible CYP1A gene in zebrafish.  The identified region, which was 
sequenced approximately 2.8 kb upstream of the transcriptional start site, contains eight 
XREs and several other elements indicative of previously characterized CYP1A 
regulatory regions including a TATA box positioned at -31.  Sequence analysis revealed 
that the XREs were organized into two distinct clusters.  The proximal cluster of XREs 
(XREs 1-3) was incapable of conveying TCDD-mediated induction to a luciferase 
reporter gene while the distal cluster, containing XREs 4-8, enhanced luciferase 
expression in the presence of dioxin more than 20 fold.  As determined by electrophoretic 
mobility shift assays, only a sub-set of the eight XREs were capable of binding 
AHR/ARNT in vitro.  Surprisingly, XRE1 and XRE3 were bound by AHR/ARNT in 
vitro in a TCDD-dependent fashion despite their inability to drive luciferase expression in 
cell culture.  The reason for the lack of function exhibited by these XREs is currently 
unclear.  Considering the region between -580 and -187 containing XREs 1-3 failed to 
convey induction when cloned immediately upstream of an SV-40 promoter or in the 
context of its native promoter, it is unlikely that the lack of functionality is promoter 
specific.  Additionally, when the region containing XREs 4-8 was cloned in the same 
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position upstream of an SV-40 promoter, it was capable of conveying significant levels of 
induction indicating that the distance from the promoter is also not responsible the 
inability of XRE1 and 3 to function.  It is possible that XREs 1 and 3 are capable of 
binding protein in vitro but fail to function in cell culture due to chromatin condensation 
causing inaccessibility of the binding sites.  To assess this possibility, tandem repeats of 
XRE1 or XRE3 along with several flanking nucleotides could be cloned upstream of a 
luciferase cassette driven by an SV-40 promoter and analyzed for TCDD-mediated 
luciferase induction.  In such a scenario, the absence of additional native DNA which 
may recruit histones or influence the structure of the DNA will allow for the assessment 
of the XRE alone to enhance transcription.  Others have characterized the mouse 
CYP1A1 XREs and found that XREC was also capable of binding AHR/ARNT in vitro 
but failed to function in vivo (Lusska et al., 1993).  In these studies, tandem repeats of 
each of the six XREs were placed upstream of an MMTV promoter controlled 
chloramphenicol acyltransferase cassette and even in such a context, XREC still failed to 
drive CAT expression.  This suggests that in the mouse, chromatin inhibition of the XRE 
is likely not responsible for the lack of function.  Another possibility for the failure of the 
XREs to contribute to gene induction may lay in the nucleotides flanking the core XRE 
sequence.  Previous experiments have shown that an A is required at position 6 (Fig. 
2.14) for XRE function in the mouse but not for in vitro binding (Lusska et al., 1993; 
Shen and Whitlock, 1992).  These results would help explain the lack of function of 
XRE1 and XREC, but not XRE3 which contains an A at that position.  It is important to 
note however that XREs 1 and 3 also diverge from the consensus suggested in Figure 
2.14 at positions 4 and 8 as well.  Although it has been previously shown through the use 
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of ligation mediated PCR that the AHR/ARNT complex likely only interacts with three 
or four guanine residues within the core XRE sequence, (Wu and Whitlock, 1993) 
flanking nucleotides may affect the ability or degree to which the DNA bends or may 
reinforce the stability of the bound AHR/ARNT complex and recruited cofactors.  
Utilizing in vitro mutagenesis to alter the nucleotides at positions 4, 6, and 8 in XRE 1 
and XRE3 within the p-580/+71 construct could shed light on the importance of these 
flanking nucleotides on XRE functionality.  Furthermore, in vivo footprinting and ligation 
mediated PCR should be performed on the zebrafish CYP1A regulatory region to 
determine whether or not protein interacts with the XREs in intact cells. 
          Nucleotides flanking the core XRE may also be implicated in the inability of 
XREs 5 and 6 to bind AHR/ARNT in vitro or function in vivo.  Inaccessibility of the 
XREs due to chromatin structure is unlikely in the case of XREs 5 and 6 since it has been 
previously established that AHR/ARNT binding at an XRE results in chromatin 
relaxation spanning approximately 200 bases around the XRE (Okino and Whitlock, 
1995).  Knowing that activated AHR likely binds to both XRE4 and XRE7, XREs 5 and 
6 should be free of any chromatin related constraints in the presence of TCDD.  
Chromatin interference can further be ruled out by the fact that AHR/ARNT does not 
bind double stranded oligonucleotides containing XREs 5 and 6 in vitro.  Failure to bind 
in vitro using in vitro translated AHR and ARNT also suggests that inhibition is not being 
caused by competition or hindrances from additional proteins binding nearby the XRE.  
The observations stated above suggest that any constraints set upon AHR/ARNT-XRE 
interactions exist within the DNA sequence itself.  Like XREs 1 and 3, mentioned 
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previously, XREs 5 and 6 both possess a T at position 6 (Fig. 2.14).  A T at this position, 
however, has been implicated in loss of XRE function but has not been shown to affect 
protein binding (Lusska et al., 1993).   The alignment in Figure 2.14 shows that XRE6 
also diverges from functional XREs at positions 4, 5, and 8 while XRE5 diverges only at 
positions 6 and 8.  Experiments described previously in this work suggest that mutations 
of nucleotides at positions 6 and 8 can enhance the ability of XRE5 to bind protein in 
vitro however the enhanced binding was not to the level observed by functional XREs.  
Furthermore, the reverse mutations made to the functional XRE4 did not appear to affect 
the level of binding observed in EMSA.  These findings suggest that additional flanking 
nucleotides may be involved in protein binding and is supported by the fact that 
statistically significant changes in luciferase activity were not observed when the same 
mutations were made in reporter constructs.  Swanson et al. have previously 
characterized XRE flanking nucleotides but their studies only examined in vitro 
interactions using synthetically generated oligonucleotides (Swanson et al., 1995).  Wu 
and Whitlock have also characterized the role of flanking nucleotides in mouse XREs but 
their studies did not examine nucleotides extending beyond four bases around the core 
XRE (Wu and Whitlock, 1993).  Utilizing a combination of synthetically generated 
double stranded oligonucleotides for EMSA and in vitro mutagenesis to alter flanking 
nucleotides of XRE5 alone and in combination until they are identical to a functional 
XRE may shed light on the precise nucleotide combination required for a functional 
XRE.  Species specificity could likewise be tested by performing the same experiments 
on mouse CYP1A1 XREs and by using mouse AHR and mouse ARNT1 in EMSA 
experiments.  Determination of specific nucleotide sequences required for AHR function 
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in transcriptional regulation could be greatly beneficial in the search for novel AHR 
target genes which contain bona fide, functional XREs within their regulatory regions. 
 It is also of interest to note that the XRE5 exhibits weak binding to AHR/ARNT 
in EMSA experiments after prolonged exposure. Characterization of the mouse CYP1B1 
promoter has previously revealed that three of the five XREs located therein bound a 
non-AHR/ARNT complex which ran identically to AHR/ARNT on EMSA (Zhang et al., 
1998a).  These XREs diverged from AHR/ARNT binding XREs within the same region 
only at positions 6 and 7.  While XRE5 in the zfCYP1A regulatory region does not share 
the same nucleotide sequence at these two positions, it would be of interest to repeat the 
EMSA of XRE5 with anti-AHR antibodies to ensure that the observed binding is indeed 
AHR/ARNT and not another protein present in the reticulocyte.   
 XRE4, XRE7, and XRE8 were capable of both binding in vitro and functioning to 
induce luciferase in TCDD treated cells transfected with luciferase reporter constructs.    
While all three of these XREs appear to be necessary for maximal induction, their 
contributions do not appear to be equal.  When luciferase reporter assays were carried out 
using p-2608/-2100Ur constructs bearing mutations at each of the individual XREs, it 
was observed that the loss of XRE4 resulted in an approximately 50% reduction in 
activity compared to the non-mutated control while loss of XRE7 yielded a 70% loss of 
activity and the mutation of XRE8 only decreased activity by approximately 30%.  These 
findings are contrary to previous studies which suggested that each of the mouse XREs 
contribute equally to maximal induction (Fisher et al., 1990).  Later studies by Lusska et 
al. showed that when duplicate copies of each of the six mouse XREs, A-F, were placed 
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upstream of an MMTV promoter driven CAT reporter, XREC failed to respond to TCDD 
and XREA exhibited a considerable reduction in responsiveness compared to XREs B, D, 
E, and F (Lusska et al., 1993).  Unfortunately, the experiments utilized by the 
investigators in these studies did not consider the enhancer elements within their native 
environment nor did they evaluate cooperation between the XREs.   Mutations of 
individual mouse XREs in the context of the full-length mouse CYP1A1 regulatory 
region have not been made, thus it is unknown what contributions mouse XREA and 
XREC make toward maximal induction of that gene.  The results presented in this report, 
however, show that in the absence of additional functional XREs, XREs 4 and 7 can 
contribute 25-30% of the induced activity observed in the non-mutated p-2608/-2100Ur 
while XRE8 is incapable of functioning alone.  This is the first time it has been shown 
that an XRE regulating a cytochrome P-450 was required for maximal gene induction but 
incapable of functioning in the absence of additional functional XREs.  The reasons 
behind this observation are currently unknown.  It is possible that the sequence flanking 
the XRE is responsible for the inability of XRE8 to function alone although this is 
unlikely due to the fact that XRE only diverges from XRE7 at positions 4, 7, and 8.  The 
nucleotides found at these three positions within XRE8 are also found at the same 
positions in other functional mouse and zebrafish XREs.  It is additionally possible that 
XRE8 is inaccessible to AHR/ARNT due to the presence of chromatin prior to chromatin 
relaxation caused by AHR/ARNT binding at XRE4 or XRE7.  In order to test these 
hypotheses, duplicate copies of XRE8 should be cloned upstream of an SV-40 or MMTV 
promoter driven luciferase promoter and assayed for TCDD-mediated induction.  
Additional inhibitory factors such as chromatin should not be present in such a construct 
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and if the XRE sequence is sufficient to regulate transcriptional activity, TCDD should 
mediate induction of the reporter.  Alternately, mutation of the nucleotides at positions 4, 
7, and 8 within XRE8 in the context of p-2608/-2100Ur(-47) such that they are identical 
to XRE7 should shed light on the importance of nucleotide specificity.  The converse 
mutations should also be made to XRE7 in the context of p-2608/-2100Ur(-48).  If 
sequence is important, the XRE7 mutant should lose functionality while XRE8 should 
gain the ability to function alone.  Finally, analysis of the p-2608/-2100Ur XRE mutants 
should be revisited in Hepa-1 cells treated with a histone deacetylase inhibitor such as 
trichostatin-A.  These studies should lessen or eliminate any inhibition chromatin has on 
the ability of AHR/ARNT to bind XREs within the reporter constructs.   
           Another observation made throughout the course of these studies is that 
XRE reporter constructs behave differently in different cell lines.  When various reporter 
constructs containing regulatory regions from zebrafish CYP1A and mouse CYP1A1 
were transfected into various cell lines from different species and tissues, a distinct 
pattern of transcriptional regulation was observed.  For instance, when the zebrafish p-
2727/+71 construct was transfected into the human A498 kidney cell line it yielded 
approximately 20-fold induction when treated with TCDD.  By comparison the mouse -
1647/+57 construct yielded less than 10-fold induction under the same conditions.  
Surprisingly however, in the C2C12 mouse myoblast cell line, transfection of p-2727/+71 
led to only an approximately 10-fold induction of reporter while a 60-fold induction was 
observed in cells transfected with the mouse p-1647/+57.  This overall trend was 
observed in several cell lines with the zebrafish constructs yielding considerably higher 
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levels of induction in the Hepa-1, A498, and B19 cells while the mouse constructs were 
favored in the C2C12, TCM, HepG2 and hRPE cell lines.  The reasons behind this 
observation are unclear, however it does not appear to correlate with the AHR allele, the 
species or tissue of origin, or the presence or absence of ARNT2.  Importantly, the data 
suggests that the differences observed may be dependent upon the proximal promoter.  
Each of the cell lines were also transfected with the pMm-1315/-819Uf construct which 
contains the indicated mouse CYP1A1 enhancer region immediately upstream of the 
zebrafish CYP1A promoter region, -580/+71.  In the Hepa-1, B19, and A498 cells which 
appear to favor the zebrafish full-length construct over the mouse, pMm-1315/-819Uf 
yielded approximately 20% less induction than the full length mouse, p-1647/+57, in the 
same cell lines.  These results are expected considering the full-length mouse construct 
contains two additional functional XREs not present between -1315 and -819 which 
should result in a 20% reduction if all 5 XREs contribute equally as reported previously. 
(Fisher et al., 1990) In the cell lines which appear to favor the mouse constructs, 
however, pMm-1315/819Uf exhibits >50% reduced fold-induction compared to p-
1647/+57.  This difference is most noticeable in the C2C12 and HepG2 cell lines which 
exhibit greater overall levels of activity.  To better understand the role the proximal 
promoter plays in these observed differences, additional constructs should be made which 
contain the zebrafish -2608/-2100 enhancer region immediately upstream of the mouse 
proximal promoter region and the mouse enhancer region between -1315 and -819 
upstream of the mouse proximal promoter.  A comparison of the luciferase activity 
exhibited by these constructs as well as p-2608/-2100Ur and pMm-1315/-819Uf should 
confirm the importance of the promoter region in begetting these differences.     
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 The mouse CYP1A1 promoter region has been previously characterized by others 
(Jones and Whitlock, 1990).  The results of these studies revealed that the mouse 
proximal promoter region contains a TATA box located at position -30, two CTF/NF1-
like sites located at positions -59 and -136, and a G-box located at position -130.  
Mutation analyses showed that loss of either the TATA-box or the proximal CTF/NF1 
sequence resulted in an 80% decrease in promoter function.  Additionally, simultaneous 
loss of the distal CTF/NF1 site and the G-box resulted in a 50% decrease of promoter 
function while individual mutations of these elements had little or no effect.  Truncation 
experiments also suggest that there may exist inhibitory elements located between 
positions -419 and -246.  Transcription Element Search Software (TESS) was used to 
identify putative transcription factor binding sites within the zebrafish CYP1A proximal 
promoter region.  A TATA-box was identified at position-31 along with several pertinent 
sites including putative CTF/NF1 sites, G-boxes and Sp1 sites.  A proximal CTF/NF1 site 
was identified by TESS at position -54 and it is likely that the zebrafish promoter is 
similar to the mouse CYP1A1 promoter and also contains a distal CTF/NF1 site and a G-
box which are required for maximal promoter function.  Luciferase reporter vectors 
containing successive truncations of the zebrafish proximal promoter suggest that two 
distal CTF/NF1 sites and two distal Sp1-like sites may be important for the 
transcriptional activity of the downstream gene.    Additionally, the data suggests that 
another element lies between bases -398 and -206 which is also required for full promoter 
activity.  TESS identified a putative ERα binding site at position -330 and a putative 
HNF-3 binding site at position -225 both of which have previously been implicated in the 
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transcriptional regulation of cytochrome containing xenobiotic metabolism enzymes 
(Bombail et al., 2004; Gibson et al., 2002; Matthews et al., 2005; Rodriguez-Antona et 
al., 2003).  Finally, the data suggests that an inhibitory element may exist between bases -
439 and -411.  An Sp1 site was identified overlapping a USF1 site within this region by 
in silico analysis and may have a role in transcriptional inhibition of the gene.   
 Overall, the zebrafish CYP1A proximal promoter greatly resembles the 
previously characterized mouse CYP1A1 promoter.  Many additional studies still need to 
be performed to better characterize this region, however.  In vitro mutagenesis needs to 
be utilized to mutate target binding sites within the promoter region both alone and in 
combination to assess the function of the sites since truncation analyses alter the physical 
characteristics of the DNA and cannot, therefore, be reliable.  Mutations should also be 
carried out in the context of p-2608/-2100Ur and assayed in TCDD treated cells to obtain 
greater levels of overall activity and thus, more substantial differences between mutants 
and control samples.  EMSA should be performed to identify the ability of the pertinent 
elements to bind protein in whole cell lysates and nuclear extracts from both DMSO and 
TCDD treated cells.  It is possible that the different patterns of regulation observed 
between the constructs containing mouse and zebrafish elements is due to differential 
binding to elements within the proximal promoters.  In order to assess this, EMSA can be 
performed using oligonucleotides containing elements of interest from both mouse 
CYP1A1 and zebrafish CYP1A and nuclear extracts from each of the seven cell lines 
used previously to determine differences in relative protein/DNA binding affinities 
between the cell lines.  DNAse in vitro footprinting should be performed as well using 
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nuclear extracts from the seven cell lines of interest to further characterize differences in 
protein binding at the two promoters.  In vivo footprinting and LMPCR should ideally be 
performed in ZFL cells to confirm protein binding at the zfCYP1A promoter in intact 
cells. 
 TESS was also used to identify putative transcription factor binding sites which 
were common between the mouse CYP1A1 and zebrafish CYP1A distal enhancers.  In 
vitro mutagenesis of selected sites within p-2608/-2100Ur and subsequent luciferase 
assays identified both a CREB and HNF-3 sites which were important to the 
transcriptional activity of the downstream gene.  Previously, no additional proteins have 
been implicated in binding at the enhancer other than AHR/ARNT and Sp1 (Fisher et al., 
1990) however mutation of the CREB binding site results in modest reductions of both 
basal and induced reporter activity.  Even more surprising was the finding that mutation 
of an HNF-3 site located at position -2547 completely ablates both basal and inducible 
transcriptional activity.  This finding suggests that loss of the putative HNF-3 site 
somehow inhibits the assembly of the transcriptional machinery at the promoter in the 
presence or absence of TCDD.  To investigate the role of the site in more detail, the 
mutation of the HNF-3 site was assessed in the context of the full-length, p-2608/+71 
construct.  Unexpectedly, mutation of the HNF-3 site in this construct resulted in a 
significant 6-fold increase in both basal and induced activity while only slightly elevating 
the overall fold induction.  The conflicting results obtained from the experiments using 
the two different constructs led to the formulation of a hypothesis that HNF-3, or an 
HNF-3-like protein is responsible for the positioning of a nucleosome at the CYP1A 
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enhancer.  In such a scenario, it can be envisioned that the nucleosome is shifted 3’-ward 
such that in the case of p-2608/-2100Ur, the nucleosome blocks assembly at the promoter 
while in p-2608/+71, the nucleosome is shifted into the 1 kb AT-rich region located 
between the proximal promoter and the enhancer region, opening up enhancer and 
leading to super-induction. Indeed, HNF-3α has been implicated by others in the 
positioning of the nucleosome  (Shim et al., 1998) and in chromatin remodeling, (Roux et 
al., 1995) supporting this hypothesis.  Fascinatingly, two similar binding motifs can be 
found in the mouse CYP1A1 regulatory region; both of which exist centrally within 200 
bp spans known to undertake a nucleosomal configuration. HNF-3 is known to bind 
nucleosomal DNA (Shim et al., 1998) and this may explain why these sites may have 
been protected from DNaseI digestion in footprints of the mouse CYP1A1 promoter and 
enhancer regions (Okino and Whitlock, 1995; Shen and Whitlock, 1992).  To test this 
hypothesis, reporter assays using p-2608/-2100Ur and p-2608/+71 HNF-3 mutants should 
be repeated in cells treated with a chromatin inhibitor such as Trichostatin A.  If the 
nucleosome is responsible for the effects observed in HNF-3 mutants then Trichostatin-A 
treatment should reduce or eliminate the inhibition observed in p-2608/-2100Ur HNF-3 
mutants while super-induction should be observed in the non-mutated p-2608/+71.  
Additionally, EMSA using oligonucleotides containing the putative HNF-3 binding site 
and Hepa-1 nuclear extracts could be utilized to confirm binding at the site in vitro while 
super-shifting with antibodies against HNF-3α could confirm that is the protein 
responsible for binding the element.  These experiments may not be successful, however, 
since the forkhead region of HNF-3α interacts directly with histones which would be 
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absent in an EMSA.  In vivo footprinting could also be utilized to detect the nucleosome 
in ZFL cells treated with control or HNF-3α siRNA. 
 Overall, the structure and function of the zebrafish CYP1A regulatory region 
appears to be similar to that which has been reported for other piscine and mammalian 
CYP1As.  Several novel findings have been identified for this model organism, however.  
Within this report, it has been shown that there exists an inequality of the contribution 
toward maximal induction exhibited by the functional XREs within this regulatory region 
which contradicts what has been previously established in the mouse.  Furthermore, 
previous studies have not identified an XRE which is required for maximal induction yet 
which fails to function in the absence of additional functional XREs as was observed for 
the zebrafish XRE8.  These findings are significant in that they support a better 
understanding of the mechanisms of AHR/ARNT-XRE binding and subsequent gene 
regulation.  Also within this report, it has been established that the degree of regulation 
mediated by CYP1A regulatory regions from different organisms is inconsistent between 
cell lines.  The data suggests that these inconsistencies may be due, at least in part, to 
selective binding of proteins at the promoter.  This novel finding may help elucidate how 
AHR target genes are differentially expressed in various tissues and organisms; 
especially as pertains to the application of findings obtained using cell culture and model 
organisms to human health.  Finally, a putative HNF-3 binding site was identified within 
the zebrafish CYP1A enhancer region which may have a role in nucleosome positioning 
based on mutational analyses.  Chromatin reorganization is a fundamental aspect of 
CYP1A regulation and an understanding the molecular mechanisms of nucleosome 
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arrangement in this regulatory region is essential to discerning the AHR-mediated control 
of this gene. 
 The characterization of the zebrafish CYP1A regulatory region was an important 
step toward using Danio as a model organism for the study of AHR-mediated signaling 
and TCDD-toxicity.  Apart from the numerous benefits this organism offers for 
developmental studies, the zebrafish CYP1A gene may be useful for future studies of 
AHR-mediated regulation of target genes.  Importantly, the distance between the 
promoter and enhancer regions in zebrafish CYP1A is far greater than observed in 
previously characterized organisms, thus making it ideal for procedures such as ChIP 
assays in that binding can be easily differentiated between the two regions.  Additionally, 
the zebrafish can be used as a bio-detector of environmental pollutants such as TCDD by 
the creation of transgenic fish which can produce a fluorescent signal in the presence of 
such chemicals at a dose dangerous to human health.  Such methods would be far more 
accurate and reliable than bio-chemical testing which is often inaccurate and incapable of 
knowing precisely the doses which may pose a threat to human health.   
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Chapter 4 
Materials and Methods 
 
Materials 
TCDD (98% stated chemical purity) was obtained from Radian Corp. (Austin, TX) or 
Cambridge Isotope Laboratories and was solubilized in dimethylsulfoxide (DMSO). 
Buffers 
PBS is 0.8% NaCl, 0.02% KCl, 0.14% Na2HPO4, 0.02% KH2PO4, pH 7.4. Lysis buffer 
is 60 mM Tris, pH 6.8, 2% SDS, 15% glycerol, 2 mM EDTA, 5 mM EGTA, 10 mM 
DTT, 5% NP-40, 20 mM sodium molybdate, 0.005% bromphenol blue. TBS is 50 mM 
Tris, 150 mM NaCl, pH 7.5. TTBS is 50 mM Tris, 0.2% Tween 20, 150 mM NaCl, pH 
7.5. TTBS_ is 50 mM Tris, 0.5% Tween 20, 300 mM NaCl, pH 7.5. BLOTTO is 5% dry 
milk in TTBS. Gel Shift Buffer is 50 mM Hepes, pH 7.5, 15 mM MgCl2, 50% glycerol. 
Cells and growth conditions 
Wild-type Hepa-1c1c7 (Hepa-1), were a generous gift from Dr. James Whitlock, Jr. 
(Department of Pharmacology, Stanford University). These cells were propagated in 
DMEM supplemented with 10% fetal bovine serum (FBS). Stable cell lines expressing 
the Ahb-2 AHR in the Hepa-1 background (B19) were propagated as detailed previously 
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(Pollenz and Dougherty, 2005). ZFL cells were obtained from ATCC (Manassas, VA) 
and propagated in a 0.5/0.35/0.15 mixture of L15:DMEM:Ham-F12 supplemented with 
bovine insulin (10 mg/L), EGF (20μg/L) and heat-inactivated FBS (5%) at 28 °C. Human 
HepG2, human ARPE-19, human A498 cells, mouse TCM cells and mouse C2C12 cells 
were purchased from ATCC and propagated as detailed by the manufacturer. All cells 
were passaged at 1-week intervals and used in experiments during a 3-month period at 
approximately 70% confluence. For treatment regimens, TCDD was administered 
directly into growth media for the indicated incubation times. DMSO was used as the 
vehicle control and the final concentration present in the culture media was between 0.05 
and 0.1%. 
Antibodies 
Specific antibodies against the zfAHR2 (zf-4) and rtARNTb (rt-84) are identical to those 
described previously. (Pollenz et al., 1996; Wentworth et al., 2004) All antibodies are 
affinity-purified IgG fractions. Antibodies specific to the zfARNT2b were purchased 
from Santa Cruz (Santa Cruz, CA). For Western blot analysis, goat-anti-rabbit antibodies 
conjugated to horseradish peroxidase (GAR-HRP) or rabbit anti-goat antibodies 
conjugated to horseradish peroxidase (RAG-HRP) were utilized (Jackson 
Immunoresearch, West Grove, PA). 
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Isolation of PAC clones containing the zfCYP1A gene 
Oligonucleotide primers: 
zfCYP1A1-UTR-upstream: 5’CTGGAAAGTATCCACTCGATCG3’ 
zFCYP1A1-ORF-downstream: 5’CCAGGACATTTCCGATAATCGG3’ 
were generated to the 5’UTR and ORF of the putative zfCYP1A mRNA (GenBank 
accession #BC094977). These primers were use to screen superpools of zebrafish 
genomic PACs, (Amemiya and Zon, 1999) by PCR. Two superpools displayed positive 
PCR products when visualized on a 2% agarose gel. The PAC 133 and 150 were then 
robotically dotted onto nitrocellulose filters and screened by colony hybridization using 
the 312 bp zfCYP1A1 cDNA fragment. One positive clone was isolated from each of the 
two superpools and termed #133 and #150. Southern blotting was used to identify 
fragments corresponding to the CYP1A gene, and these were subcloned into pBluescript 
SK- (Stratagene, Madison, WI) and sequenced. Sequence analysis and alignments were 
carried out using Lasergene software (DNAStar, Madison, WI). Analysis of regulatory 
elements was carried out using Transcription Element Search Software (TESS) freeware 
available through the University of Pennsylvania (http://www.cbil.upenn.edu/ tess). The 
sequence of the putative zfCYP1A promoter region (-2710 ± 65) that includes a portion of 
the 5’UTR and the splice site for intron 1 has been entered into GenBank (Accession# 
DQ182546). 
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Generation of reporter constructs and site-directed mutagenesis 
PCR was used to amplify the indicated regions of the zfCYP1A promoter/enhancer from 
subcloned SpeI fragment of PAC #150.  The PCR fragments were then ligated into 
pGL3promoter (Promega), to generate p-2608/-2100Fup, p-2608/-2100Rup, p-2608/-
2100Fdown, p-2608/-2100Rdown, p-580/-187Fup, and p-580/-187F or ligated into 
pGL3Basic (Promega) to generate p-580/+71Basic, p-2608/-2100Uf, p-2608/-2100Ur,or 
p-2727/-2100Ur. Orientation was determined by restriction analysis.  To generate 
constructs containing the full-length promoter/enhancer, the 12kb SpeI fragment was 
digested with SacI to yield a 2.7 kb fragment containing all of the previously examined 
XREs but terminating at−42 and missing the TATA box and transcriptional start site. To 
deal with this issue, the fragment was ligated into pSK- (Stratagene) and then cut out with 
SacI and KpnI. This fragment was ligated into the SacI and KpnI sites of p-2727/−2100Ur 
that had been cut to remove all but the +71 to −42 portion of the −2727/−2100Ur 
fragment. The full-length promoter/enhancer construct was termed p-2699/+71. The 
reporter vector containing the full promoter region from the mouse and the full promoter 
region from rainbow trout (p-1897Om1A3luc) were generous gifts from Dr. Michael 
Carvan (University of Wisconsin—Milwaukee) (Carvan et al., 1999).  To generate Om-
1897/-1392Uf, Om-1897/-1392Ur,Mm-1315/-819Uf,  and Mm-1315/-819Ur, the 
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indicated regions were amplified by PCR and ligated into  pGL3Basic (Promega) 
upstream of the -580/+71 region of the zfCYP1A.    
 Site-directed mutagenesis of specific cis regions of the zfCYP1A was carried out 
on the appropriate parental vectors using the Quikchange II XL site-directed mutagenesis 
kit using the manufacturer’s protocol (Stratagene). The primer sets used are listed with 
the specific base changes indicated in bold. 
XRE1: 5’-CCATGTATGTGTGAGTGTGTTACATAC  
            5’- GTATGTAACACACTCACACATACATGG.                                            
XRE3: 5’-CTCTCATTCACACTCACACTCATACAC 
            5’-GTGTATGAGTGTGAGTGTGAATGAGAG. 
XRE4: 5’-CACACCTTTGCACTCGATGCTTTACCTGTTGC 
           5’-GCAACAGGTAAAGCATCGAGTGCAAAGGTGTG. 
XRE7: 5’-CAGGTGCGCGCACTCGATGCTGTTTGATC 
           5’-GATCAAACAGCATCGAGTGCGCGCACCTG. 
XRE8: 5’-CCTCCTCCAGCTCACTCAACGTGGCCAATC 
           5’-GATTGGCCACGTTGAGTGAGCTGGAGGAGG. 
Sp1: 5’-CTTCCCATAAACCAACCGCAGAACAAAC 
        5’-GTTTGTTCTGCGGTTGGTTTATGGGTAG. 
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HNF-3(7): 5’-GCACGCGATGCTGTGGGATCAGTTTATCGTAGC 
                 5’-GCTACGATAAACTGATCCCACAGCATCGCGTGC. 
HNF-3(5): 5’-CGCACGCACATACTCTCACAC 
                 5’-GTGTGAGAGTATGTGCGTGCG. 
AP2: 5’-CCAATCTTTAACCAGCGCTACAGGTGC 
         5’-GCACCTGTAGCGCTGGTTAAAGATTGG. 
CREB: 5’-CGACGGCCACGCGCTTATACCCCATTCTGC 
            5’-GCAGAATGGGGTATAAGCGCGTGGCCGTCG. 
XRE4(6/8): 5’-CACACACACACACTTATGACAGCGATG 
                   5’-CATCGCGTGCATAAGTGTGTGTGTGTG. 
XRE5(6): 5’-GCAGCGGTTCACCATCGCACGCACAC 
                5’-GTGTGCGTGCGATGGTGAACCGCTGC. 
XRE5(8): 5’-GCAGCGGTTCACCATCGCACGCACAC 
                5’-GTGTGCGTGCGATGGTGAACCGCTGC. 
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Transfection and reporter assays 
Approximately 2×105 cells were plated into 35mm culture dishes and incubated at 37°C 
for 16–24 h.  Transfection cocktails were set up so that multiple dishes could be 
transfected with aliquots of the same sample. This was accomplished by mixing the 
reporter plasmid and pSV-β-galactosidase in OptiMEM media (Gibco) and then 
incubating the mixture with either LipofectAMINETM or LipofectAMINE 2000TM 
(Gibco) as specified by the manufacturer. Aliquots were 
then applied to the appropriate plates and after 24 h; the cells were exposed to TCDD or 
DMSO (0.05%) for 6–16 h. When multiple reporter plasmids were tobe used in an 
experiment, the concentration of DNA utilized was the same and was verified by OD260 
readings as well as agarose gel electrophoresis. Cells were harvested from plates by 
scraping directly into 200–400μl Reporter Lysis Buffer as specified by the manufacture 
(Promega). Luciferase activity was measured using identical sample volumes for 30 s in a 
Turner Instruments luminometer.   β-Galactosidase activity was measured using the β-
galactosidase assay kit as specified by the manufacturer (Promega). Typically, each data 
point was evaluated in triplicate and luciferase values were normalized by dividing the 
relative luciferase units (RLU) of each sample by the corresponding level of β-
galactosidase activity (OD420 reading). In most experiments, the relative transfection 
efficiency for all plasmids was similar in a given cell line, although the level of 
transfection efficiency across cell lines was different.  Results are presented as 
normalized luciferase units (raw) as well as fold-change between control and treated 
samples. 
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In vitro expression of protein 
Recombinant protein was produced from zfAHR2, rtARNTb, and zfARNT2b expression 
plasmids using the TNT™ Coupled Rabbit Reticulocyte Lysate Kit essentially as detailed 
by the manufacturer (Promega). Upon completion of the 90 min reaction, samples were 
either combined with an equal volume of 2X gel sample buffer and boiled for 5 min, or 
stored at -80°C for use in functional studies. The actual concentration of protein 
expressed in each reaction is estimated to be 6ng/μL, based on previous studies.  
In vitro activation of AHR:ARNT complexes and electrophoretic mobility shift assay 
The following oligonucleotides containing the core zfXRE sequences (bold) and 5’GG3’ 
overhangs (underlined) were synthesized by IDT (Coralville, IA). 
zfXRE1: 5’GGTGTAACACACGCACACATAC3’ 
zfXRE2: 5’GGGGAAACCCACGCCATGCAAA3’ 
zfXRE3: 5’GGATGAGTGTGCGTGTGAATGA3’ 
zfXRE4: 5’GGTAAAGCATCGCGTGCAAAGG3’ 
zfXRE5: 5’GGAGAGTGTGTGCGTGCGTTTG3’ 
zfXRE6: 5’GGTGTGAAACACGCTACGATAA3’ 
zfXRE7: 5’GGAACAGCATCGCGTGCGCGCA3’ 
zfXRE8: 5’GGGGCCACGTTGCGTGAGCTGG3’ 
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Duplex DNA was produced by mixing each oligonucleotide with its complementary 
strand, heating to 95°C and cooling to 25°C. Duplex DNAs were labeled with [32P]dCTP 
by Klenow fill in. In vitro binding assays and EMSA were carried out by combining 
approximately 25 ng of in vitro translated AHR and ARNT protein with 60 μL of MENG 
and incubated for 2 h at 30°C in the presence of TCDD (16 nM) or DMSO (0.5%). 14 μL 
of the activated sample was then incubated at 2°C for 15 min in 1X gel shift buffer 
supplemented with KCl (80 mM) and polydIdC (0.1mg/mL). 4 ng of the labeled zfXRE 
were added to each sample and incubated an additional 15 min at 22°C. The samples 
were resolved on 5% acrylamide/0.5% TBE gels, dried, and exposed to film. 
Western blot analysis and quantification of protein 
Protein samples were resolved by denaturing electrophoresis on discontinuous 
polyacrylamide slab gels (SDS-PAGE) and electrophoretically transferred to 
nitrocellulose.  Immunochemical staining was carried out with varying concentrations of 
primary antibody in BLOTTO buffer supplemented with DL-histidine (20 mM) for 1–2 h 
at 22°C. Blots were washed with three changes of TTBS+ for a total of 45 min. The blot 
was then incubated in BLOTTO buffer containing a secondary antibody for 1 h at 22°C 
and washed in 3 changes of TTBS+ as above.  Bands were visualized with the enhanced 
chemiluminescence (ECL) kit as specified by the manufacturer (Amersham, Arlington 
Hts, IL). Multiple exposures of each set of samples were produced. 
Statistical analysis 
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Normalized RLU values were compared by ANOVA and Tukey-Kramer multiple 
comparison tests using InStat software (GraphPad Software Inc. San Diego, CA). Results 
are presented as mean ±SE.  A probability value of ± 0.05 was considered significant. 
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Appendix A 
 
PAC 133 Sequencing Data 
 
 In order to obtain the sequence of the putative CYP1A regulatory region located 
within the fragments obtained from PAC 133 via restriction enzyme digestion, the 
12kb SpeI fragment and the 2.5kb and 0.5kb HindIII fragments were subcloned 
into pBluescript ks- and sequenced.  The initial sequencing was carried out using 
the T7 and T3 primers native to the vector.  Subsequent primers were designed 
against the sequence retrieved from the initial sequencing (Figure AA1).    Since 
the completion of this work, the zfCYP1A gene has been identified in the Sanger 
zebrafish genome project database.  The zfCYP1A has been assigned to 
chromosome 18.  The closest neighboring genes are the transient receptor 
potential cation channel, subfamily M, member 7 (trpm7), approximately 150 kb 
5’-ward of CYP1A and fibroblast growth factor 7 (fgf7), approximately 50kb 3’-
ward.  The sequence obtained from the sequencing outlined above follows in this 
appendix.  Directly sequenced nucleotides are capitalized.  Sequence obtained in 
silico from other sources is represented by lowercase characters.  Introns are 
italicized.  Splice donor/acceptor sites are bold faced.  The TATA box is 
underlined.  SpeI and HindIII restriction enzyme sites are bold faced.  XREs are 
bold and underlined.  Numbering is relative to the transcriptional start site such 
that -1 is immediately 5’ of the transcriptional start site and +1 is immediately 3’. 
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Appendix A continued 
Figure AA1.  Schematic Overview of Sequencing Strategy 
 
 
 
 
 
 
 
 
 
Fig. AA1.  Schematic overview of sequencing strategy.   Visual representation of 
the sequencing strategy employed on the subcloned constructs containing the region 
upstream of the zfCYP1A.  The 12kb SpeI fragment as well as the 2.5kb and 0.5kb 
HindIII fragments were subcloned into pBluescript ks- and sequenced using T7 and 
T3 primers.  Subsequent primers were generated based upon the sequence retrieved 
from the initial sequencing.  Primers and direction are indicated by arrows.  The 
shaded region indicates the relative location of the HindIII fragments within the 
larger SpeI fragment.  The positions of the 5’ untranslated region, the translational 
start codon, open reading frame, and splice donor/acceptor sites are labeled.  
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Appendix A continued 
>Danio rerio Cytochrome P4501A 5’ Regulatory Region, 5’-UTR, and Intron 1 
 
-3359 gttcataccattgtgaatgcataatctgtctatacaacaaaaaaagtcagtcaacagtctgaaac 
-3294 tggcagatttagagcaccgtaagagttcacaaaaaatagctgtttgtttctacatagactaaaag 
-3229 taaactaaaagtaaattagatgcatggagtgtatagtttgagctaaggtaagcctatgtaagtca 
-3164 gaatacactaatttgcctatccctatctctcagaaaacactgaaaacttaaacacatttcattaa 
-3099 taaattagatgtcatttaattaaatacataactttgattaactgaagcatgtattacacaattct 
-3034 catggggaaaattttaaatatatgtatatatttgtaatatttatttgtacaatttatttataatt 
-2969 tcatgttagtaattatttgttgtgaatgataacaacttgtttgtaaagttttttttttccttaac 
-2904 aacaaaactatagctgtagggttaatcaggctgagtgttaggacagggtttgtacatttgtaaag 
-2839 tgttttaatgaagcaaaaaaatctgaaaaccaaataatgacatactttcctttacaaaacaactc 
-2774 acagaaatcaaccatcgggccattttagtcatgtttgggatgaaatacttgcattcactgtattt 
-2709 atgtttttatttcaaggtcagataatgtttctcttaggatgtcctacatataaagccgaacagga 
-2644 gggtaaatagagcagaACTAGTGAACCTCTTCTCCTCCTCCAGCTCACGCAACGTGGCCAATCTT 
-2579 TAACCCGCGCTACAGGTGCGCGCACGCGATGCTGTTTGATCAGTTTATCGTAGCGTGTTTCACAC 
-2514 AGCGATAACAGTCTGAGGTCGCAGGAACTCTTCCCATAAACCCACCGCAGAACAAACACTCCGGC 
-2449 TTTAACACTCCTCGTGCTTTTGTGCATGAACCGCTGACATGCACGCTCTCCGACGGCCACGCGCG 
-2384 TCTACCCCATTCTGCCAGCTCTTCCTGTTGACAGTCAATGAGATGCATGAAAAATGTGTGAAGGA 
-2319 ATCTGCAGCAGCGGTTCACAAACGCACGCACACACTCTCACACACACACACCTTTGCACGCGATG 
-2254 CTTTACCTGTTGCTTAATGAGTTACGAGCGCGTGCCAGATCAGCAGAGACTCAAACATGCAGGCA 
-2189 ATTATCGGATGTGTTGCAACAAACAATTTATTTAGTTCACATAATTGCCTAAACCATCACACTGA 
-2124 TTTATGACACTTTAGCTTAGACAGCTTTAAAAGATAAATAAACATCTCGAGCATGCTGTTTAACT 
-2059 TTTCATGATTTATATATTCTGATTTTATTGGGCTTATTTATTTCTCACATAATTATTATCCGCAT 
-1994 TGAGTTTGCTGTATTAAGAGTTGTGATGAAATGTGGGATTGATTTCTCAGTTAATGCACGTCGCT 
-1929 TTTGTCTACAAACTGTTCTGTAAATATTAACATTACATTACATAACATCAAAAAACACTGATAAG 
-1864 CCCAGTTCTGCCTTAATTATAAAGGCTAATTAAGCGTCTCATTTATTAATTTATTTCATTTATTT 
-1799 ATGTTTTAAATATATATTTGTTTACATATTGCAAATTTAGTTGGAAATGCATGTTAAAAATATTA 
-1734 GTGCTGTATAATTATTACCCAATCAAAAATGTTGCATTTGTGTTAAATATTGACATATATATGAT 
-1669 CACATTACATAAATATTGACATATATATGATTACAATACATAAATATTGACATATATATATATAA 
-1604 TAATGTTACATAAATATTGACATATATGATTACGTTACATAAATATTGACATATATATAATTACT 
-1539 TTACATAAATATTGATATATATATAATTACATTACATAAATATGAGCATATATATATAATTACAT 
-1474 TACATAAATATTGACATATATATTTAATTACAATACATAAATATTGACATATATATAATTACATT 
-1409 ACATAAATATTGACATATATGATTACATTACATAAATATTGACATATATAAGTACGTTACATAAA 
-1344 TATTGAGATATATATATATAATTACAATACATAAATATTGGCATATATATAATTACGTTACATAA 
-1279 ATATTGACATATATATATATATATATATATATATATATATATATATATATATATATATATATATA 
126 
 
Appendix A continued 
-1214 ATTACAATACATAAATATTGACATATATGATTACGTTACATAAATATTGACACATATATAATTAC 
-1149 GTTACATAAATATTGACATATATATAATTACGTTTCATAAATATTGACATATATATAATAACGAT 
-1084 ACATAAATATTGACATATATATGATTACAATACATAAATATTGGCATAATTAAAATGACATTACA 
-1019 TAAATATTGACATATATATGACTATATTACAAAAATATTGACATATATATATATACACACACACA 
 -954 CACATATATATATACAATTACGTTGAATCAATATTGACATATATATGAATGAATTACAAAAATAT 
 -889 TGACATATATATAATAACGTTACATAAATATTGACATATATTTGATTTTATTAAATAAATATTGG 
 -824 CATATATATAATTACATTACATAAATATTGACATATATATGATTACATTACATAAATATTGACAT 
 -759 ATATATAATAACGTTACATAAATATTGACATATATTTGATTTTATTAAATAAATATTGGCATATA 
 -694 TATGATTACATTACATAAATATTGACATATATATATATATATATATATATATATATATATATATA 
 -629 TATATATATATATTTACTTTACATAAATATTGACATATTTGACTTAGTCCCTTTAATCAGGGGTC 
 -564 GCCACTGCGGAATGAACCGCCAACTTATCCAGCATAGTTTTTACGCAGCAGATGCCCTTCCAGCT 
 -499 GCAACCCAACACTGGGAAACACACATACCCTCTCATTCACACGCACACTCATACACTACGGCCAA 
 -434 TTTAGTTCATCAGTTCCCCTAAAGTGCATGTGTTTGGACTGTGGAGAAAACCGGAGCACCCGGAG 
 -369 GAAACCCACGCCATGCAAACTCCACACAGAAATGCCAGCTGACCCAGCTCGAACCAGCGATCGTG 
 -304 CTACTCACTGCACTTTATAAATATATATTTTTCATTCATAACTTTTGTATACATTTTACATAGTC 
 -239 TTTTGTACCATGTATGTGTGCGTGTGTTACATACATCAATCTCCTTCCCACAGTTTAGATATGTG 
 -174 TGAGGTGAGTGTGTGTAATTACTCAGGGAGTTTACTCAGTGCAATCGATCAGCCTGTAATAAAAT 
 -109 CTCAGCCCTTCTCAGCATCAAAGCCTCCTGCGCTCGGTGACGTCCGCGGAGGACAGCCAATCACG 
  -44 GCGAGCTCTGCGCTATAAAAGATTTACCGCTGGAATAGTGCAGCACTCCTCTGGAGCTAATTGGC 
  +21 ACTGGATAGAAACAGCTGAGAACTGGAAAGTATCCACTCGATCGCTCCGGGTGAGTCTGATGTCA 
  +86 ATGGTTTTGTCTTATATTGAATATGTGATCATTGTGCAGGTGCTTTATGCAACTTTTAAACGTCA 
 +151 AAACATTAACTTTCTTTACTTTTTCTACATGTTTTGCACAATATTGTACAGCTTAAATGGTGTGC 
 +216 ATGTCACTTTTATAATAATTTTAGAGTTGAAAAAAAATGTATGTATAATATATATACTATAATTA 
 +281 TATTATATATTATATTTTAATATCACTGTATTCCATTATAATGACATTTTTTGATTGCAAAGCAT 
 +346 TTATTCATGCACCATTTTGCTCTTCATCATCAGTTTCAGTGCACATAAAGCCTATTTCCAGCTTT 
 +411 TATATGAAGTTATATGGAGTATAGCGTGTGTATGTGTGTGTATATATAGGTTTTTCTAACTTTAG 
 +476 AATTATTATTTATCATTGTTATTAATATAATTATTATTATTATTGGTTTGATGATGATTGTTAAT 
 +541 TATTTATTGCTTTGAATACTCCATATGGTCATTTAAACCCTTTATTGTTTCCCCACTTCTTTATT 
 +606 TGAAATCATACTTGAAAATGCTATAAGATTTATGCATATGGTTGATGTTCAGA 
 
 
> Danio rerio Cytochrome P4501A Intron 1 partial sequence and Exon 1 partial sequence 
 
 
 
…TATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATA
TATATATATATTTATATTTATATGTAGGTTGTAGGTTTTTATGTTGCTGCACAGTATGCATGTGT
GAGTATATCTTGCCTAATACAGGTGTGTGTGCATGTGCGTGTGTGTCTCAGATATGTGCTCTGAC
CTTGAGACAAATCACTCCATGTGTAGTTTATCATTAATGAATTTTGCAATTCAAATAACCAACCA
ATGCGCACTGGTTAAGCTGCACACTTATAGCATTTAGTTGCATAAAAACTCATGCATGTGCAGCA 
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TTAATGACAGACAGGTTGCGGAAACACACACCTTTCTCAGTATCGTTCATCTAAGAAGTGTTACT
GTTAGACTTCTGCTGGCATCAAATTTACTTGTTGCAATTTATTGCTGAAGCTTGTAACTTGATAT
ATGGTGTTATCACAATAGACTGCAAAATAAACTACTTTAACAGGTATAGCAACAATAATACTTGT
ATTGATTTATCATTCAGGATAAACACATTTTTCAACTAAAATAAATTCTGAAAAAAATTATAAAG 
TACAACAGGTAACACTTTACATTAAAGATGAGTTAACACTAATTAATGTATTAAAATCTACAGTG
ATAAAATGACATATTATGGTTGTGTTAAAGAAATATAAATAAATATTTTAAAATATCTTCTGTAA
AACAACCGTCCTGGATGTTCTTGATCCCACTTAATACAATCCAGCCACAAAACATAGAAATTAGA
CACAAACATTGTTCTGAACCGTAATAGTTTATTAAATCATTAAATAAATGCAAAGCTGACAGAGA
CTTAAACAGCTGATGGAGTATAAACTAACCTGCACATTATTCAGACACTAGATGGCGCTAAAAAC
AGTCAAAAACACAAAAGAAACTAAACAGCTGATGGAGTATACATTAACCTGCGCATTATTCACAC
ACTAGATGGCGCTAAAAACAGTCAAAAACACAAAGCTGACAGACACTAAAACAGCTGATGGAGTA
TACACTAACCTGCGCATTATTCAGACACTAGATGGCGCCAAACAGTCAAAAACACAACAGACACT
AAAACAGCTGATGGAGTATACACTAACCTGCGCATTATTCAGACACTAGATGGCGCCAAACAGTC
AAAAACACAACAGACACTAAAACAGCTGATGGAGTATGCACTAACCTGTGCATTATTCAGACACT
AGATGGCACTAAAACAGTCAAAAACACAAAGCTAAAAAAACACGAACAGCTGATGGAGTATACAC
TAACCTGCACATTATTCAGACACTAGATGGCGCTAAAAACAGTCAAAAACACAAAGCTGACAGAC
ACTAAAACAGCTGATGGAGTATACACTAACCTGTGCATTATTCAGACACTAGATGGCGCTAAAAA
CAGTCAAAAACACAAAGCTGACAGACACTAAAACAGCTGATGGAGTATACACTAACCTGCACATT
ATTCAGACACTA… 
…TTCCATTTTCAGACACTAGATGGCGCCAACAGTCAAAACACACAAAAACACAACAGTTGATGGA
GTATACACTAACCTGTGCATTATTCAGACACTAGAAGGCGCCAAACAGTTAAAAACACAACAGAC
ACTAAAACAGCTGATGGAGTATACACTAACCTGCGCATTATTCAGACACTAGATGGCGCCAAACA
GTTAAAAACACAACAGACACTAAAACAGCTGATGGAGTATACACTAACCTGCGCATTATTCAGAC
ACTAGATGGCGCTAAACAGACAAAATCTGCAGTGTAAGTCAGCAGATACGTATAAACATGGACGT
GTATTTAAATTTTGACATATGTGAATCTCAGTTCCGGGATGAGTCTGTATTATCCTGCAGTTGTT
ATCTGTAAATAACATACCTTATTATTGTCACAACTGACCAATCAGAATCAAGTATTCTACACAAA
ACCATGTAATAATTTTTACTAACAACCACCTGAATGTACTTAATTCCGCTTATTACATGGCTACT
TACCACAAAGCATAAAAAAAGACTCAAAAATCAATTCAACAGTATATATTTAATAACTGATGGTG
ATAATTACTGATATTCCCTCTCTAATACCTCATTTATGTCTGCTTCCTTCTAAACAGGTTATTAA
ATCAGCAATGGCTCTGACTATTCTTCCAATATTGGGTCCGATTTCTGTGTCTGAGAGTCTCGTGG
CCATTATAACAATATGTTTGGTGTATCTGCTCATGCGCCTAAACCGCACGAAAATCCCAGACGGG
CTACAGAAGCTT 
 
> Danio rerio Cytochrome P4501A Exon 1 partial sequence 
 
 
 
AAGCTTCCCGGCCCGAAGCCTCTGCCGATTATCGGAAATGTCCTGGAAATCGGAAACAACCCACA
TTTGAGTCTGACGGCCATGAGTAAGTGCTATGGCCCGGTTTTTCAGATCCAGATCGGCATGCGTC
CTGTTGTCGTACTCAGTGGGAATGATGTGATCCGACAGGCGCTCCTAAAACAGGGCGAAGAGTTT 
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TCCGGACGTCCAGAATTGTACAGCACCAAGTTCATCAGTGATGGAAAGAGTCTGGCGTTCAGTAC
GGATCAAGTCGGAGTCTGGAGAGCACGCCGAAAGCTGGCGCTCAATGCCCTGCGAACATTTTCAA
CGGTGCAGGGAAAGAGTCCCAAATATTCCTGCGCCCTAGAGGAGCACATCAGTAATGAGGGTTTA
TATTTGGTCCAGAGGCTGCACTCTGTTATGAAAGCCGATGGAAGCTTTGATCCATTCAGACATAT
CGTAGTATCCGTGGCTAACGTAATCTGCGGGATCTGTTTCGGACGCCGGCATAGTCATGATGATG 
ATGAACTGGTGCGACTGGTTAATATGAGCGATGAGTTCGGGAAGATCGTGGGCAGCGGAAACCCT
GCCGATTTCATCCCTTTCCTGCGCATTCTGCCGAGCACGACGATGAAGAAGTTCCTGGATATCAA
CGAACGCTTCAGTAAATTCATGAAGAGGCTGGTGATGGAGCATTACGATACGTTCGATAAGG 
 
 
 
 
 
 
 
> Danio rerio Cytochrome P4501A Intron 2 partial sequence and Exon 2 partial sequence 
 
 
TGGGGTGGGTTACGTTTGTGTGTGAGCTTATAGGAACATTCATTCATTCATTTTCGGCTTAGTCC
CTTTATTAATCAGGGGTCACCACAGCAGAATGAACCACCAACTTATCCAGCACATGCTTTATGAA
GCGCATGCCCTTCCAGCCGCAACCCATCACTGGGAAACACCCACACACTCTCATTCACACTCACA
CACTACGGACAATTTAGCCTACCCAATTCCCCTACACCGCATGTGTTTGGACAGTGGGGGAAACC
GGAGCACCCGGAGGAAACCCACACGAACGCAGGGAGAACATGCAAACTCCACACAGAAACACCAa
ctgacccagctgaggatcgaaccagcaaccttcttgctgtgatgcgacagaagtacctactttta
taatctttttatttattcaggagcagttttagcttagcttagcatccatcattgaatcagattag
accattagcatctctctcaaaatattcaaaagttagactcttccatagtcgtgtatttattagtc
acactggatcaataaaagcgggctgcacggtggcgtagtgggtagcacattcacctcacagcaag
aaggtggctggttcgagcctcggctgggtcaggtggcgtttctgtgtggattttgcatgttctcc
ctgtgtttgcgtgggtttcctccaggtgctccggtttcccccactgtccaaacgcatgtggtata
ggtgaattgggtaggcgaaatgtgtgtgaataagtgtgtatgaatgattcccagtgatgggttgc
agttggaagggcatccactgcataaaacatatgatgaataggttggtggttcattccgctgtggc
gactccagattaatagagggacaaacctctagcttagcttagcttagcatagttcattgaatcag
attagaccattagcatctctttcaaaaatgattatcaaagagttttgatgatttttctgactcct
caagctttgaataggaaaataatccaaacaccttttacagttttttttagcaagatgctaatggt
ctaatccgattcaatggtctatgctaagctaagttataagtcctccggccaaacttggagatcgg
ctgaataaatccaataatgaaaaactcaaccgttaaactttagatctggggtgtccaaactcggt
cctggagggctgttgtcctgcagattttagctccaacttgcctcaacacacctgcaaggatgttt
ctagcttgttaaacagtggagtgtatcggtacttcacccaaaaatgtaaattctgtatataatta
gttactcatcctcatttttaatccatcaccctaaaagcgacaatttgaatttattttaaaaaata
gtaaatctgttgtaacttaaaagagttgacttaatttctaagttaatagtattttaaaaataaca
gttatgcacacagtttttatttctattgtttattaagatccccattggccacaatattcctgggg 
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tccgacaaatgaaatgacaagtttagattaattcatcattaaaaacaataacaaaaaagctaatt
taaattaaaataaaacaatagaaactttaaaaaaacacagaaaaaggctaattcacactaaacac
aacaatagacatcaaaaccacaaccaactaaagacaaataagcattaaattacaaaaccaacaca
ataaaacacactgtttcaatcatttgaaactatttatttaatttcaaggcaacgcattactcaaa
ttttattgcatttattttagtttgatctccacatagataaacgatcttaaaaataggtcatttta
aatagtgtttctctatcaggcaaatgtaatgttgcaagtttttccagtgtcgtgtggctcttcgt
agctcattgtctgttaaatttttttcaggACAACATCAGAGACATCACCGACTCTCTTATCAACC 
ACTGCGAAGACCGAAAACTGGACGAAAACTCCAACCTGCAAGTGTCCGATGAGAAGATCGTAGGA
ATCGTCAATGACCTATTCGGAGCCGGTTTCGACACTATCAGTACGGCTCTGTCCTGGGCGGTTGT
CTATCTAGTGCACTACCCAGAGGTCCAGGAGCGACTGCAAAGAGAATTGGATGAAAAGATCGGGA
AGGATCGCACACCACTGTTATCTGACAGGGCGAACCTGCCGCTTCTGGAGTCCTTCATTCTGGAG
ATCTTCCGTCATTCATCCTTCCTTCCCTTCACCATTCCTCACTGCACATCCAAAGACACGTCACT
CAATGGCTATTTTATTCCCAAAGACACCTGCGTGTTTGTAAACCAGTGGCAAGTCAACCATGACC
CGTAAGTTTCTCGTTATTAATCTGGTCTGATTTACAATGCTTTCTCAACACATTAAAAATACTGT
AGTACTTACATACTATAGTCTATAAGTAACCATACCATAGTTTAGTTCTTGAACTGTTGTGGTGA
TTCTACAGTTGCTATGGTAACACAACAACTTCAGTAATTAATCCATTGTGGCGATTGTACAGTTG
CTATGGAAACACAATGACTAGAGTAATTGAGTTGTGGTGATTATACAGTTGCTATGGTAACAACA
ACTATAGTAATTAATCTGTTGTGGTGATTCTACAGTTGCTATGGAAACACAACAACTATAGTAAT
TGAGTTGTTGTGGTGATTCTACAGTTGCTATGGTAACACAACAACTATAGTAATTAATCCGTTGT
GGTGATTCTACAATTGGTATGGAAACACAATGACTACCGTAATTGAGTTGTTGTGGTGATTCTAC
AGTTGCTATGGTAACTCAACCACGATTGTAATTGATTGTTGTGGTTATTCTACAGTTGCTATGGT
AACACAACAACTATAGTAATTAATCTGCTTTGATGATTCTAAAGTTGCTATGGTGACACAACAAC
TATAGTATTTAATCCGTTGTGGTGATTCTACAGTTGCTATGGTAACACAACAACTATAGTTAATG
ATCTGCTTTGATGATTCTATAGTTGCTATGGTAACACAACAACTGTACTATTATAAACAAATGAT
CCAATACTGTAGTTTTCTACAACTATAGGGTATATTATACTACACTACATCACAGTGTACTAGTa
aaaaaggagtatgttacagtatttattataatttatcaggtcactgttgttaaactacagtatac
tggaacattcattaacaaagtgttgtaaaaactataatatatatatgatattttacactttacta
cagtatggttcacaaacactacagtattcaccatggatgaattgatatttaatttgtgactgata
ccattagccgatgacttttaaaatttggagggtgttatctgatatataggccaatcaatgtgaat
aataacatttctgcttgattgctaaaccaaaaggcaaacacatacagagaacaactctgaaatta
atttatttagcaactattcatttctatggccagctttgctttcatataaaggaaatctattgaca
aaaaacaacaacaacaaagcaataaagccattgaaaaagtggcacgcagcaagcatgtaaaatgg
ctaaaccagaagaaataatacatctttaatcagcttattgaaccgataacaataatattaaatat
agcgtataagactgtacattaatttagttaagcatttcatttgtgatttaacagtctttttatta
atatgcagttttgcttattcattgtttttatcgtagtgtgatttattattgtgatctgattatgc
ataagatgcaaatatatccacttaattctgttattggagctacaataatattacaaatagcattt
atcagctgatattcatatggccactatcatgaatccccagtatttactataaattactgcacatt
tatatgtgagtcaaaccaagctgaacctgttatttgtgtttgcagAGAACTGTGGAAGGATCCCT
CGTCTTTTATTCCCGACCGGTTCCTCACTGCGGACGGTACTGAACTGAATAAGTTGGAAGGCGAG
AAGGTGTTGGTTTTCGGTTTGGGAAAGCGCCGCTGCATTGGAGAGTCCATCGGACGCGCTGAAGT
CTTCCTGTTCCTGGCCATCCTGCTGCAAAGGTTAAAGTTCACCGGGATGCCAGGAGAAATGCTGG
ATATGACCCCAGAGTACGGGTTGACCATGAAACACAAGCGGTGTCTTCTTCGGGTCACACCACAG
CCTGGGTTCTAGATCCAGAACTCCTCATCATGATCCAAAAATCAAAGATTGAGCCCCTGAAATCC
AGGAAAACTGGCCAGCAGGTGGAGATGCTGAATATTAGAGATGTTTGTTCGCAGGTCAAAGCATC
CGATGCATTCTGATGCAAGCACACTGCAAAATATATGCTATTATTACTTACTATTAGAGTTTTTG
TCTTGCTTCTAGTCCAAATATCTCAAACGTCATTAATCAAGAAGCATTTTGTTGGCAAGTGAAAC
ATCTTGTCTTGTTTTCAAATATAATGAGTGAAAATTAAATGACGTTTTCCGTAAAACAAGCAAAA
TAATCTGCTTGCTCTGTTTAAAAAACTCTGTTAAACAGCTCTTTGGTAAGGAACTTTAATAATTG
GATAGTTTTGTTGTAAATTGTGCATATATGCATATCAGATGCACGCTTGCATGGCCTTGTCCTTT
CAAAACTGGAATGCTGATAATGTATTTGTGCTTTCAAACATACCGCGGTAAAGCACAGATCAGGA
TGAAGAGTGCCTGTTTTAGCTGCGGTTTAGCTGTCTATCAAAGCAATGCCTTCTGTCTTCATAAG
CTTAATGCAGATTCATCTGCCTGTCGACATACACTGATGCTGTTTTCTAATTGATGATGATCCCC
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GAATGTGATCCACATGTAAATACGCAGCGGCTGTTTCAATATGCACATTTTTTTTCCCATGTGCC
TGATTTTACTTGTGTACAGATTTGTAATATCTACTTTTTGTATTTATCAAAGTGCTTAATCAGAT
GTTTATTTCCTTGAGATATCGTGTCTGTGACCTGCTGAAACTCTTCGCAGGTGCTCATAATTGTA
TTATGAAGGAATTCTGAAGTACTACTGCTATAATTAATTCATGCTAACATGGTCTCCAATGGCAG
TTTGTTGTTGCATAGCATATTTATGATGTTGGCAAAATAAATAATAAAACTTCTACTGCTG 
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Appendix B 
 
Construct Maps 
 
 
 This appendix contains maps of constructs uses in the experiments outlined in 
this report.  The names and size of the constructs in base pairs are indicated.  Pertinent 
restriction enzyme sites are noted along with their numerical positions.  Bold faced 
numbers represent the position of the indicated DNA insert relative to the transcriptional 
start site.  The diagrams below the maps represent the portion(s) of the regulatory region 
within the construct.  XREs are shown as shaded rectangles.  The XRE designation and 
its position relative to the transcriptional start site are indicated. 
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Figure AB1.  p-2608/-2100Fup 
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Figure AB2.  p-2608/-2100Rup 
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Figure AB3.  p-2608/-2100Fdown 
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Figure AB4.  p-2608/-2100Rdown 
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Figure AB5.  p-580/-187Fup 
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Figure AB6.  p-580/-187Fdown 
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Figure AB7.  P-580/+71Basic 
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Figure AB8.  p-2608/-2100Uf 
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Figure AB9.  p-2608/-2100Ur 
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Figure AB10.  p-Om-1897/-1392Uf 
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Figure AB11.  p-Om-1897/-1392Ur 
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Figure AB12.  p-Mm—1315/-819Uf 
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Figure AB13.  p-Mm-1315/-819Ur 
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Figure AB14.  p--2699/+71 
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Figure AB15.  p—2608/+71 
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Appendix C 
 
Additional Studies 
 
Generation of destabilized EGFP and EYFP constructs 
 In order to gain a better understanding of the timecourse of AHR-induced 
genes, constructs were generated which contain a gene encoding a destabilized enhanced 
green fluorescent protein (dEGFP) under control of the zfCYP1A regulatory region.  The 
purpose of destabilizing the EYFP was to ensure that the fluorescent signal produced is 
not persistent and can be representative of transcriptional activity over time without 
protein accumulation from earlier transcriptional activity.  To produce a destabilized 
EGFP, the degradation domain of the mouse ornithine decarboxylase gene was fused to 
the EGFP coding sequence.  Additionally, a 3x nuclear localization signal was fused to 
the amino terminus of EGFP to generate a nuclear fluorescent signal which would be 
easier to view via fluorescent microscopy.   PCR was utilized to make the constructs such 
that primers were synthesized which amplified both the 3xNLS and the dEGFP with 
overhangs respectively complementary to each other.  An additional PCR cycle was run 
using both products as template, the forward NLS primer, and the reverse dEGFP primer.  
A non-destabilized EGFP was also generated by using a reverse EYFP primer which 
precedes the ornithine decarboxylase degradation domain and includes a stop codon.  The  
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 3xNLS template was purchased as a double stranded oligonucleotide.  The pd2EGFP 
vector (Clontech) was used as a template for the dEGFP. 
 The primers used are listed below.  Indicated restriction enzyme sites are 
underlined. 
 
3xNLS double stranded oligonucleotide: 
 
5’- CCGAGATCCGGTGGATCCCACTCTTTTCTTTTTGGGGTCCACCCTTTTTTTTTTT 
3’- GGCTCTAGGCCACCTAGGGTGAGAAAAGAAAAACCCCAGGTGGGAAAAAAAAAAA 
 
 
GGGTCAACCCGCTTCTTCTTAGGATCCATGGTGGGATATCTGAC -3’ 
CCCAGTTGGGCGAAGAAGAATCCTAGGTACCACCCTATAGACTG -5’ 
 
P1 FOR 3XNLS EcoRV – 5’- ATCGTCAGATATCCCACCATGGATCC 
 
P2 REV 3XNLS –5’ - CAGCTCCTCGCCCTTGCTCACCATCCGAGATCCGGTGGAT     
              CCCACTCT 
 
P3 FOR GFP – 5’- AGAGTGGGATCCACCGGATCTCGGATGGTGAGCAAGGGCG 
             AGGAGCTG 
 
P4 REV GFP XbaI – 5’- CCTCCATCTAGACTACACATTGATCCTAGCAG 
 After creating the recombinant GFP inserts they were ligated into the multiple 
cloning site of pcDNA 3.1 (Clontech) and termed p-EGFP and p-dEGFP.  Transfection of 
the constructs into Hepa1c1c7 cells, however failed to produce fluorescence.  The reason 
for the failure of the constructs to work is unknown.  To allow for the problem lying 
within the GFP, additional constructs were made containing the coding sequence for an 
enhanced yellow fluorescent protein (EYFP) known to work previously.  These 
constructs were assembled modularly such that PCR was utilized to amplify the ODC and 
NLS from p-dEGFP with primers containing restriction enzyme sites integrated into 
them.  EYFP was amplified from p-EYFP-C1 (Clontech) using primers with  
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Figure AC1.  Strategy for Generating EYFP Constructs 
 
 
   
 
 
 
 
 
Fig. AC1.  Strategy for Generating EYFP Constructs.  Schematic 
representation of the EYFP inserts used to generate EYFP constructs.  
EYFP = Enhanced yellow fluorescent protein.  NLS = 3x nuclear 
localization signal.  ODC = ornithine decarboxylase degradation domain.  
Restriction sites and the PCR primers within which they are integrated are 
indicated 
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corresponding restriction enzyme sites.  To ensure the lack of function exhibited by p-
dEGFP was not due to the ornithine decarboxylase cassette or the nuclear localization 
sequence, the new constructs were assembled containing only the EYFP cassette, (p-
EYFP), the EYFP cassette with the ODC degradation domain, (p-dEYFP), the EYFP 
cassette with the 3xNLS, (p-NLSEYFP), and the EYFP with both the ODC and NLS, (p-
NLSdEYFP).  A schematic overview of the modular assembly of the EYFP constructs is 
shown in Figure AC1.  The primers used for the creation of the EYFP constructs follow. 
3xNLS double stranded oligonucleotide: 
 
3xNLS – 5’- CTAGCCCCACCATG CCA CCT AAG AAA AAA AGA AAG GTT  
        3’-     GGGGTGGTAC GGT GGA TTC TTT TTT TCT TTC CAA  
 
        GAA GAT CCTGGTAC-3’ 
        CTT CTA GGAC    -5’ 
            
 
P1 FOR 3xNLS NheI – 5’- ATCGTCAGCTAGCCCACCATGGATCC 
 
EYFP IN NheI – 5’- TTTTGCTAGCCCACCATGGTGAGCAAGGGC 
 
P4 REV EYFP HindIII – 5’- TTTTAAGCTTTCACTTGTACAGCTCGT 
 
EYFP OUT FOR ODC – 5’- TTTTAAGCTTGTACAGCTCGTC 
 
ODC IN HindIII – 5’- TTTTAAGCTTAGCCATGGCTTC 
ODC OUT BamHI – 5’- TTTTGGATCCCTACACATTGATCCT 
 
 The appropriate modules were ligated into pcDNA 3.1 and the constructs were 
once again transfected into Hepa1c1c7 cells.  Fluorescence microscopy revealed that a  
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Figure AC2.  Constrct Maps of p-EYFP and p-dEYFP 
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Fig. AC2.  Construct maps of p-EYFP and p-dEYFP.  Maps of the p-EYFP 
and p-dEYFP plasmids.  The size of the constructs in base pairs is shown.  
Pertinent restriction enzyme sites are indicated.  EYFP = enhanced yellow 
fluorescent protein.  NLS = 3x nuclear localization signal.  ODC = ornithine 
decarboxylase degradation domain.   
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fluorescent signal was produced by all constructs.  The cells transfected with p-
NLSEYFP and p-NLSdEYFP however, did not appear to localize to the nucleus and was 
dispersed throughout the cells.  Treatment of transfected cells with cycloheximide 
additionally did not show a difference in the rate of degradation between p-EYFP and p-
dEYFP as expected.    
 To test whether or not the EYFP could be controlled by an AHR dependant 
promoter, the recombinant EYFP inserts were cloned downstream of the zebrafish 
CYP1A enhancer region (-2628/-2100) and the zfCYP1A promoter (-580/+71).  Maps of 
these constructs can be seen in Figure AC2.  These constructs, termed p-2628/-  
2100UrEYFP, p-2628/-2100UrdEYFP, p-2628/-2100UrNLSEYFP, and p-2628/-
2100UrNLSdEYFP were then transfected into Hepa1c1c7 which were treated with 
vehicle dimethylsulfoxide or TCDD.  The cells produced a fluorescent signal, however 
the signal was produced even in the absence of TCDD to the same levels as TCDD 
treated cells.  The reason for the constitutive activity is unknown but may be due to 
moderate basal levels exhibited by luciferase constructs bearing the same regulatory 
region.  As seen in previous experiments with p-EYFP, p-dEYFP, and p-NLSEYFP, the 
signal did not localize to the nucleus or appear to degrade at an accelerated rate when 
treated with cycloheximide.  Sequencing of the constructs revealed that the inserts had no 
aberrations.  Further work will have to be done to design constructs capable of being used 
to address the timecourse of AHR-induced genes.   
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ARNT Domain Swapping 
 To assess the role the bHLH, PAS, and TAD domains of ARNT and ARNT2 
have on their function, the coding regions of the human ARNT and mouse ARNT2 genes 
were analyzed and a strategy to insert restriction enzyme sites between domains was  
devised.  PCR was utilized to alter nucleotides within the coding region to create unique 
restriction sites which did not alter the amino acids being  
encoded.  The nucleotide and corresponding amino acid sequences of the human and 
mouse ARNT and ARNT2 are listed below.  Generated restriction enzyme sites are bold 
faced. Mutated nucleotides are capitalized and underlined.  A schematic overview of the 
domains and the restriction enzyme sites can be seen in Figure AC3.   
>C57/BL6 Mouse ARNT 
     I  S  T  M  A  A  T  T  A  N  P  E  M  T  S  D  V  P  S  L   
3     atctcgaccatggcggcgactacagctaacccagaaatgacatcagatgtaccatcgctg  62 
      G  P  T  I  A  S  G  N  P  G  P  G  I  Q  G  G  G  A  V  V   
63    ggtcccaccattgcttctggaaaccctggacctgggattcaaggtggaggagctgttgta  122 
      Q  R  A  I  K  R  R  S  G  L  D  F  D  D  E  V  E  V  N  T   
123   cagagggctattaagcgacggtcagggctggattttgatgatgaagtagaagtgaacact  182 
      K  F  L  R  C  D  D  D  Q  M  C  N  D  K  E  R  F  A  R  S   
183   aaatttttgagatgcgatgatgaccagatgtgtaatgacaaggagcggtttgccaggtcg  242 
      D  D  E  Q  S  S  A  D  K  E  R  L  A  R  E  N  H  S  E  I   
243   gatgatgagcagagctctgcggataaagagagacttgccagggaaaatcatagtgaaata  302 
      E  R  R  R  R  N  K  M  T  A  Y  I  T  E  L  S  D  M  V  P   
303   gaacggcggcgacggaacaagatgacagcttacatcacagaactgtcagacatggtacct  362 
      T  C  S  A  L  A  R  K  P  D  K  L  T  I  L  R  M  A  V  S   
363   acatgtagtgccctggctcgaaaaccagacaagctaaccatcttacgcatggccgtttct  422 
      H  M  K  S  L  R  G  T  G  N  T  S  T  D  G  S  Y  K  P  S   
423   cacatgaagtccttgaggggaactggcaacacatctactgatggctcctacaagccatct  482 
      F  L  T  D  Q  E  L  K  H  L  I  L  E  A  A  D  G  F  L  F   
483   ttcctcactgatcaggaactgaaacatttgatcCtCgaggcagcagatggctttctgttt  542 
      I  V  S  C  E  T  G  R  V  V  Y  V  S  D  S  V  T  P  V  L   
543   attgtctcctgtgagactggacgggtggtgtatgtctctgactcagtgactcccgttttg  602 
      N  Q  P  Q  S  E  W  F  G  S  T  L  Y  D  Q  V  H  P  D  D   
603   aaccagccacagtctgaatggttcgggagcacactgtatgatcaggtgcacccagatgat  662 
      V  D  K  L  R  E  Q  L  S  T  S  E  N  A  L  T  G  R  V  L   
663   gtggataaacttcgagagcagctctctacatcagaaaatgccctaacagggcgggtcctg  722 
      D  L  K  T  G  T  V  K  K  E  G  Q  Q  S  S  M  R  M  C  M   
723   gatctgaagactggaacagtgaaaaaggaaggccagcagtcttccatgaggatgtgcatg  782 
      G  S  R  R  S  F  I  C  R  M  R  C  G  T  S  S  V  D  P  V   
783   ggctcacgaaggtcgttcatctgccgcatgaggtgtggtactagctccgtggaccctgtt  842 
      S  M  N  R  L  S  F  L  R  N  R  C  R  N  G  L  G  S  V  K   
843   tccatgaatagactgagctttttgaggaacagatgcaggaatgggcttggctctgtgaag  902 
      E  G  E  P  H  F  V  V  V  H  C  T  G  Y  I  K  A  W  P  P   
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903   gaaggagaacctcactttgtggtagtccactgcacCggTtacatcaaggcctggccacca  962 
      A  G  V  S  L  P  D  D  D  P  E  A  G  Q  G  S  K  F  C  L   
963   gcaggtgtctccctcccagatgatgacccagaggctggccaggggagcaaattctgccta  1022 
      V  A  I  G  R  L  Q  V  T  S  S  P  N  C  T  D  M  S  N  I   
1023  gtggccattggcaggctgcaggtaactagttctcccaactgtacagacatgagtaacatt  1082 
      C  Q  P  T  E  F  I  S  R  H  N  I  E  G  I  F  T  F  V  D   
1083  tgtcagccaacagagttcatctcccgacacaacattgaagggatattcacttttgtagac  1142 
      H  R  C  V  A  T  V  G  Y  Q  P  Q  E  L  L  G  K  N  I  V   
1143  catcgttgtgtggctactgttggctaccagccacaggagctcttagggaagaatattgta  1202 
      E  F  C  H  P  E  D  Q  Q  L  L  R  D  S  F  Q  Q  V  V  K   
1203  gaattttgtcatcctgaagaccaacaacttctaagagacagctttcagcaggtggtgaaa  1262 
      L  K  G  Q  V  L  S  V  M  F  R  F  R  S  K  T  R  E  W  L   
1263  ttaaaaggtcaggtgctgtccgtcatgttccgattccgatctaagacccgagaatggctg  1322 
      W  M  R  T  S  S  F  T  F  Q  N  P  Y  S  D  E  I  E  Y  I   
1323  tggatgagaacgagctcctttaccttccaaaacccttattcagatgaaattgagtatatt  1382 
      I  C  T  N  T  N  V  K  N  S  S  Q  E  P  R  P  T  L  S  N   
1383  atctgcaccaacaccaatgtgaagaactctagccaggaaccacggcctacactgtccaac  1442 
      T  I  P  R  S  Q  L  G  P  T  A  N  L  S  L  E  M  G  T  G   
1443  accatcccaaggtcacaactaggtccgacagccaatttatccctagagatgggtacaggg  1502 
      Q  L  P  S  R  Q  Q  Q  Q  Q  H  T  E  L  D  M  V  P  G  R   
1503  cagctgccatcTagAcagcagcagcagcagcacacagaactggatatggtaccaggaaga  1562 
      D  G  L  A  S  Y  N  H  S  Q  V  S  V  Q  P  V  A  S  A  G   
1563  gatgggctggccagctataatcattcccaggtttctgtccagcctgtggcaagtgcagga  1622 
      S  E  H  S  K  P  L  E  K  S  E  G  L  F  A  Q  D  R  D  P   
1623  tcagaacacagcaagccccttgagaagtcagaaggtctctttgcacaggacagagatcca  1682 
      R  F  P  E  I  Y  P  S  I  T  A  D  Q  S  K  G  I  S  S  S   
1683  aggtttccagaaatctatcccagcatcactgcagatcagagtaaaggcatctcctccagc  1742 
      T  V  P  A  T  Q  Q  L  F  S  Q  G  S  S  F  P  P  N  P  R   
1743  actgtccctgccacccaacagctgttctcccagggcagctcattccctcctaacccccgg  1802 
      P  A  E  N  F  R  N  S  G  L  T  P  P  V  T  I  V  Q  P  S   
1803  ccggcagagaatttcaggaatagtggtcttacccctcctgtaaccattgtccagccatca  1862 
      S  S  A  G  Q  I  L  A  Q  I  S  R  H  S  N  P  A  Q  G  S   
1863  tcttctgcagggcagatactggcccagatttcacgtcactccaaccctgcccagggatca  1922 
      A  P  T  W  T  S  T  S  R  P  G  F  A  A  Q  Q  V  P  T  Q   
1923  gcgccgacctggacctctacgtcccgcccaggctttgccgcccagcaggtgcccacccag  1982 
      A  T  A  K  T  R  S  S  Q  F  G  V  N  N  F  Q  T  S  S  S   
1983  gctacagccaagactcgttcttcccaatttggtgtgaacaactttcagacttcttcctcc  2042 
      F  S  A  M  S  L  P  G  A  P  T  A  S  S  G  T  A  A  Y  P   
2043  ttcagtgctatgtctcttccgggtgctcccactgcctcatctggtactgctgcctaccct  2102 
      A  L  P  N  R  G  S  N  F  P  P  E  T  G  Q  T  T  G  Q  F   
2103  gctctccccaaccgtggctccaactttcctcctgagactggacagaccacaggacagttc  2162 
      Q  A  R  T  A  E  G  V  G  V  W  P  Q  W  Q  G  Q  Q  P  H   
2163  caggcccggacagcagagggcgtgggggtctggccacagtggcagggccagcagccccat  2222 
      H  R  S  S  S  S  E  Q  H  V  Q  Q  T  Q  A  Q  A  P  S  Q   
2223  catcggtctagttccagtgagcagcatgttcagcagacacaagcacaagcacctagccag  2282 
      P  E  V  F  Q  E  M  L  S  M  L  G  D  Q  S  N  T  Y  N  N   
2283  cctgaggtctttcaagaaatgctgtccatgctgggagaccaaagcaacacctacaacaat  2342 
      E  E  F  P  D  L  T  M  F  P  P  F  S  E  *  N  Y  W  G  E   
2343  gaagaatttcctgatctaactatgtttccccccttttccgaatagaactattggggtgag  2402 
      D  K  G  G  G  K  S  L  F  V  F  K  S  K  S  F  V  N  R  I   
2403  gataagggtggggggaaatcactgtttgtttttaaaagcaaatcttttgtaaacagaata  2462 
      K  V  L  S  L  R  S  S  P  F  P  S  L  T  P  D  M  Y  P  F   
2463  aaagtcctctccctccgttcctctcccttcccttccctcacccctgatatgtaccctttc  2522 
      P  P  P  *  L  A  E  E  T  Y  R  R  N  *  M  N  F  P  G  F   
2523  ccacccccttgacttgctgaagaaacgtatagaagaaattaaatgaatttcccaggcttt  2582 
      *  D  P  L  K  F  *  G  *  V  R  P  E 
2583  taggatcctctgaaattttgaggataggtgaggcctgaatc  2623 
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>C57/BL6 Mouse ARNT2 
 
      P  A  L  R  S  L  P  G  K  M  A  T  P  A  A  V  N  P  P  E   
3     ccggcgctccggtcccttcccggcaagatggcaaccccggccgccgtcaaccctccggag  62 
      M  A  S  D  I  P  G  S  V  A  L  P  V  A  P  M  A  A  T  G   
63    atggcgtcagacataccaggatctgtggccttgcctgttgcccccatggcagccaccgga  122 
      Q  V  R  M  A  G  A  M  P  A  R  G  G  K  R  R  S  G  M  D   
123   caggtgagaatggcaggggccatgcctgcccgaggaggaaagcgtcgatccggaatggac  182 
      F  D  D  E  D  G  E  G  P  S  K  F  S  R  E  N  H  S  E  I   
183   ttcgatgacgaagatggtgaaggtcccagtaaattctcaagagagaaccacagtgagatt  242 
      E  R  R  R  R  N  K  M  T  Q  Y  I  T  E  L  S  D  M  V  P   
243   gagcggcgcaggcggaacaagatgactcaatatattacggaactctccgacatggttccc  302 
      T  C  S  A  L  A  R  K  P  D  K  L  T  I  L  R  M  A  V  S   
303   acctgcagtgcactggctaggaagccagacaagctgaccatcctgcgcatggcggtctcg  362 
      H  M  K  S  M  R  G  T  G  N  K  S  T  D  G  A  Y  K  P  S   
363   cacatgaagtccatgaggggcaccggcaacaaatcgactgacggcgcctacaagccttcc  422 
      F  L  T  E  Q  E  L  K  H  L  I  L  E  A  A  D  G  F  L  F   
423   ttcctcactgagcaggaactgaagcatctcatcctCgaGgccgctgatggatttctgttt  482 
      V  V  A  A  E  T  G  R  V  I  Y  V  S  D  S  V  T  P  V  L   
483   gtggtggcagctgagacagggagagtcatctacgtgtctgattcggtcactcctgtcctg  542 
      N  Q  P  Q  S  E  W  F  G  S  T  L  Y  E  Q  V  H  P  D  D   
543   aaccagccacagtcagagtggtttgggagcacgctttatgagcaggtgcaccctgatgac  602 
      V  E  K  L  R  E  Q  L  C  T  S  E  N  S  I  T  G  R  I  L   
603   gtggagaaactgagggaacagctgtgcacttcggaaaactccattacaggccgcatcctg  662 
      D  L  K  T  G  T  V  K  K  E  G  Q  Q  S  S  M  R  M  C  M   
663   gacctgaagactgggacagtgaagaaggagggacagcagtcatccatgcgcatgtgtatg  722 
      G  S  R  R  S  F  I  C  R  M  R  C  G  N  A  P  L  D  H  L   
723   ggctctcggcgctccttcatctgtaggatgaggtgtggaaacgctcccttggaccacctg  782 
      P  L  N  R  I  T  T  M  R  K  R  F  R  N  G  L  G  P  V  K   
783   cctttgaacagaataaccaccatgaggaaaaggttcaggaatggccttggccctgtgaaa  842 
      E  G  E  A  Q  Y  A  V  V  H  C  T  G  Y  I  K  A  W  P  P   
843   gaaggagaagcccagtatgctgtggtccactgcacCggttacatcaaggcttggccacca  902 
      A  G  M  T  I  P  E  E  D  A  D  V  G  Q  G  S  K  Y  C  L   
903   gcaggaatgaccatacccgaagaagatgctgatgtcggacaaggcagtaaatattgcctc  962 
      V  A  I  G  R  L  Q  V  T  S  S  P  V  C  M  D  M  S  G  M   
963   gtggcaattgggaggctccaggtgaccagctctcctgtgtgcatggacatgagcggcatg  1022 
      S  V  P  T  E  F  L  S  R  H  N  S  D  G  I  I  T  F  V  D   
1023  tcagtgcccacagagttcctgtcacggcacaactctgatgggattatcacgtttgtggac  1082 
      P  R  C  I  S  V  I  G  Y  Q  P  Q  D  L  L  G  K  D  I  L   
1083  cccagatgcatcagtgtgattggctaccagccccaggaccttctgggaaaggatattttg  1142 
      E  F  C  H  P  E  D  Q  S  H  L  R  E  S  F  Q  Q  V  V  K   
1143  gaattttgccaccctgaggatcagagccacctacgggagagcttccaacaggtggttaag  1202 
      L  K  G  Q  V  L  S  V  M  Y  R  F  R  T  K  N  R  E  W  L   
1203  ctgaagggccaagtgctgtcggtcatgtatcggttccgcaccaagaaccgggagtggctg  1262 
      L  I  R  T  S  S  F  T  F  Q  N  P  Y  S  D  E  I  E  Y  V   
1263  ttgatccgtaccagcagcttcaccttccagaacccctactctgatgagatcgagtacgtc  1322 
      I  C  T  N  T  N  V  K  Q  L  Q  Q  Q  Q  A  E  L  E  V  H   
1323  atctgcaccaacaccaatgtcaagcaacttcagcaacagcaggcagaactggaggtacat  1382 
      Q  R  D  G  L  S  S  Y  D  L  S  Q  V  P  V  P  N  L  P  A   
1383  cagcgagatgggctgtcgtcatatgacttatctcaggtcccagtacccaacctacccgct  1442 
      G  V  H  E  A  G  K  S  V  E  K  A  D  A  I  F  S  Q  E  R   
1443  ggtgttcacgaggccgggaagtctgtggaaaaggcagatgcaatcttctcccaagagaga  1502 
      D  P  R  F  A  E  M  F  A  G  I  S  A  S  E  K  K  M  M  S   
1503  gaccctcgttttgctgagatgtttgcaggcatcagtgcatctgagaagaagatgatgagc  1562 
      S  A  S  A  S  G  S  Q  Q  I  Y  S  Q  G  S  P  F  P  A  G   
1563  tcagcctcagcatcaggcagccagcagatctactcccaaggaagtccattccctgccggg  1622 
      H  S  G  K  A  F  S  S  S  V  V  H  V  P  G  V  N  D  I  Q   
1623  cactcgggcaaggccttcagctcttccgtggtccatgtgcctggagtgaatgacattcag  1682 
      S  S  S  S  T  G  Q  N  I  S  Q  I  S  R  Q  L  N  Q  G  Q   
1683  tcctcctcctcaacgggacagaacatatcccagatctctAgAcagctgaaccagggccag  1742 
      V  A  W  T  G  S  R  P  P  F  P  G  Q  P  S  K  T  Q  S  S   
1743  gtggcatggacaggcagccgtccaccgttcccagggcagcccagcaagacgcagtcatct  1802 
      A  F  G  I  G  S  S  H  P  Y  P  A  D  P  S  S  Y  S  P  L   
1803  gccttcggaattggatcaagccacccttacccggctgacccttcatcctacagtcctctc  1862 
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      S  S  P  A  A  S  S  P  S  G  N  A  Y  P  S  L  A  N  R  T   
1863  tccagcccagctgcctcctcaccaagtggaaacgcataccccagtcttgccaacaggact  1922 
      P  G  F  A  E  S  G  Q  S  G  G  Q  F  Q  G  R  P  S  E  V   
1923  ccagggtttgctgagagtggacagagtggcgggcagttccagggccggccctcggaggtc  1982 
      W  S  Q  W  Q  S  Q  H  H  G  Q  Q  S  G  E  Q  H  S  H  Q   
1983  tggtcccagtggcagagccagcatcacggacagcagagcggtgagcagcactcgcatcag  2042 
      Q  P  G  Q  T  E  V  F  Q  D  M  L  P  M  P  G  D  P  T  Q   
2043  cagcctggccagactgaagtgttccaggacatgctacccatgccgggcgacccgacgcag  2102 
      G  T  G  N  Y  N  I  E  D  F  A  D  L  G  M  F  P  P  F  S   
2103  gggactggcaactataacatcgaggactttgctgacctgggcatgttccctccattttct  2162 
      E  *  L  Q  A  K  P  G  F  Y  C  P  D  A  I  I  M  P  *  M   
2163  gagtagcttcaggcaaagccaggcttctactgcccagacgctattatcatgccatagatg  2222 
      P  M  F  K  E  G  P  P  H  P  A  C  P  A  V  E  P  P  E  I   
2223  cccatgttcaaagagggtccccctcacccagcttgccctgctgtagaacccccagaaatc  2282 
      S  L  I  P  H  P  P  W  T  W  H  H  L  A  L  T  H  S  P  G   
2283  tcccttattccccatcctccctggacatggcatcacctggctctaacccacagccctggc  2342 
      F  L  G  L  G  S  L  Y  L  L  Y  F  I  C  V  L  G  R  G  P   
2343  ttcttgggtttgggatctttgtatttattgtactttatctgtgtgctcggaagggggccg  2402 
      P  G  S  *  I  P  L  *  I  I  Y  *  W 
2403  ccagggtcttaaatcccattgtgaataatctattaatggac  2443 
 
>Human ARNT 
 
     G  G  S  S  H  W  G  G  G  G  A  A  A  V  A  S  A  A  M  A   
3     ggcggctcctcccactggggggggggtggcgcggcggcggtggcatctgcggccatggcg  62 
      A  T  T  A  N  P  E  M  T  S  D  V  P  S  L  G  P  A  I  A   
63    gcgactactgccaaccccgaaatgacatcagatgtaccatcactgggtccagccattgcc  122 
      S  G  N  S  G  P  G  I  Q  G  G  G  A  I  V  Q  R  A  I  K   
123   tctggaaactctggacctggaattcaaggtggaggagccattgtccagagggctattaag  182 
      R  R  P  G  L  D  F  D  D  D  G  E  G  N  S  K  F  L  R  C   
183   cggcgaccagggctggattttgatgatgatggagaagggaacagtaaatttttgaggtgt  242 
      D  D  D  Q  M  S  N  D  K  E  R  F  A  R  S  D  D  E  Q  S   
243   gatgatgatcagatgtctaacgataaggagcggtttgccaggtcggatgatgagcagagc  302 
      S  A  D  K  E  R  L  A  R  E  N  H  S  E  I  E  R  R  R  R   
303   tctgcggataaagagagacttgccagggaaaatcacagtgaaattgaacggcggcgacgg  362 
      N  K  M  T  A  Y  I  T  E  L  S  D  M  V  P  T  C  S  A  L   
363   aacaagatgacagcctacatcacagaactgtcagatatggtacccacctgtagtgccctg  422 
      A  R  K  P  D  K  L  T  I  L  R  M  A  V  S  H  M  K  S  L   
423   gctcgaaaaccagacaagctaaccatcttacgcatggcagtttctcacatgaagtccttg  482 
      R  G  T  G  N  T  S  T  D  G  S  Y  K  P  S  F  L  T  D  Q   
483   cggggaactggcaacacatccactgatggctcctataagccgtctttcctcactgatcag  542 
      E  L  K  H  L  I  L  E  A  A  D  G  F  L  F  I  V  S  C  E   
543   gaactgaaacatttgatcCtCgaggcagcagatggctttctgtttattgtctcatgtgag  602 
      T  G  R  V  V  Y  V  S  D  S  V  T  P  V  L  N  Q  P  Q  S   
603   acaggcagggtggtgtatgtgtctgactccgtgactcctgttttgaaccagccacagtct  662 
      E  W  F  G  S  T  L  Y  D  Q  V  H  P  D  D  V  D  K  L  R   
663   gaatggtttggcagcacactctatgatcaggtgcacccagatgatgtggataaacttcgt  722 
      E  Q  L  S  T  S  E  N  A  L  T  G  R  I  L  D  L  K  T  G   
723   gagcagctttccacttcagaaaatgccctgacagggcgtatcctggatctaaagactgga  782 
      T  V  K  K  E  G  Q  Q  S  S  M  R  M  C  M  G  S  R  R  S   
783   acagtgaaaaaggaaggtcagcagtcttccatgagaatgtgtatgggctcaaggagatcg  842 
      F  I  C  R  M  R  C  G  S  S  S  V  D  P  V  S  V  N  R  L   
843   tttatttgccgaatgaggtgtggcagtagctctgtggacccagtttctgtgaataggctg  902 
      S  F  V  R  N  R  C  R  N  G  L  G  S  V  K  D  G  E  P  H   
903   agctttgtgaggaacagatgcaggaatggacttggctctgtaaaggatggggaacctcac  962 
      F  V  V  V  H  C  T  G  Y  I  K  A  W  P  P  A  G  V  S  L   
963   ttcgtggtggtccactgcacCggTtacatcaaggcctggcccccagcaggtgtttccctc  1022 
      P  D  D  D  P  E  A  G  Q  G  S  K  F  C  L  V  A  I  G  R   
1023  ccagatgatgacccagaggctggccagggaagcaagttttgcctagtggccattggcaga  1082 
      L  Q  V  T  S  S  P  N  C  T  D  M  S  N  V  C  Q  P  T  E   
1083  ttgcaggtaactagttctcccaactgtacagacatgagtaatgtttgtcaaccaacagag  1142 
      F  I  S  R  H  N  I  E  G  I  F  T  F  V  D  H  R  C  V  A   
1143  ttcatctcccgacacaacattgagggtatcttcacttttgtggatcaccgctgtgtggct  1202 
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      T  V  G  Y  Q  P  Q  E  L  L  G  K  N  I  V  E  F  C  H  P   
1203  actgttggctaccagccacaggaactcttaggaaagaatattgtagaattctgtcatcct  1262 
      E  D  Q  Q  L  L  R  D  S  F  Q  Q  V  V  K  L  K  G  Q  V   
1263  gaagaccagcagcttctaagagacagcttccaacaggtagtgaaattaaaaggccaagtg  1322 
      L  S  V  M  F  R  F  R  S  K  N  Q  E  W  L  W  M  R  T  S   
1323  ctgtctgtcatgttccggttccggtctaagaaccaagaatggctctggatgagaaccagc  1382 
      S  F  T  F  Q  N  P  Y  S  D  E  I  E  Y  I  I  C  T  N  T   
1383  tcctttactttccagaacccttactcagatgaaattgagtacatcatctgtaccaacacc  1442 
      N  V  K  N  S  S  Q  E  P  R  P  T  L  S  N  T  I  Q  R  P   
1443  aatgtgaagaactctagccaagaaccacggcctacactctccaacacaatccagaggcca  1502 
      Q  L  G  P  T  A  N  L  P  L  E  M  G  S  G  Q  L  A  P  R   
1503  caactaggtcccacagctaatttacccctggagatgggctcaggacagctggcacccagg  1562 
      Q  Q  Q  Q  Q  T  E  L  D  M  V  P  G  R  D  G  L  A  S  Y   
1563  cagcagcaacagcaaacagaattggacatggtaccaggaagagatggactggccagctac  1622 
      N  H  S  Q  V  V  Q  P  V  T  T  T  G  P  E  H  S  K  P  L   
1623  aatcattcccaggtggttcagcctgtgacaaccacaggaccagaacacagcaagcccctt  1682 
      E  K  S  D  G  L  F  A  Q  D  R  D  P  R  F  S  E  I  Y  H   
1683  gagaagtcagatggtttatttgcccaggatagagatccaagattttcagaaatctatcac  1742 
      N  I  N  A  D  Q  S  K  G  I  S  S  S  T  V  P  A  T  Q  Q   
1743  aacatcaatgcggatcagagtaaaggcatctcctccagcactgtccctgccacccaacag  1802 
      L  F  S  Q  G  N  T  F  P  P  T  P  R  P  A  E  N  F  R  N   
1803  ctattctcccagggcaacacattccctcctaccccccggccggcagagaatttcaggaat  1862 
      S  G  L  A  P  P  V  T  I  V  Q  P  S  A  S  A  G  Q  M  L   
1863  agtggcctagcccctcctgtaaccattgtccagccatcagcttctgcaggacagatgttg  1922 
      A  Q  I  S  R  H  S  N  P  T  Q  G  A  T  P  T  W  T  P  T   
1923  gcccagatttcTAgAcactccaaccccacccaaggagcaaccccaacttggacccctact  1982 
      T  R  S  G  F  S  A  Q  Q  V  A  T  Q  A  T  A  K  T  R  T   
1983  acccgctcaggcttttctgcccagcaggtggctacccaggctactgctaagactcgtact  2042 
      S  Q  F  G  V  G  S  F  Q  T  P  S  S  F  S  S  M  S  L  P   
2043  tcccagtttggtgtgggcagctttcagactccatcctccttcagctccatgtccctccct  2102 
      G  A  P  T  A  S  P  G  A  A  A  Y  P  S  L  T  N  R  G  S   
2103  ggtgccccaactgcatcgcctggtgctgctgcctaccctagtctcaccaatcgtggatct  2162 
      N  F  A  P  E  T  G  Q  T  A  G  Q  F  Q  T  R  T  A  E  G   
2163  aactttgctcctgagactggacagactgcaggacaattccagacacggacagcagagggt  2222 
      V  G  V  W  P  Q  W  Q  G  Q  Q  P  H  H  R  S  S  S  S  E   
2223  gtgggtgtctggccacagtggcagggccagcagcctcatcatcgttcaagttctagtgag  2282 
      Q  H  V  Q  Q  P  P  A  Q  Q  P  G  Q  P  E  V  F  Q  E  M   
2283  caacatgttcaacaaccgccagcacagcaacctggccagcctgaggtcttccaggagatg  2342 
      L  S  M  L  G  D  Q  S  N  S  Y  N  N  E  E  F  P  D  L  T   
2343  ctgtccatgctgggagatcagagcaacagctacaacaatgaagaattccctgatctaact  2402 
      M  F  P  P  F  S  E  *  N  Y  W  G  E  D  K  G  W  G  R  K   
2403  atgtttccccccttttcagaatagaactattggggtgaggataaggggtgggggagaaaa  2462 
      N  H  C  L  F  L  K  S  K  S  F  C  K  Q  N  K  S  S  S  P   
2463  aatcactgtttgtttttaaaaagcaaatctttctgtaaacagaataaaagttcctctccc  2522 
      F  P  S  L  T  P  D  M  Y  P  L  S  L  L  A  V  P  L  L  C   
2523  ttcccttccctcacccctgacatgtaccccctttcccttctggctgttcccctgctctgt  2582 
      C  L  L  R  *  H  L  *  K  K  K 
2583  tgcctcctaaggtaacatttataaaaaaaaaaaa  2616 
 
 
>Human ARNT2 
 
     F  V  W  R  R  R  R  L  G  L  T  G  S  P  G  L  S  A  G  L   
2     tttgtgtggcggcggcggcgcctgggcctgaccgggtccccggggctgagcgccgggctc  61 
      R  A  A  P  P  A  P  L  P  S  G  R  L  S  S  P  S  K  M  A   
62    cgcgccgcccctcccgcgcccctgccaagcgggcgcctatcctctccgagcaagatggca  121 
      T  P  A  A  V  N  P  P  E  M  A  S  D  I  P  G  S  V  T  L   
122   accccggcggcggtcaaccctccggaaatggcttcagacatacctggatctgtgacgttg  181 
      P  V  A  P  M  A  A  T  G  Q  V  R  M  A  G  A  M  P  A  R   
182   cccgttgcccccatggcggccaccggacaggtgaggatggcgggggccatgcctgcccgt  241 
      G  G  K  R  R  S  G  M  D  F  D  D  E  D  G  E  G  P  S  K   
242   ggaggaaagcggcgttccggaatggacttcgatgatgaagatggtgaaggccccagtaaa  301 
      F  S  R  E  N  H  S  E  I  E  R  R  R  R  N  K  M  T  Q  Y   
302   ttttcaagagagaatcatagtgaaatcgaaaggcgcagacggaacaagatgactcagtac  361 
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      I  T  E  L  S  D  M  V  P  T  C  S  A  L  A  R  K  P  D  K   
362   atcacggagctctccgacatggtccccacatgcagcgcactggctcggaagccagacaag  421 
      L  T  I  L  R  M  A  V  S  H  M  K  S  M  R  G  T  G  N  K   
422   ctcaccatcctccgcatggccgtctcgcacatgaagtccatgaggggtacagggaacaag  481 
      S  T  D  G  A  Y  K  P  S  F  L  T  E  Q  E  L  K  H  L  I   
482   tccaccgatggcgcgtacaagccttccttcctcacagagcaggaactgaagcatctcatc  541 
      L  E  A  A  D  G  F  L  F  V  V  A  A  E  T  G  R  V  I  Y   
542   ctCgaGgcagctgatggatttctgtttgtggtggctgctgagacagggcgagtgatttat  601 
      V  S  D  S  V  T  P  V  L  N  Q  P  Q  S  E  W  F  G  S  T   
602   gtgtctgactccgtcacccctgttctgaaccagccccagtcagagtggtttgggagcaca  661 
      L  Y  E  Q  V  H  P  D  D  V  E  K  L  R  E  Q  L  C  T  S   
662   ctgtatgaacaggtgcatcctgatgacgtggagaagctgagagagcaactgtgcacctca  721 
      E  N  S  M  T  G  R  I  L  D  L  K  T  G  T  V  K  K  E  G   
722   gaaaactcaatgacaggccggatcttggacctgaagactgggacggtcaagaaagaaggg  781 
      Q  Q  S  S  M  R  M  C  M  G  S  R  R  S  F  I  C  R  M  R   
782   cagcagtcatccatgaggatgtgcatgggctcgcggcggtctttcatctgcaggatgagg  841 
      C  G  N  A  P  L  D  H  L  P  L  N  R  I  T  T  M  R  K  R   
842   tgtggaaatgctcctttggaccaccttcctctaaacagaataaccaccatgaggaaaagg  901 
      F  R  N  G  L  G  P  V  K  E  G  E  A  Q  Y  A  V  V  H  C   
902   ttcaggaatggccttggccctgtgaaagaaggagaagcccaatatgctgtggtccactgt  961 
      T  G  Y  I  K  A  W  P  P  A  G  M  T  I  P  E  E  D  A  D   
962   acCggTtacatcaaggcctggccaccagcaggaatgaccatacctgaagaagacgctgat  1021 
      V  G  Q  G  S  K  Y  C  L  V  A  I  G  R  L  Q  V  T  S  S   
1022  gtgggacaaggcagtaaatattgcctcgtggcaattgggagactccaggtgaccagctct  1081 
      P  V  C  M  D  M  N  G  M  S  V  P  T  E  F  L  S  R  H  N   
 
1082  cctgtatgcatggacatgaatgggatgtcggtgcccacagagttcttatcccggcataac  1141 
      S  D  G  I  I  T  F  V  D  P  R  C  I  S  V  I  G  Y  Q  P   
1142  tccgatggaatcatcacatttgtggatccaagatgtatcagtgtgattggctaccaaccg  1201 
      Q  D  L  L  G  K  D  I  L  E  F  C  H  P  E  D  Q  S  H  L   
1202  caggatcttctgggaaaggacattttggaattctgccaccctgaggatcaaagccatctg  1261 
      R  E  S  F  Q  Q  V  V  K  L  K  G  Q  V  L  S  V  M  Y  R   
1262  cgtgagagcttccagcaggtggttaagctgaaaggccaagtcctgtcggtcatgtatcga  1321 
      F  R  T  K  N  R  E  W  M  L  I  R  T  S  S  F  T  F  Q  N   
1322  tttcgcaccaagaaccgggagtggatgttgatccgcaccagcagcttcacattccagaat  1381 
      P  Y  S  D  E  I  E  Y  I  I  C  T  N  T  N  V  K  Q  L  Q   
1382  ccctattctgatgagattgagtacatcatctgcaccaacaccaacgtcaagcaacttcag  1441 
      Q  Q  Q  A  E  L  E  V  H  Q  R  D  G  L  S  S  Y  D  L  S   
1442  caacagcaggcagaattggaagtgcaccagagagatggattgtcatcgtatgacttatcc  1501 
      Q  V  P  V  P  N  L  P  A  G  V  H  E  A  G  K  S  V  E  K   
1502  caggtccccgtccccaacctaccagccggtgttcatgaggccgggaagtccgtggaaaag  1561 
      A  D  A  I  F  S  Q  E  R  D  P  R  F  A  E  M  F  A  G  I   
1562  gcggatgcaatcttctcccaggaaagagatcctcggtttgctgaaatgtttgcaggaatt  1621 
      S  A  S  E  K  K  M  M  S  S  A  S  A  A  G  T  Q  Q  I  Y   
1622  agtgcatcggagaagaagatgatgagctcagcctctgcagcaggaacccagcagatctac  1681 
      S  Q  G  S  P  F  P  S  G  H  S  G  K  A  F  S  S  S  V  V   
1682  tcccaaggaagcccatttccctctggacactccgggaaggccttcagctcttcagtggtt  1741 
      H  V  P  G  V  N  D  I  Q  S  S  S  S  T  G  Q  N  M  S  Q   
1742  catgtgcctggagtgaatgatattcagtcctcttcttccacgggccagaacatgtcccaa  1801 
      I  S  R  Q  L  N  Q  S  Q  V  A  W  T  G  S  R  P  P  F  P   
1802  atctcTAgAcagctaaaccagagtcaggtggcatggacagggagtcgtccgccctttccg  1861 
      G  Q  Q  I  P  S  Q  S  S  K  T  Q  S  S  P  F  G  I  G  T   
1862  ggacagcaaatcccatctcagtccagcaagactcagtcatctccctttgggattggaacg  1921 
      S  H  T  Y  P  A  D  P  S  S  Y  S  P  L  S  S  P  A  T  S   
1922  agccacacctacccggcagacccctcttcctacagccccctctccagcccagctacctcc  1981 
      S  P  S  G  N  A  Y  S  S  L  A  N  R  T  P  G  F  A  E  S   
1982  tcgccaagtgggaatgcctactccagtcttgccaacaggactccagggttcgctgaaagt  2041 
      G  Q  S  S  G  Q  F  Q  G  R  P  S  E  V  W  S  Q  W  Q  S   
2042  ggacaaagtagcgggcagttccaagggcggccctcggaagtctggtcgcagtggcaaagc  2101 
      Q  H  H  G  Q  Q  S  G  E  Q  H  S  H  Q  Q  P  G  Q  T  E   
2102  cagcaccatggccagcagagcggtgagcagcactcccaccagcagcccggtcagactgaa  2161 
      V  F  Q  D  M  L  P  M  P  G  D  P  G  N  E  W  W  S  P  H   
2162  gtgttccaggacatgctgcccatgccaggagatccagggaatgaatggtggtctccccac  2221 
      S  R  Q  H  F  R  Q  P  I  S  Y  A  R  M  *  T  L  T  L  L   
2222  tcccggcagcactttaggcagcccataagctatgcgagaatgtgaacgctcaccttgctc  2281 
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      R  H  G  S  D  L  P  H  K  Q  E  E  A  S  D  R  N  S  S  R   
2282  cgtcacggttctgacctaccacataaacaggaagaagccagtgaccggaacagctctagg  2341 
      N  N  K  S  E  *  K  C  P  L  Y  Y  Q  K  I  W  A  W  P  K   
2342  aataacaagtcagaatagaagtgtcctttatattaccagaaaatatgggcttggcctaag  2401 
      S  L  S  P  N  L  P  G  S  F  P  T  K  H  P  I  L  R  S  H   
2402  tcgctgtctcctaacctgccggggtcattccccaccaaacaccccatactaaggagccat  2461 
      E  P  P  G  H  S  P  F  L  *  P  S  G  V  W  G  N  L  R  R   
2462  gagccacctggacattcaccttttctttgaccatctggagtctggggcaacttaaggagg  2521 
      H  H  T  V  V  Q  A  H  F  Q  A  *  V  S  L  A  F  V  A  K   
2522  caccacacagtggtgcaggcacatttccaagcgtaggtgtccctggcttttgtggccaaa  2581 
      A  S  V  M  V  N  N  R  P  G  S  V  G  H  *  P  *  K  W  Q   
2582  gctagtgttatggtcaacaacaggccagggtctgtggggcactgaccttgaaagtggcaa  2641 
      N  G  G  F  T  G  C  A  G  A  G  R  L  A  S  S  N  N  L  S   
2642  aatggaggtttcacaggctgtgcgggagcaggacggcttgcttcatctaacaatctcagt  2701 
      F  L  *  K  K  K  E  R  K  R  F  H  K  Q  V  S  V  D  S  L   
2702  ttcctttaaaaaaagaaagaaaggaaaagatttcataagcaggtgtcagtggacagttta  2761 
      S  T  *  P  F  L  F  L  L  M  D  V  N  C  A  V  D  K  S  F   
2762  agtacttaaccatttctctttcttcttatggatgtgaactgtgctgtggataaatcattt  2821 
      V  F  L  E  C  S  L  *  L  T  V  I  K  S  V  V  Y  M  C  N   
2822  gtatttcttgaatgttctctatgactaacagttattaagtcggttgtgtatatgtgtaac  2881 
      *  C  N  C  L  L  K  F  H  Y  N  K  N  D  F  A  L  K  K  K   
2882  taatgtaactgccttttaaaatttcattacaataaaaatgactttgctctgaaaaaaaaa  2941 
      K  K 
2942  aaaaaaa  2948 
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Figure AC3.  Schematic of ARNT Domain Swapping 
 
 
NheI:
mARNT (63)
mARNT2 (36)
hARNT2 (36)
hARNT (63)
C. elegans (75 P-->A)
D. melanogaster (36)
XhoI:
mARNT2 (426)
mARNT (504)
hARNT2 (426)
hARNT (504)
C. elegans (366)
D. melanogaster (276)
AgeI:
mARNT (924)
mARNT2 (846)
hARNT (924)
hARNT2 (846)
C. elegans (744)
D. melanogaster (687)
mARNT (1588)
mARNT2 (1689, 1728)
hARNT (1875)
hARNT2 (1014, 1728)
C. elegans ()
D. melanogaster ()
XbaI:
PvuI MluI
Fig. AC3.  Schematic of ARNT domain swapping.    Schematic representation of 
the restriction enzyme sites generated within ARNT and ARNT2 to create 
interchangeable domains.  The basic,helix-loop-helix, PAS A, PAS B, and 
transactivation domains are shaded.  Numbers in parentheses represent the 
nucleotide position of the indicated restriction enzyme site in the context of the 
cDNA.   
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Figure AC4.  Construct Maps of p-hARNT-ID and p-mARNT2-ID 
 
 
 
 
 
 
 
 
phARNT-ID
7859 bp
NheI
XhoI AgeI
XbaI
HindIII
(895)
(1471) (1897)
(2854)
(229)MluI
(3346)
pmARNT2-ID
7511 bp
NheI
XhoI AgeI
XbaI
HindIII
(895)
(1329) (1755)
(2643)
(229)MluI
(2998)
Fig. AC4.  Construct 
maps of p-hARNT-ID 
and p-mARNT2-ID.   
Maps of the p-hARNT-
ID and p-mARNT2-ID 
plasmids.  The size of 
the constructs in base 
pairs is shown.  
Pertinent restriction 
enzyme sites along with 
their positions are 
indicated.  bHLH = 
basic helix-loop-helix 
domain.  PAS A and 
PAS B = Per ARNT 
Sim domains A and B.  
TAD = transactivation 
domain.  
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Appendix C continued 
 
 
 After generating the domains with the specified mutations via PCR, the 
fragments were digested with the appropriate enzymes and subcloned sequentially into 
pcDNA 3.1 (Clontech).  The resultant constructs, named p-hARNT-ID and p-mARNT2-
ID (Figure AC4) were then digested with restriction enzymes and visualized in an 
agarose gel to ensure the proper sized fragments were produced.  A representative photo 
of the agarose gel can be observed in Figure AC5.  Next the constructs were used to 
produce in vitro transcribed/translated proteins, however the products were ~200kD in 
size, far smaller than the expected size.  Sequence data did not reveal any early stop 
codons.  The reason for the improperly sized proteins is unclear and will require further 
investigation. 
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